Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
abacavir	abacavir	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
zidovudine	zidovudine	NN	I-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abacavir	abacavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Abacavir	Abacavir	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Ethanol	Ethanol	NN	B-NP	O	S-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abacavir	abacavir	NN	B-NP	O	S-drug-ME-2
causing	cause	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
overall	overall	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O
The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methadone	methadone	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
abacavir	abacavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
11	11	CD	B-NP	O	O
HIV	HIV	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
infected	infect	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
methadone	methadone	NN	B-NP	O	S-drug-ME-1
-	-	HYPH	O	O	O
maintenance	maintenance	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	O	O	O
90	90	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZIAGEN	ZIAGEN	NN	B-NP	B-protein	S-brand-ME-2
twice	twice	RB	O	O	O
daily	daily	RB	O	O	O
(	(	(	O	O	O
twice	twice	RB	B-NP	O	O
the	the	DT	I-NP	O	O
currently	currently	RB	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
42	42	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
will	will	MD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
modification	modification	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
methadone	methadone	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
cholestyramine	cholestyramine	NN	I-NP	O	S-drug-ME-1
administration	administration	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug-ME-2
approximately	approximately	RB	B-NP	O	O
55	55	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incremental	incremental	JJ	I-NP	O	O
LDL	LDL	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
C	C	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
adding	add	VBG	B-VP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug-EF-1
to	to	TO	B-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Fibrates	Fibrate	NNS	B-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fibrates	fibrate	NNS	B-NP	O	S-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Fibrates	Fibrate	NNS	B-NP	O	S-group
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
cholesterol	cholesterol	NN	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bile	bile	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
cholelithiasis	cholelithiasis	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
preclinical	preclinical	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
,	,	,	O	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
increased	increase	VBD	B-VP	O	O
cholesterol	cholesterol	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gallbladder	gallbladder	NN	I-NP	O	O
bile	bile	NN	I-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand-AD-1
with	with	IN	B-PP	O	O
fibrates	fibrate	NNS	B-NP	O	S-group-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
until	until	IN	B-PP	O	O
use	use	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Fenofibrate	Fenofibrate	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
fenofibrate	fenofibrate	NN	I-NP	O	S-drug-ME-1
administration	administration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
approximately	approximately	RB	B-NP	O	O
1.5	1.5	CD	I-NP	O	O
-	-	HYPH	B-VP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

Gemfibrozil	Gemfibrozil	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
gemfibrozil	gemfibrozil	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
approximately	approximately	RB	B-NP	O	O
1.7	1.7	CD	I-NP	O	O
-	-	HYPH	B-VP	O	O
fold	fold	RB	B-ADVP	O	O
.	.	.	O	O	O

HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	B-protein	I-group
reductase	reductase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
atorvastatin	atorvastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
simvastatin	simvastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
pravastatin	pravastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
lovastatin	lovastatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
fluvastatin	fluvastatin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug-ME-1
level	level	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
12	12	CD	B-NP	O	O
-	-	HYPH	B-ADVP	O	O
fold	fold	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
renal	renal	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
take	take	VBP	B-VP	O	O
both	both	CC	O	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Carcinogenesis	Carcinogenesis	NNP	B-NP	O	O
,	,	,	O	O	O
Mutagenesis	Mutagenesis	NNP	B-NP	O	O
,	,	,	O	O	O
Impairment	Impairment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Fertility	Fertility	NN	B-NP	O	O
A	A	NN	I-NP	O	O
104	104	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
carcinogenicity	carcinogenicity	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
1500	1500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
males	male	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
females	female	NNS	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
~	~	NN	B-NP	O	O
20	20	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
24hr	24hr	NN	I-NP	O	O
for	for	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
104	104	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
dietary	dietary	JJ	I-NP	O	O
carcinogenicity	carcinogenicity	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
>	>	SYM	O	O	O
150	150	CD	O	O	O
times	time	NNS	O	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
24hr	24hr	NN	I-NP	O	O
for	for	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	O
incidences	incidence	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mutagenicity	mutagenicity	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
microbial	microbial	JJ	I-NP	O	O
mutagenicity	mutagenicity	NN	I-NP	O	O
(	(	(	O	O	O
Ames	Ame	NNS	B-NP	O	O
)	)	)	O	O	O
test	test	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Salmonella	Salmonella	NNP	B-NP	O	O
typhimurium	typhimurium	NNP	I-NP	O	O
and	and	CC	O	O	O
Escherichia	Escherichia	NNP	B-NP	O	O
coli	coli	NNP	I-NP	O	O
with	with	IN	B-PP	O	O
or	or	CC	I-PP	O	O
without	without	IN	I-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
activation	activation	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clastogenicity	clastogenicity	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
chromosomal	chromosomal	JJ	I-NP	O	O
aberration	aberration	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
peripheral	peripheral	JJ	I-NP	I-cell_type	O
blood	blood	NN	I-NP	I-cell_type	O
lymphocytes	lymphocyte	NNS	I-NP	I-cell_type	O
with	with	IN	B-PP	O	O
or	or	CC	I-PP	O	O
without	without	IN	I-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
activation	activation	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
genotoxicity	genotoxicity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
micronucleus	micronucleus	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
(	(	(	O	O	O
gavage	gavage	NN	B-NP	O	O
)	)	)	O	O	O
fertility	fertility	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
conducted	conduct	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reproductive	reproductive	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
1000	1000	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
~	~	NN	B-NP	O	O
7	7	CD	I-NP	O	O
times	time	NNS	B-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
24hr	24hr	NN	I-NP	O	O
for	for	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Pregnancy	Pregnancy	NNP	B-NP	O	O
Pregnancy	Pregnancy	NNP	I-NP	O	O
Category	Category	NNP	I-NP	O	O
:	:	:	O	O	O
C	C	NNP	B-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
adequate	adequate	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

Ezetimibe	Ezetimibe	NNP	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
only	only	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
justifies	justify	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
fetus	fetus	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
(	(	(	O	O	O
gavage	gavage	NN	B-NP	O	O
)	)	)	O	O	O
embryo	embryo	AFX	O	O	O
-	-	HYPH	B-NP	O	O
fetal	fetal	JJ	I-NP	O	O
development	development	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
conducted	conduct	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
rabbits	rabbit	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
organogenesis	organogenesis	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
embryolethal	embryolethal	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
tested	test	VBN	B-VP	O	O
(	(	(	O	O	O
250	250	CD	B-NP	O	O
,	,	,	I-NP	O	O
500	500	CD	I-NP	O	O
,	,	,	I-NP	O	O
1000	1000	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
incidences	incidence	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
common	common	JJ	B-NP	O	O
fetal	fetal	JJ	I-NP	O	O
skeletal	skeletal	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
(	(	(	O	O	O
extra	extra	JJ	B-NP	O	O
pair	pair	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thoracic	thoracic	JJ	B-NP	O	O
ribs	rib	NNS	I-NP	O	O
,	,	,	O	O	O
unossified	unossified	JJ	B-NP	O	O
cervical	cervical	JJ	I-NP	O	O
vertebral	vertebral	JJ	I-NP	O	O
centra	centra	NN	I-NP	O	O
,	,	,	O	O	O
shortened	shorten	VBD	B-VP	O	O
ribs	rib	NNS	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
~	~	NN	B-NP	O	O
10	10	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
24hr	24hr	NN	I-NP	O	O
for	for	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
rabbits	rabbit	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
extra	extra	JJ	B-NP	B-protein	O
thoracic	thoracic	JJ	I-NP	I-protein	O
ribs	rib	NNS	I-NP	I-protein	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
150	150	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
human	human	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
AUC0	AUC0	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
24hr	24hr	NN	I-NP	O	O
for	for	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Ezetimibe	Ezetimibe	NNP	B-NP	O	S-drug
crossed	cross	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
placenta	placenta	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
pregnant	pregnant	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
rabbits	rabbit	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
multiple	multiple	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Multiple	Multiple	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
given	give	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
HMG	HMG	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
reductase	reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
statins	statin	NNS	B-NP	O	S-group
)	)	)	O	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
rabbits	rabbit	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
organogenesis	organogenesis	NN	B-NP	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
statin	statin	NN	I-NP	O	O
exposures	exposure	NNS	I-NP	O	O
.	.	.	O	O	O

Reproductive	Reproductive	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
occur	occur	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
monotherapy	monotherapy	NN	B-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	O	I-group
reductase	reductase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
nursing	nursing	NN	I-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
CoA	CoA	NN	I-NP	B-protein	I-group
reductase	reductase	NN	I-NP	I-protein	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
woman	woman	NN	I-NP	O	O
of	of	IN	B-PP	O	O
childbearing	childbeare	VBG	B-VP	O	O
potential	potential	NN	B-NP	O	O
,	,	,	O	O	O
refer	refer	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pregnancy	pregnancy	NN	I-NP	O	O
category	category	NN	I-NP	O	O
and	and	CC	I-NP	O	O
package	package	NN	I-NP	O	O
labeling	labeling	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
HMG	HMG	NN	I-NP	B-protein	B-drug
-	-	HYPH	B-NP	I-protein	I-drug
CoA	CoA	NN	I-NP	I-protein	I-drug
reductase	reductase	NN	I-NP	I-protein	I-drug
inhibitor	inhibitor	NN	I-NP	O	E-drug
.	.	.	O	O	O

Labor	Labor	NN	B-NP	O	O
and	and	CC	I-NP	O	O
Delivery	Delivery	NN	I-NP	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
on	on	IN	B-PP	O	O
labor	labor	NN	B-NP	O	O
and	and	CC	I-NP	O	O
delivery	delivery	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

Nursing	Nurse	VBG	B-VP	O	O
Mothers	Mother	NNS	B-NP	O	O
In	In	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
exposure	exposure	NN	B-VP	O	O
to	to	TO	B-PP	O	O
total	total	JJ	B-NP	O	O
ezetimibe	ezetimibe	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
nursing	nursing	NN	B-NP	O	O
pups	pup	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
half	half	NN	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
maternal	maternal	JJ	B-NP	B-cell_type	O
plasma	plasma	NN	I-NP	I-cell_type	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
ezetimibe	ezetimibe	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	O
milk	milk	NN	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
nursing	nurse	VBG	B-VP	O	O
mothers	mother	NNS	B-NP	O	O
unless	unless	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
justifies	justify	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
infant	infant	NN	I-NP	O	O
.	.	.	O	O	O

Pediatric	Pediatric	JJ	B-NP	O	O
Use	Use	NN	I-NP	O	O
The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
adolescents	adolescent	NNS	B-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
to	to	TO	I-NP	O	O
18	18	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	B-cell_type	O
population	population	NN	I-NP	I-cell_type	O
is	be	VBZ	B-VP	O	O
limited	limit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
4	4	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
to	to	TO	I-NP	O	O
17	17	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sitosterolemia	sitosterolemia	NN	I-NP	O	O
study	study	NN	I-NP	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
11	11	CD	B-NP	O	O
to	to	TO	I-NP	O	O
17	17	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
HoFH	HoFH	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
(	(	(	O	O	O
<	<	SYM	B-NP	O	O
10	10	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Geriatric	Geriatric	JJ	B-NP	O	O
Use	Use	NN	I-NP	O	O
Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
948	948	CD	B-NP	O	O
were	be	VBD	B-VP	O	O
65	65	CD	B-NP	O	O
and	and	CC	O	O	O
older	old	JJR	B-ADJP	O	O
(	(	(	O	O	O
this	this	DT	B-NP	O	O
included	include	VBD	B-VP	O	O
206	206	CD	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
75	75	CD	B-NP	O	O
and	and	CC	O	O	O
older	old	JJR	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZETIA	ZETIA	NN	B-NP	B-protein	S-brand
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
between	between	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
younger	young	JJR	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Greater	Greater	JJ	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
older	old	JJR	I-NP	O	O
individuals	individual	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
ruled	rule	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
.	.	.	O	O	O

Clinically	Clinically	RB	B-ADVP	O	O
or	or	CC	I-ADVP	O	O
potentially	potentially	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
classes	class	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
detail	detail	NN	I-NP	O	O
below	below	IN	B-PP	O	O
:	:	:	O	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
classes	class	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
detail	detail	NN	I-NP	O	O
below	below	IN	B-PP	O	O
:	:	:	O	O	O
Oral	Oral	JJ	B-NP	O	O
hypoglycemics	hypoglycemic	NNS	I-NP	O	S-group
,	,	,	O	O	O
Coumarin	Coumarin	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
type	type	NN	I-NP	O	I-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
,	,	,	O	O	O
Phenytoin	Phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
Rifampin	Rifampin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
Theophylline	Theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
Terfenadine	Terfenadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
Cisapride	Cisapride	NN	B-NP	O	S-drug
,	,	,	O	O	O
Astemizole	Astemizole	NN	B-NP	O	S-drug
,	,	,	O	O	O
Rifabutin	Rifabutin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
Tacrolimus	Tacrolimus	NNP	B-NP	O	S-drug
,	,	,	O	O	O
Short	Short	NNP	B-NP	O	B-group
-	-	HYPH	B-VP	O	I-group
acting	act	VBG	B-NP	O	I-group
benzodiazepines	benzodiazepine	NNS	I-NP	O	E-group
,	,	,	O	O	O
Oral	Oral	JJ	B-NP	O	O
hypoglycemics	hypoglycemic	NNS	I-NP	O	S-group
:	:	:	O	O	O
Clinically	Clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
precipitated	precipitate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O

one	one	CD	B-NP	O	O
fatality	fatality	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
DIFLUCAN	DIFLUCAN	NN	I-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
glyburide	glyburide	NN	I-NP	O	S-drug-EF-2
use	use	NN	I-NP	O	O
.	.	.	O	O	O

DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-ME-1
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
glipizide	glipizide	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-AD-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
or	or	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	B-group-AD-2
oral	oral	JJ	I-NP	O	I-group-AD-2
hypoglycemic	hypoglycemic	JJ	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Coumarin	Coumarin	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
type	type	NN	I-NP	O	I-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
:	:	:	O	O	O
Prothrombin	Prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
DIFLUCAN	DIFLUCAN	NN	I-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group-EF-2
-	-	HYPH	B-NP	O	I-group-EF-2
type	type	NN	I-NP	O	I-group-EF-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
marketing	marketing	NN	B-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
azole	azole	NN	I-NP	O	B-group
antifungals	antifungal	NNS	I-NP	O	E-group
,	,	,	O	O	O
bleeding	bleed	VBG	B-VP	O	O
events	event	NNS	B-NP	O	O
(	(	(	O	O	O
bruising	bruising	NN	B-NP	O	O
,	,	,	O	O	O
epistaxis	epistaxis	NN	B-NP	O	O
,	,	,	O	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
,	,	,	O	O	O
hematuria	hematuria	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
melena	melena	NN	B-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-EF-1
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
type	type	NN	I-NP	O	I-group-AD-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
See	See	NN	B-NP	O	O
<	<	SYM	O	O	O
a	a	DT	B-NP	O	O
href	href	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
``	``	``	O	O	O
flucon_cp.htm	flucon_cp.htm	NN	B-NP	O	O
#	#	#	I-NP	O	O
CP	CP	NN	I-NP	B-DNA	O
``	``	``	O	O	O
>	>	SYM	B-NP	O	O
CLINICAL	CLINICAL	NN	I-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
:	:	:	O	O	O
Drug	Drug	NNP	B-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Studies	Studies	NNP	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
See	See	NN	B-NP	O	O
<	<	SYM	O	O	O
a	a	DT	B-NP	O	O
href	href	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
``	``	``	O	O	O
flucon_cp.htm	flucon_cp.htm	NN	B-NP	O	O
#	#	#	I-NP	O	O
CP	CP	NN	I-NP	B-DNA	O
``	``	``	O	O	O
>	>	SYM	B-NP	O	O
CLINICAL	CLINICAL	NN	I-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
:	:	:	O	O	O
Drug	Drug	NNP	B-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Studies	Studies	NNP	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-ME-1
may	may	MD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

(	(	(	O	O	O
See	See	VB	B-VP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
:	:	:	O	O	O
Drug	Drug	NNP	B-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Studies	Studies	NNP	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

Rifampin	Rifampin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Rifampin	Rifampin	NN	B-NP	B-protein	S-drug-ME-1
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concurrently	concurrently	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
DIFLUCAN	DIFLUCAN	NN	I-NP	O	S-brand-ME-2
.	.	.	O	O	O

Depending	Depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
circumstances	circumstance	NNS	I-NP	O	O
,	,	,	O	O	O
consideration	consideration	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-AD-1
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Terfenadine	Terfenadine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QTc	QTc	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
azole	azole	NN	B-NP	O	B-group-EF-1
antifungals	antifungal	NNS	I-NP	O	E-group-EF-1
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
interaction	interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
study	study	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
200	200	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
a	a	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

Another	Another	DT	B-NP	O	O
study	study	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
400	400	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
800	800	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
DIFLUCAN	DIFLUCAN	NN	B-NP	O	S-brand-ME-1
taken	take	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
or	or	CC	O	O	O
greater	great	JJR	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
increases	increase	VBZ	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-2
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-AD-1
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	O	O	O
greater	great	JJR	B-ADJP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-AD-1
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Cisapride	Cisapride	NN	B-NP	O	S-drug
:	:	:	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
torsade	torsade	FW	B-NP	O	O
de	de	FW	I-NP	O	O
pointes	pointe	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
whom	whom	WP	B-NP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
cisapride	cisapride	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug-ME-1
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
and	and	CC	O	O	O
cisapride	cisapride	VBP	B-VP	O	S-drug-ME-2
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
four	four	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
yielded	yield	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
prolongation	prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Astemizole	Astemizole	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-1
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-ME-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
elevations	elevation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
definitive	definitive	JJ	B-NP	O	O
information	information	NN	I-NP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministering	coadministere	VBG	B-VP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Rifabutin	Rifabutin	NN	B-NP	O	S-drug
:	:	:	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
uveitis	uveitis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
whom	whom	WP	B-NP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
rifabutin	rifabutin	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug-AD-2
concomitantly	concomitantly	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Tacrolimus	Tacrolimus	NN	B-NP	O	S-drug
:	:	:	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
whom	whom	WP	B-NP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
fluconazole	fluconazole	NN	I-NP	O	S-drug-AD-2
concomitantly	concomitantly	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Short	Short	JJ	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
acting	act	VBG	I-NP	O	I-group
Benzodiazepines	Benzodiazepine	NNS	I-NP	O	E-group
:	:	:	O	O	O
Following	Follow	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
substantial	substantial	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
psychomotor	psychomotor	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-EF-1
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
following	follow	VBG	B-PP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-EF-2
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
administered	administer	VBN	B-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
short	short	JJ	B-ADJP	O	B-group-AD-1
-	-	HYPH	O	O	I-group-AD-1
acting	act	VBG	B-NP	O	I-group-AD-1
benzodiazepines	benzodiazepine	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
concomitantly	concomitantly	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
consideration	consideration	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
decreasing	decrease	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
appropriately	appropriately	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Fluconazole	Fluconazole	NN	B-NP	O	S-drug-ME-1
tablets	tablet	NNS	I-NP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug-ME-2
estradiol	estradiol	NN	I-NP	O	E-drug-ME-2
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
levonorgestrel	levonorgestrel	NN	I-NP	O	S-drug-ME-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
mean	mean	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
levonorgestrel	levonorgestrel	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
decreases	decrease	VBZ	B-VP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
47	47	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
levonorgestrel	levonorgestrel	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
presently	presently	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
individual	individual	JJ	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
and	and	CC	O	O	O
levonorgestrel	levonorgestrel	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
likely	likely	RB	B-ADJP	O	O
the	the	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
random	random	JJ	B-NP	O	O
variation	variation	NN	I-NP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
evidence	evidence	NN	B-NP	O	O
that	that	IN	B-SBAR	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-1
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug-ME-2
estradiol	estradiol	NN	I-NP	O	E-drug-ME-2
and	and	CC	I-NP	O	O
levonorgestrel	levonorgestrel	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
net	net	JJ	I-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
or	or	CC	O	O	O
levonorgestrel	levonorgestrel	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
presently	presently	RB	B-ADJP	O	O
unknown	unknown	JJ	I-ADJP	O	O
.	.	.	O	O	O

Physicians	Physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
interaction	interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
listed	list	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
<	<	SYM	I-NP	O	O
a	a	DT	B-NP	O	O
href	href	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
``	``	``	O	O	O
flucon_cp.htm	flucon_cp.htm	NN	B-NP	O	O
#	#	#	I-NP	O	O
CP	CP	NN	I-NP	B-DNA	O
``	``	``	O	O	O
>	>	SYM	B-NP	O	O
CLINICAL	CLINICAL	JJ	I-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
section	section	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
such	such	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

You	You	PRP	B-NP	B-protein	O
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
take	take	VB	I-VP	O	O
mazindol	mazindol	NN	B-NP	O	S-drug-AD-1
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
taken	take	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
monoamine	monoamine	NN	I-NP	O	B-group-AD-2
oxidase	oxidase	NN	I-NP	O	I-group-AD-2
inhibitor	inhibitor	NN	I-NP	O	E-group-AD-2
(	(	(	O	O	O
MAOI	MAOI	NN	B-NP	O	S-group-AD-2
)	)	)	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
isocarboxazid	isocarboxazid	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
Marplan	Marplan	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
tranylcypromine	tranylcypromine	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
Parnate	Parnate	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
phenelzine	phenelzine	NN	B-NP	O	S-drug-AD-2
(	(	(	O	O	O
Nardil	Nardil	NN	B-NP	O	S-brand-AD-2
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
14	14	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-AD-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
diabetes	diabetes	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
mazindol	mazindol	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Mazindol	Mazindol	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
Ismelin	Ismelin	NN	B-NP	B-protein	S-brand-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
could	could	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Tell	Tell	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Before	Before	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
,	,	,	O	O	O
tell	tell	VB	B-VP	O	O
your	your	PRP$	B-NP	O	O
doctor	doctor	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
you	you	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	B-group
antidepressant	antidepressant	NN	I-NP	O	E-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug
(	(	(	O	O	O
Elavil	Elavil	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
amoxapine	amoxapine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Asendin	Asendin	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
doxepin	doxepin	NN	B-NP	O	S-drug
(	(	(	O	O	O
Sinequan	Sinequan	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
nortriptyline	nortriptyline	NN	B-NP	O	S-drug
(	(	(	O	O	O
Pamelor	Pamelor	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
imipramine	imipramine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Tofranil	Tofranil	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
clomipramine	clomipramine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Anafranil	Anafranil	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
protriptyline	protriptyline	NN	B-NP	O	S-drug
(	(	(	O	O	O
Vivactil	Vivactil	NN	B-NP	O	S-brand
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
desipramine	desipramine	NN	B-NP	O	S-drug
(	(	(	O	O	O
Norpramin	Norpramin	NN	B-NP	O	S-brand
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mazindol	mazindol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Preliminary	Preliminary	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
mebendazole	mebendazole	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mebendazole	mebendazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
antibiotics	antibiotic	NNS	B-NP	O	S-group-AD-1
and	and	CC	I-NP	O	O
sulfonamides	sulfonamide	NNS	I-NP	O	S-group-AD-1
generally	generally	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ganglion	ganglion	NN	B-NP	O	B-group-AD-2
blockers	blocker	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mecamylamine	Mecamylamine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
and	and	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
depo	depo	AFX	B-NP	O	B-brand
-	-	HYPH	I-NP	O	I-brand
subQ	subQ	NN	I-NP	O	I-brand
provera	provera	NN	I-NP	O	I-brand
104	104	CD	I-NP	O	E-brand
.	.	.	O	O	O

Aminoglutethimide	Aminoglutethimide	NN	B-NP	O	S-drug-ME-1
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
depo	depo	AFX	B-NP	O	B-brand-ME-2
-	-	HYPH	I-NP	O	I-brand-ME-2
subQ	subQ	NN	I-NP	O	I-brand-ME-2
provera	provera	NN	I-NP	O	I-brand-ME-2
104	104	CD	I-NP	O	E-brand-ME-2
may	may	MD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MPA	MPA	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Laboratory	Laboratory	NN	B-NP	O	O
Tests	Test	VBZ	B-VP	O	O
The	The	DT	B-NP	O	O
pathologist	pathologist	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
progestin	progestin	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
relevant	relevant	JJ	B-NP	O	O
specimens	specimen	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
submitted	submit	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
informed	inform	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
certain	certain	JJ	B-NP	O	O
endocrine	endocrine	NN	I-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
blood	blood	NN	B-NP	B-protein	O
components	component	NNS	I-NP	I-protein	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
progestin	progestin	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
(	(	(	B-LST	O	O
a	a	LS	I-LST	O	O
)	)	)	O	O	O
Plasma	Plasma	NN	B-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
steroid	steroid	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
progesterone	progesterone	NN	B-NP	O	O
,	,	,	O	O	O
estradiol	estradiol	NN	B-NP	O	O
,	,	,	O	O	O
pregnanediol	pregnanediol	NN	B-NP	O	O
,	,	,	O	O	O
testosterone	testosterone	NN	B-NP	O	O
,	,	,	O	O	O
cortisol	cortisol	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

(	(	(	O	O	O
b	b	NN	B-NP	O	O
)	)	)	O	O	O
Plasma	Plasma	NN	B-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
gonadotropin	gonadotropin	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
LH	LH	NN	B-NP	O	O
,	,	,	O	O	O
FSH	FSH	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

(	(	(	O	O	O
c	c	NN	B-NP	O	O
)	)	)	O	O	O
SHBG	SHBG	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

(	(	(	B-LST	O	O
d	d	LS	I-LST	O	O
)	)	)	O	O	O
T3	T3	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
e	e	NN	B-NP	O	O
)	)	)	O	O	O
There	There	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
coagulation	coagulation	NN	B-NP	B-protein	O
factors	factor	NNS	I-NP	I-protein	O
.	.	.	O	O	O

(	(	(	B-LST	O	O
f	f	LS	I-LST	O	O
)	)	)	O	O	O
Sulfobromophthalein	Sulfobromophthalein	NN	B-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
test	test	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
slightly	slightly	RB	B-ADVP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
g	g	NN	B-NP	O	O
)	)	)	O	O	O
There	There	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
profiles	profile	NNS	I-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	O	S-drug
to	to	TO	B-VP	O	O
warrant	warrant	VB	I-VP	O	O
dosage	dosage	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
megestrol	megestrol	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
megestrol	megestrol	NN	B-NP	O	B-drug-ME-1
acetate	acetate	NN	I-NP	O	E-drug-ME-1
and	and	CC	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-ME-2
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
(	(	(	O	O	O
~	~	NN	B-NP	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
~	~	NN	I-NP	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
for	for	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
coadministering	coadministere	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
megestrol	megestrol	NN	B-NP	O	B-drug-AD-2
acetate	acetate	NN	I-NP	O	E-drug-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
rifabutin	rifabutin	NN	I-NP	B-protein	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
megestrol	megestrol	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Melatonin	Melatonin	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-IN-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-IN-2
(	(	(	O	O	O
may	may	MD	B-VP	O	O
lower	lower	VB	I-VP	O	O
melatonin	melatonin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
bioavailability	bioavailability	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
melatonin	melatonin	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
beta	beta	NN	B-NP	O	B-group-IN-2
blockers	blocker	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
melatonin	melatonin	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-IN-2
(	(	(	O	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
psychotic	psychotic	JJ	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
progestin	progestin	NN	B-NP	O	S-group-IN-2
(	(	(	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
melatonin	melatonin	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
progestin	progestin	NN	B-NP	O	S-group-EF-2
can	can	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
ovarian	ovarian	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
benzodiazepenes	benzodiazepene	NNS	B-NP	O	S-group-IN-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
sedating	sedate	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-IN-2
(	(	(	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
melatonin	melatonin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group
)	)	)	O	O	O
.	.	.	O	O	O

ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
Reports	Report	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B-protein	B-group-EF-2
-	-	HYPH	O	I-protein	I-group-EF-2
converting	convert	VBG	B-VP	I-protein	I-group-EF-2
enzyme	enzyme	NN	B-NP	I-protein	I-group-EF-2
(	(	(	O	O	I-group-EF-2
ACE	ACE	NN	B-NP	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
inhibitors	inhibitor	NNS	B-NP	O	E-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
consideration	consideration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-1
(	(	(	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
TID	TID	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
tended	tend	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Cmax	Cmax	NN	B-NP	O	O
(	(	(	O	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-1
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
generally	generally	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
MOBIC	MOBIC	NN	B-NP	O	S-brand-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MOBIC	MOBIC	NN	B-NP	O	S-brand
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

MOBIC	MOBIC	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substitute	substitute	NN	I-NP	O	O
for	for	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
for	for	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Pretreatment	Pretreatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
four	four	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-ME-1
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
t1	t1	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
19.2	19.2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
12.5	12.5	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
35	35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AUC	AUC	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
existence	existence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
recirculation	recirculation	NN	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
for	for	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug
QID	QID	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
meloxicam	meloxicam	NN	I-NP	O	S-drug
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Meloxicam	Meloxicam	NNP	B-NP	O	S-drug
15	15	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
after	after	IN	B-PP	O	O
b	b	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
acetyldigoxin	acetyldigoxin	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
testing	testing	NN	I-NP	O	O
found	find	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
meloxicam	meloxicam	NN	I-NP	O	S-drug
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
post	post	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
marketing	market	VBG	B-VP	O	O
observations	observation	NNS	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natriuretic	natriuretic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group-EF-2
diuretics	diuretic	NNS	I-NP	O	E-group-EF-2
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
natriuretic	natriuretic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Furosemide	Furosemide	NN	B-NP	O	S-drug
:	:	:	O	O	O
single	single	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
multiple	multiple	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
MOBIC	MOBIC	NN	I-NP	O	S-brand-AD-2
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
declining	decline	VBG	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
to	to	TO	B-VP	O	O
assure	assure	VB	I-VP	O	O
diuretic	diuretic	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
produced	produce	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
conducted	conduct	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
pre	pre	AFX	I-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-ME-1
doses	dose	NNS	I-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
804	804	CD	B-NP	O	O
to	to	TO	I-NP	O	O
1072	1072	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
with	with	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug-ME-2
15	15	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
QD	QD	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
MOBIC	MOBIC	NN	B-NP	O	S-brand
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-1
treatment	treatment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
MOBIC	MOBIC	NN	B-NP	O	S-brand-AD-2
is	be	VBZ	B-VP	O	O
introduced	introduce	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

Methotrexate	Methotrexate	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
13	13	CD	B-NP	O	O
rheumatoid	rheumatoid	JJ	I-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
(	(	(	O	O	O
RA	RA	NN	B-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
taken	take	VBN	B-VP	O	O
once	once	RB	B-ADVP	O	O
weekly	weekly	RB	I-ADVP	O	O
.	.	.	O	O	O

Meloxicam	Meloxicam	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
displace	displace	VB	I-VP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
human	human	JJ	I-NP	B-DNA	O
serum	serum	NN	I-NP	I-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Anticoagulant	Anticoagulant	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
few	few	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
or	or	CC	I-VP	O	O
changing	change	VBG	I-VP	O	O
MOBIC	MOBIC	NN	B-NP	O	S-brand-AD-1
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
similar	similar	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
daily	daily	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
that	that	WDT	B-NP	O	O
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
(	(	(	O	O	O
International	International	NNP	B-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
)	)	)	O	O	O
between	between	IN	B-PP	O	O
1.2	1.2	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1.8	1.8	CD	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
meloxicam	meloxicam	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
as	as	IN	B-SBAR	O	O
determined	determine	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
subject	subject	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
from	from	IN	B-PP	O	O
1.5	1.5	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2.1	2.1	CD	B-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
MOBIC	MOBIC	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
since	since	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
experience	experience	VB	I-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
complications	complication	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
introduced	introduce	VBN	I-VP	O	O
.	.	.	O	O	O

DRUG	DRUG	NN	B-NP	O	O
INTERACTIONS	INTERACTIONS	NNS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
ALKERAN	ALKERAN	NN	I-NP	O	S-brand
Vaccinations	Vaccination	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
live	live	JJ	B-NP	O	B-group
organism	organism	NN	I-NP	O	I-group
vaccines	vaccine	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
immunocompromised	immunocompromised	JJ	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
Nalidixic	Nalidixic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
melphalan	melphalan	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
caused	cause	VBN	I-VP	O	O
deaths	death	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
haemorrhagic	haemorrhagic	JJ	B-NP	O	O
enterocolitis	enterocolitis	NN	I-NP	O	O
.	.	.	O	O	O

Impaired	Impaired	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
conditioned	condition	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
melphalan	melphalan	NN	I-NP	O	S-drug-EF-1
and	and	CC	O	O	O
who	who	WP	B-NP	O	O
subsequently	subsequently	RB	B-VP	O	O
received	receive	VBD	I-VP	O	O
cyclosporin	cyclosporin	NN	B-NP	O	S-drug-EF-2
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
graft	graft	NN	B-NP	O	O
-	-	HYPH	B-ADVP	O	O
versus	versus	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
host	host	NN	I-NP	O	O
disease	disease	NN	I-NP	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
certain	certain	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
or	or	CC	O	O	O
side	side	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
:	:	:	O	O	O
amantadine	amantadine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
antiarrhythmic	antiarrhythmic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	I-group-EF-2
of	of	IN	B-PP	O	I-group-EF-2
class	class	NN	B-NP	O	I-group-EF-2
I	I	CD	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
antipsychotic	antipsychotic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
MAO	MAO	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
narcotic	narcotic	JJ	B-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
meperidine	meperidine	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
nitrates	nitrate	NNS	B-NP	O	S-group-EF-2
and	and	CC	I-NP	O	O
nitrites	nitrite	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
having	have	VBG	B-VP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Anticholinergics	Anticholinergic	NNS	B-NP	O	S-group-EF-1
antagonize	antagonize	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antiglaucoma	antiglaucoma	NN	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
intraocular	intraocular	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
hazardous	hazardous	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
slowly	slowly	RB	B-VP	O	O
dissolving	dissolve	VBG	I-VP	O	O
dosage	dosage	NN	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
antacids	antacid	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
simultaneous	simultaneous	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
inhibiting	inhibit	VBG	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
hydrochloric	hydrochloric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
achlorhydria	achlorhydria	NN	B-NP	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
test	test	VB	I-VP	O	O
gastric	gastric	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Other	Other	NNP	B-NP	O	O
Central	Central	NNP	I-NP	O	B-group
Nervous	Nervous	NNP	I-NP	O	I-group
System	System	NNP	I-NP	O	I-group
Depressants	Depressant	NNPS	I-NP	O	E-group
:	:	:	O	O	O
MEPERIDINE	MEPERIDINE	NN	B-NP	O	S-drug-AD-1
SHOULD	SHOULD	NN	I-NP	O	O
BE	BE	NN	I-NP	O	O
USED	USED	VBD	B-VP	O	O
WITH	WITH	NN	B-NP	O	O
GREAT	GREAT	NN	I-NP	O	O
CAUTION	CAUTION	NN	I-NP	O	O
AND	AND	CC	B-PP	O	O
IN	IN	IN	B-PP	O	O
REDUCED	REDUCED	NNP	B-NP	O	O
DOSAGE	DOSAGE	NNP	I-NP	O	O
IN	IN	NNP	I-NP	O	O
PATIENTS	PATIENTS	NNP	I-NP	O	O
WHO	WHO	NNP	I-NP	O	O
ARE	ARE	NNP	I-NP	O	O
CONCURRENTLY	CONCURRENTLY	NNP	I-NP	O	O
RECEIVING	RECEIVING	NNP	I-NP	O	O
OTHER	OTHER	NNP	I-NP	O	O
NARCOTIC	NARCOTIC	NNP	I-NP	O	B-group-AD-2
ANALGESICS	ANALGESICS	NNP	I-NP	O	E-group-AD-2
,	,	,	O	O	O
GENERAL	GENERAL	NNP	B-NP	O	O
ANESTHETICS	ANESTHETICS	NNP	I-NP	O	S-group-AD-2
,	,	,	O	O	O
PHENOTHIAZINES	PHENOTHIAZINES	NNP	B-NP	O	S-group-AD-2
,	,	,	O	O	O
OTHER	OTHER	NNP	B-NP	O	O
TRANQUILIZERS	TRANQUILIZERS	NNP	I-NP	O	S-group-AD-2
,	,	,	O	O	O
SEDATIVE	SEDATIVE	NNP	B-NP	O	B-group-AD-2
-	-	HYPH	O	O	I-group-AD-2
HYPNOTICS	HYPNOTICS	NN	B-NP	O	E-group-AD-2
(	(	(	O	O	O
INCLUDING	INCLUDING	NN	B-NP	O	O
BARBITURATES	BARBITURATES	NNS	I-NP	O	S-group-AD-2
)	)	)	O	O	O
,	,	,	O	O	O
TRICYCLIC	TRICYCLIC	NN	B-NP	B-protein	B-group-AD-2
ANTIDEPRESSANTS	ANTIDEPRESSANTS	NNS	I-NP	I-protein	E-group-AD-2
AND	AND	CC	O	O	O
OTHER	OTHER	NN	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-AD-2
DEPRESSANTS	DEPRESSANTS	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
INCLUDING	INCLUDING	NN	B-NP	O	O
ALCOHOL	ALCOHOL	NN	I-NP	O	S-drug-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

RESPIRATORY	RESPIRATORY	NN	B-NP	O	O
DEPRESSION	DEPRESSION	NN	I-NP	O	O
,	,	,	O	O	O
HYPOTENSION	HYPOTENSION	NN	B-NP	O	O
,	,	,	O	O	O
AND	AND	CC	O	O	O
PROFOUND	PROFOUND	NNP	B-NP	O	O
SEDATION	SEDATION	NNP	I-NP	O	O
OR	OR	NNP	I-NP	O	O
COMA	COMA	NNP	I-NP	O	O
MAY	MAY	NNP	I-NP	O	O
RESULT	RESULT	NNP	I-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
anticonvulsants	anticonvulsant	NNS	I-NP	O	S-group-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
Mephenytoin	Mephenytoin	NN	B-NP	B-protein	S-drug-IN-2
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
can	can	MD	B-VP	O	O
either	either	CC	I-VP	O	O
increase	increase	VB	I-VP	O	O
or	or	CC	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mephenytoin	Mephenytoin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Those	Those	DT	B-NP	O	O
anticonvulsants	anticonvulsant	NNS	I-NP	O	S-group
include	include	VBP	B-VP	O	O
divalproex	divalproex	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
.	.	.	O	O	O

Mephenytoin	Mephenytoin	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
include	include	VBP	B-VP	O	O
some	some	DT	B-NP	O	O
steroid	steroid	JJ	I-NP	O	B-group-EF-2
medications	medication	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
,	,	,	O	O	O
birth	birth	NN	B-NP	O	O
control	control	NN	I-NP	O	O
pills	pill	NNS	I-NP	O	O
,	,	,	O	O	O
anti	anti	AFX	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
infective	infective	JJ	B-NP	O	I-group-EF-2
medicines	medicine	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-EF-2
Please	Please	NN	I-NP	O	O
note	note	NN	I-NP	O	O
that	that	IN	B-NP	O	O
Mephenytoin	Mephenytoin	NN	B-NP	B-protein	S-drug
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
listed	list	VBN	I-VP	O	O
here	here	RB	B-ADVP	O	O
.	.	.	O	O	O

Mequitazine	Mequitazine	NN	B-NP	O	S-drug-IN-1
can	can	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
CNS	CNS	NN	B-NP	B-protein	B-group-IN-2
depressant	depressant	NN	I-NP	O	E-group-IN-2
,	,	,	O	O	O
antichlolinergic	antichlolinergic	JJ	B-NP	O	S-group-IN-2
,	,	,	I-NP	O	O
TCA	TCA	NN	I-NP	B-protein	S-group-IN-2
,	,	,	O	O	O
MAOIs	MAOI	NNS	B-NP	B-protein	S-group-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
competes	compete	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
meropenem	meropenem	NN	B-NP	O	S-drug-ME-2
for	for	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
and	and	CC	O	O	O
thus	thus	RB	B-VP	O	O
inhibits	inhibit	VBZ	I-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meropenem	meropenem	NN	B-NP	O	S-drug
.	.	.	O	O	O

This	This	DT	B-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
statistically	statistically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
(	(	(	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
56	56	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
meropenem	meropenem	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
evidence	evidence	NN	B-NP	O	O
that	that	IN	B-SBAR	O	O
meropenem	meropenem	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
valproic	valproic	JJ	B-NP	O	B-drug-ME-2
acid	acid	NN	I-NP	O	E-drug-ME-2
to	to	TO	B-PP	O	O
subtherapeutic	subtherapeutic	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
range	range	NN	I-NP	O	O
considered	consider	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
50	50	CD	B-NP	O	O
to	to	TO	I-NP	O	O
100	100	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
mL	mL	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
valproate	valproate	NN	I-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

ARAMINE	ARAMINE	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
digitalized	digitalized	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-2
amines	amine	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
ectopic	ectopic	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	O	B-group-EF-1
oxidase	oxidase	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
or	or	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-2
amines	amine	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
pressor	pressor	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
and	and	CC	O	O	O
given	give	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

SKELAXIN	SKELAXIN	NN	B-NP	B-protein	S-brand-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Methazolamide	Methazolamide	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
steroid	steroid	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
methazolamide	methazolamide	NN	I-NP	O	S-drug-AD-2
concomitantly	concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
anorexia	anorexia	NN	B-NP	O	O
,	,	,	O	O	O
tachypnea	tachypnea	NN	B-NP	O	O
,	,	,	O	O	O
lethargy	lethargy	NN	B-NP	O	O
,	,	,	O	O	O
coma	coma	NN	B-NP	O	O
and	and	CC	I-NP	O	O
death	death	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-1
and	and	CC	O	O	O
carbonic	carbonic	JJ	B-NP	O	B-group-EF-2
anhydrase	anhydrase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
(	(	(	O	O	O
oral	oral	JJ	B-ADJP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
K	K	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
attributed	attribute	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
methimazole	methimazole	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	B-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
:	:	:	O	O	O
Hyperthyroidism	Hyperthyroidism	NN	B-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
hyperthyroid	hyperthyroid	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
becomes	become	VBZ	B-VP	O	O
euthyroid	euthyroid	JJ	B-ADJP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	B-group
glycosides	glycoside	VBZ	B-VP	O	E-group
:	:	:	O	O	O
Serum	Serum	NN	B-NP	O	O
digitalis	digitalis	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
hyperthyroid	hyperthyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
digitalis	digitalis	NN	I-NP	O	B-group
glycoside	glycoside	NN	I-NP	O	E-group
regimen	regimen	NN	I-NP	O	O
become	become	VBP	B-VP	O	O
euthyroid	euthyroid	JJ	B-ADJP	O	O
;	;	:	O	O	O

reduced	reduce	VBN	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	B-group
glycosides	glycoside	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	O	S-drug
:	:	:	O	O	O
Theophylline	Theophylline	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
hyperthyroid	hyperthyroid	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
regimen	regimen	NN	I-NP	O	O
become	become	VBP	B-VP	O	O
euthyroid	euthyroid	JJ	B-ADJP	O	O
;	;	:	O	O	O

a	a	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Dosages	Dosage	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
opioids	opioid	NNS	I-NP	O	S-group-EF-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
half	half	NN	I-NP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
levomepromazine	levomepromazine	NN	B-NP	O	S-drug-EF-M
amplifies	amplify	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
side	side	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
opioids	opioid	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
tramadol	tramadol	NN	B-NP	O	S-drug
(	(	(	O	O	O
Ultram	Ultram	NN	B-NP	O	S-brand
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	O
.	.	.	O	O	O

Additive	Additive	JJ	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
confusional	confusional	JJ	B-NP	O	O
states	state	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
emerge	emerge	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
levomepromazine	levomepromazine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group-EF-2
or	or	CC	I-NP	O	O
barbiturates	barbiturate	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
lowest	low	JJS	I-NP	O	O
dose	dose	NN	I-NP	O	O
possible	possible	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substances	substance	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
question	question	NN	B-NP	O	O
.	.	.	O	O	O

Exert	Exert	JJ	B-NP	O	O
particular	particular	JJ	I-NP	O	O
caution	caution	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combining	combine	VBG	B-VP	O	O
levomepromazine	levomepromazine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
and	and	CC	O	O	O
antiparkinsonian	antiparkinsonian	JJ	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
:	:	:	O	O	O
Particularly	Particularly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
delirium	delirium	NN	B-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
fever	fever	NN	I-NP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
obstipation	obstipation	NN	I-NP	O	O
,	,	,	O	O	O
even	even	RB	B-NP	O	O
ileus	ileus	NN	I-NP	O	O
and	and	CC	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	O
.	.	.	O	O	O

Reduce	Reduce	NNP	B-NP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levomepromazine	levomepromazine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
avoid	avoid	VB	B-VP	O	O
such	such	JJ	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
stimulantes	stimulante	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ephedrine	ephedrine	NN	I-NP	O	S-drug-EF-1
/	/	SYM	B-VP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug-EF-1
type	type	NN	I-NP	O	O
may	may	MD	B-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levomepromazine	levomepromazine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
substances	substance	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Coffee	Coffee	NN	B-NP	O	O
and	and	CC	I-NP	O	O
black	black	JJ	I-NP	O	O
tea	tea	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
decrease	decrease	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levomepromazine	levomepromazine	NN	B-NP	O	S-drug
considerably	considerably	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
is	be	VBZ	B-VP	O	O
true	true	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
;	;	:	O	O	O

these	these	DT	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
2	2	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
or	or	CC	I-PP	O	O
after	after	IN	I-PP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
leveomepromazine	leveomepromazine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
Celontin	Celontin	NN	B-NP	O	S-brand-AD-1
(	(	(	O	O	O
methsuximide	methsuximide	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
concurrently	concurrently	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
periodic	periodic	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
level	level	NN	I-NP	O	O
determinations	determination	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
(	(	(	O	O	O
eg	eg	NN	B-NP	O	O
methsuximide	methsuximide	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Hypokalemia	Hypokalemia	NN	B-NP	O	O
can	can	MD	B-VP	O	O
sensitize	sensitize	VB	I-VP	O	O
or	or	CC	I-VP	O	O
exaggerate	exaggerate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
irritability	irritability	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Hypokalemia	Hypokalemia	NN	B-NP	O	O
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
steroids	steroid	NNS	B-NP	O	S-group
or	or	CC	O	O	O
ACTH	ACTH	NN	B-NP	O	S-drug
.	.	.	O	O	O

Insulin	Insulin	NN	B-NP	O	S-drug
requirements	requirement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
decreased	decrease	VBN	B-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

Thiazides	Thiazide	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
arterial	arterial	JJ	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
diminution	diminution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
preclude	preclude	VB	I-VP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Thiazide	Thiazide	NN	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug-ME-1
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
thiazides	thiazide	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Thiazides	Thiazide	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
add	add	VB	I-VP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
potentiate	potentiate	VB	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Potentiation	Potentiation	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
ganglionic	ganglionic	JJ	B-NP	O	S-group
or	or	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	B-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
blocking	blocking	NN	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
potentiation	potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
detect	detect	VB	I-VP	O	O
side	side	NN	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
or	or	CC	O	O	O
unusual	unusual	JJ	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
idiosyncrasy	idiosyncrasy	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
reduced	reduce	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-AD-1
when	when	WRB	B-ADVP	O	O
on	on	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
hypotension	hypotension	NN	B-NP	O	O
does	do	VBZ	B-VP	O	O
occur	occur	VB	I-VP	O	O
during	during	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
usually	usually	RB	B-ADVP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
controlled	control	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
vasopressors	vasopressor	NNS	B-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	B-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
remain	remain	VBP	B-VP	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Read	Read	VB	B-VP	O	O
the	the	DT	B-NP	O	O
circular	circular	JJ	I-NP	O	O
for	for	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-ME-1
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
ingested	ingest	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ferrous	ferrous	JJ	B-NP	O	B-drug-ME-2
sulfate	sulfate	NN	I-NP	O	E-drug-ME-2
or	or	CC	O	O	O
ferrous	ferrous	JJ	B-NP	O	B-drug-ME-2
gluconate	gluconate	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
adversely	adversely	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
control	control	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
ferrous	ferrous	JJ	B-NP	O	B-drug-AD-2
sulfate	sulfate	NN	I-NP	O	E-drug-AD-2
or	or	CC	O	O	O
ferrous	ferrous	JJ	B-NP	O	B-drug-AD-2
gluconate	gluconate	NN	I-NP	O	E-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Monoamine	Monoamine	NN	B-NP	B-protein	B-group
oxidase	oxidase	NN	I-NP	I-protein	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
:	:	:	O	O	O
See	See	VB	B-VP	O	O
CONTRAINDICATIONS	CONTRAINDICATIONS	NNS	B-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Methyldopa	Methyldopa	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
:	:	:	O	O	O
urinary	urinary	JJ	B-NP	O	O
uric	uric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
phosphotungstate	phosphotungstate	NN	I-NP	O	O
method	method	NN	I-NP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alkaline	alkaline	NN	I-NP	O	O
picrate	picrate	NN	I-NP	O	O
method	method	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
SGOT	SGOT	NN	B-NP	B-protein	O
by	by	IN	B-PP	O	O
colorimetric	colorimetric	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
.	.	.	O	O	O

Interference	Interference	NN	B-NP	O	O
with	with	IN	B-PP	O	O
spectrophotometric	spectrophotometric	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
SGOT	SGOT	NN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug
causes	cause	VBZ	B-VP	O	O
fluorescence	fluorescence	NN	B-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
wave	wave	NN	I-NP	O	O
lengths	length	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
,	,	,	O	O	O
falsely	falsely	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
catecholamines	catecholamine	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
will	will	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pheochromocytoma	pheochromocytoma	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
recognize	recognize	VB	I-VP	O	O
this	this	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
before	before	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
pheochromocytoma	pheochromocytoma	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
subjected	subject	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
.	.	.	O	O	O

Methyldopa	Methyldopa	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VMA	VMA	NN	B-NP	B-protein	S-drug_n
(	(	(	O	O	O
vanillylmandelic	vanillylmandelic	JJ	B-NP	O	B-drug_n
acid	acid	NN	I-NP	O	E-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
pheochromocytoma	pheochromocytoma	NN	B-NP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
those	those	DT	B-NP	O	O
methods	method	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
convert	convert	VBP	B-VP	O	O
VMA	VMA	NN	B-NP	B-protein	S-drug_n
to	to	TO	B-PP	O	O
vanillin	vanillin	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

Methyldopa	Methyldopa	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
pheochromocytoma	pheochromocytoma	NN	B-NP	O	O
.	.	.	O	O	O

Rarely	Rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
urine	urine	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
air	air	NN	B-NP	O	O
after	after	IN	B-PP	O	O
voiding	void	VBG	B-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
darken	darken	VB	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
breakdown	breakdown	NN	B-NP	O	O
of	of	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
.	.	.	O	O	O

CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
Inhibitors	Inhibitor	NNS	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
Macrolide	Macrolide	NNP	B-NP	O	B-group
Antibiotics	Antibiotics	NNP	I-NP	O	E-group
and	and	CC	O	O	O
Protease	Protease	NNP	B-NP	B-protein	B-group
Inhibitors	Inhibitor	NNPS	I-NP	O	E-group
)	)	)	O	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
rare	rare	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
connection	connection	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
ergot	ergot	NN	I-NP	O	B-group
alkaloid	alkaloid	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
potent	potent	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
vasospasm	vasospasm	NN	B-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	O
ischemia	ischemia	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
ischemia	ischemia	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extremities	extremity	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
methylergonovine	methylergonovine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
potent	potent	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
methylergonovine	methylergonovine	NN	B-NP	O	O
.	.	.	O	O	O

Examples	Example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
macrolide	macrolide	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
HIV	HIV	NN	B-NP	B-protein	B-group
protease	protease	NN	I-NP	I-protein	E-group
or	or	CC	O	O	O
reverse	reverse	JJ	B-NP	B-protein	B-group
transcriptase	transcriptase	NN	I-NP	I-protein	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
delavirdine	delavirdine	NN	B-NP	O	S-drug
)	)	)	O	O	O
or	or	CC	O	O	O
azole	azole	NN	B-NP	O	B-group
antifungals	antifungal	NNS	I-NP	O	E-group
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
voriconazole	voriconazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Less	Less	RBR	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP	CYP	NN	I-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Less	Less	RBR	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
zileuton	zileuton	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
clotrimazole	clotrimazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

These	These	DT	B-NP	O	O
lists	list	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
exhaustive	exhaustive	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
prescriber	prescriber	NN	I-NP	O	O
should	should	MD	B-VP	O	O
consider	consider	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
being	be	VBG	B-VP	O	O
considered	consider	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
methylergonovine	methylergonovine	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Methergine	Methergine	NN	B-NP	O	S-brand-AD-1
(	(	(	O	O	O
methylergonovine	methylergonovine	NN	B-NP	O	B-drug-AD-1
maleate	maleate	NN	I-NP	O	E-drug-AD-1
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
vasoconstrictors	vasoconstrictor	NNS	I-NP	O	S-group-AD-2
or	or	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group-AD-2
alkaloids	alkaloid	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Ritalin	Ritalin	NN	B-NP	B-protein	S-brand-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
pressor	pressor	NN	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Human	Human	JJ	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Ritalin	Ritalin	NN	B-NP	B-protein	S-brand-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-ME-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group-ME-2
(	(	(	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
primidone	primidone	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-ME-2
drugs	drug	NNS	I-NP	O	E-group-ME-2
(	(	(	O	O	O
imipramine	imipramine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clomipramine	clomipramine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
desipramine	desipramine	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Downward	Downward	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Ritalin	Ritalin	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Serious	Serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
causality	causality	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
methylphenidate	methylphenidate	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-ADJP	O	O
centrally	centrally	RB	B-VP	O	O
acting	act	VBG	I-VP	O	O
alpha	alpha	SYM	B-NP	O	B-group
-	-	HYPH	B-ADJP	O	I-group
2	2	CD	B-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systemically	systemically	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
listed	list	VBN	B-VP	O	O
below	below	IN	B-PP	O	O
are	be	VBP	B-VP	O	O
potentially	potentially	RB	B-ADJP	O	O
clinically	clinically	RB	I-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

Mutual	Mutual	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
methylprednisolone	methylprednisolone	NN	I-NP	O	S-drug-ME-2
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
individual	individual	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
apt	apt	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

convulsions	convulsion	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
cyclosporin	cyclosporin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-MU-1
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-MU-1
,	,	,	O	O	O
and	and	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-MU-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug-AD-2
dose	dose	NN	I-NP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
thus	thus	RB	B-ADVP	O	O
decrease	decrease	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
steroid	steroid	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Methylprednisolone	Methylprednisolone	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
could	could	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylate	salicylate	NN	B-NP	O	S-group-EF-1
toxicity	toxicity	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-AD-2
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
hypoprothrombinemia	hypoprothrombinemia	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
variable	variable	JJ	B-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
enhanced	enhance	VBN	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
diminished	diminish	VBN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulant	anticoagulant	NN	B-NP	O	S-group-EF-1
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
coagulation	coagulation	NN	B-NP	O	O
indices	index	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Methscopolamine	Methscopolamine	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group
(	(	(	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	S-group-IN-2
type	type	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
MAO	MAO	NN	B-NP	O	B-group-IN-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
phenelzine	phenelzine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
linezolid	linezolid	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
tranylcypromine	tranylcypromine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
isocarboxazid	isocarboxazid	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
selegiline	selegiline	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
furazolidone	furazolidone	NN	B-NP	O	S-drug-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
amantadine	amantadine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
diphenhydramine	diphenhydramine	NN	B-NP	O	S-drug-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
anticholinergics	anticholinergic	NNS	I-NP	O	S-group-IN-2
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	B-drug-IN-2
chloride	chloride	NN	I-NP	O	E-drug-IN-2
supplements	supplement	NNS	I-NP	O	O
,	,	,	O	O	O
antacids	antacid	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
absorbent	absorbent	JJ	B-NP	O	B-group-IN-2
-	-	HYPH	I-NP	O	I-group-IN-2
type	type	NN	I-NP	O	I-group-IN-2
anti	anti	AFX	B-NP	O	I-group-IN-2
-	-	HYPH	I-NP	O	I-group-IN-2
diarrhea	diarrhea	NN	B-NP	O	I-group-IN-2
medicines	medicine	NNS	I-NP	O	E-group-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
kaolin	kaolin	NN	B-NP	B-protein	S-drug-IN-2
-	-	HYPH	B-NP	I-protein	O
pectin	pectin	NN	I-NP	I-protein	S-drug-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
promethazine	promethazine	NN	B-NP	O	S-drug-IN-2
)	)	)	O	O	O
.	.	.	O	O	O

Methyprylon	Methyprylon	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
addictive	addictive	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
likelyhood	likelyhood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
addiction	addiction	NN	B-NP	O	O
and	and	CC	I-NP	O	O
abuse	abuse	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-EF-1
depression	depression	NN	I-NP	O	I-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
producing	produce	VBG	B-VP	O	I-group-EF-1
drugs	drug	NNS	B-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methyprylon	methyprylon	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
these	these	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

Methysergide	Methysergide	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
reverse	reverse	VB	I-VP	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
narcotic	narcotic	JJ	B-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
vasoconstrictor	vasoconstrictor	NN	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
including	include	VBG	B-PP	O	O
ergot	ergot	NN	B-NP	O	B-group
alkaloids	alkaloid	NNS	I-NP	O	E-group
,	,	,	O	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
nicotine	nicotine	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	I-NP	O	O
smoking	smoking	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
enhanced	enhance	VBN	B-NP	O	O
vasoconstriction	vasoconstriction	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-EF-1
on	on	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
narcotic	narcotic	JJ	B-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Additive	Additive	JJ	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-AD-1
releases	release	VBZ	B-VP	O	O
catecholamines	catecholamine	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
essential	essential	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
at	at	IN	B-ADVP	O	O
all	all	DT	I-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-AD-2
oxi	oxi	AFX	O	O	I-group-AD-2
-	-	HYPH	O	O	I-group-AD-2
dase	dase	NN	B-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stomach	stomach	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
diminished	diminish	VBN	I-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
by	by	IN	B-PP	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-ME-M
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
extent	extent	NN	B-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
bowel	bowel	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug
,	,	,	O	O	O
levodopa	levodopa	NN	B-NP	O	S-drug
,	,	,	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Gastroparesis	Gastroparesis	NN	B-NP	O	O
(	(	(	O	O	O
gastric	gastric	JJ	B-NP	O	O
stasis	stasis	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
poor	poor	JJ	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Exogenously	Exogenously	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
may	may	MD	B-VP	O	O
begin	begin	VB	I-VP	O	O
to	to	TO	I-VP	O	O
act	act	VB	I-VP	O	O
before	before	IN	B-SBAR	O	O
food	food	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
left	leave	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
stomach	stomach	NN	I-NP	O	O
and	and	CC	O	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
hypoglycemia	hypoglycemia	NN	B-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-AD-1
will	will	MD	B-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
delivery	delivery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
food	food	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
intestines	intestine	NNS	I-NP	O	O
and	and	CC	O	O	O
thus	thus	RB	O	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
,	,	,	O	O	O
insulin	insulin	NN	B-NP	O	S-drug-AD-2
dosage	dosage	NN	I-NP	O	O
or	or	CC	I-NP	O	O
timing	timing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
adjustment	adjustment	NN	B-NP	O	O
.	.	.	O	O	O

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Furosemide	Furosemide	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
probably	probably	RB	B-ADVP	O	O
other	other	JJ	B-NP	O	O
loop	loop	NN	I-NP	O	B-group-EF-1
diuretics	diuretic	NNS	I-NP	O	E-group-EF-1
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
metolazone	metolazone	NN	B-NP	O	S-drug-EF-2
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
unusually	unusually	RB	B-NP	O	O
large	large	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
losses	loss	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fluid	fluid	NN	B-NP	O	O
and	and	CC	I-NP	O	O
electrolytes	electrolyte	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Antihypertensives	Antihypertensive	NNS	I-NP	O	S-group
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
MYKROX	MYKROX	NN	B-NP	B-DNA	S-brand-AD-1
Tablets	Tablet	NNS	I-NP	I-DNA	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
care	care	NN	B-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antihypertensives	antihypertensive	NNS	I-NP	O	S-group
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
Barbiturates	Barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
Narcotics	Narcotic	NNS	B-NP	O	S-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
volume	volume	NN	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
metolazone	metolazone	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Digitalis	Digitalis	NNP	B-NP	O	B-group
Glycosides	Glycoside	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Diuretic	Diuretic	JJ	B-NP	O	S-group-EF-1
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
to	to	TO	B-PP	O	O
digitalis	digitalis	NN	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Serious	Serious	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group
or	or	CC	I-NP	O	O
ACTH	ACTH	NN	I-NP	O	S-drug
:	:	:	O	O	O
May	May	MD	B-VP	O	O
increase	increase	VBP	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	O
and	and	CC	I-NP	O	O
increase	increase	NN	I-NP	O	O
salt	salt	NN	I-NP	O	O
and	and	CC	O	O	O
water	water	NN	B-NP	O	O
retention	retention	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Serum	Serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
.	.	.	O	O	O

Curariform	Curariform	JJ	B-NP	O	B-group
Drugs	Drug	NNS	I-NP	O	E-group
:	:	:	O	O	O
Diuretic	Diuretic	JJ	B-ADJP	O	S-group-EF-1
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
blocking	blocking	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
curariform	curariform	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
tubocurarine	tubocurarine	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
serious	serious	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
respiratory	respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
proceed	proceed	VB	I-VP	O	O
to	to	TO	B-PP	O	O
apnea	apnea	NN	B-NP	O	O
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
MYKROX	MYKROX	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
three	three	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
elective	elective	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

Salicylates	Salicylate	NNS	B-NP	O	S-group-EF-1
and	and	CC	O	O	O
Other	Other	JJ	B-NP	O	O
Non	Non	NNP	I-NP	O	B-group-EF-1
-	-	HYPH	I-NP	O	I-group-EF-1
Steroidal	Steroidal	NNP	I-NP	O	I-group-EF-1
Anti	Anti	AFX	O	O	I-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
Inflammatory	Inflammatory	JJ	B-NP	O	I-group-EF-1
Drugs	Drug	NNS	I-NP	O	E-group-EF-1
:	:	:	O	O	O
May	May	MD	O	O	O
decrease	decrease	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MYKROX	MYKROX	NN	B-NP	B-protein	S-brand-EF-2
Tablets	Tablet	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Sympathomimetics	Sympathomimetic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Metolazone	Metolazone	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
arterial	arterial	JJ	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
but	but	CC	O	O	O
this	this	DT	B-NP	O	O
diminution	diminution	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
preclude	preclude	VB	I-VP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Methenamine	Methenamine	NN	B-NP	O	S-drug-EF-1
:	:	:	O	O	O
Efficacy	Efficacy	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
alkalizing	alkalize	VBG	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metolazone	metolazone	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
:	:	:	O	O	O
Metolazone	Metolazone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
other	other	JJ	B-NP	O	O
thiazide	thiazide	NN	I-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
like	like	JJ	I-NP	O	I-group
diuretics	diuretic	NNS	I-NP	O	E-group
,	,	,	O	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypoprothrombinemic	hypoprothrombinemic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-2
;	;	:	O	O	O

dosage	dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Catecholamine	Catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-PP	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
extended	extend	VBN	B-NP	O	O
release	release	NN	I-NP	O	O
metoprolol	metoprolol	NN	I-NP	O	B-drug
succinate	succinate	NN	I-NP	O	E-drug
plus	plus	CC	O	O	O
a	a	DT	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	O
depletor	depletor	NN	I-NP	O	O
should	should	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
vertigo	vertigo	RB	B-ADVP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
metronidazole	metronidazole	NN	I-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	S-group-EF-2
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
METROGEL	METROGEL	NN	B-NP	O	S-brand
(	(	(	O	O	O
metronidazole	metronidazole	NN	B-NP	O	S-drug
gel	gel	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
less	less	RBR	B-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
topical	topical	JJ	B-NP	O	O
metronidazole	metronidazole	NN	I-NP	O	S-drug
administration	administration	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
low	low	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
affecting	affect	VBG	B-VP	O	O
pituitary	pituitary	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
adrenocortical	adrenocortical	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
all	all	DT	B-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
and	and	CC	B-PP	O	O
during	during	IN	I-PP	O	O
testing	testing	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Metopirone	Metopirone	NN	B-NP	O	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Metopirone	Metopirone	NN	B-NP	O	S-brand-ME-1
is	be	VBZ	B-VP	O	O
accelerated	accelerate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
results	result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
inaccurate	inaccurate	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
within	within	IN	B-PP	O	O
two	two	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
before	before	RB	B-ADVP	O	O
.	.	.	O	O	O

Asubnormal	Asubnormal	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Metopirone	Metopirone	NN	B-NP	O	S-brand-MU-1
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
glucuronidation	glucuronidation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
could	could	MD	B-VP	O	O
possibly	possibly	RB	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-EF-2
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
administering	administer	VBG	B-VP	O	O
DEMSER	DEMSER	NN	B-NP	O	S-brand-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-AD-2
or	or	CC	O	O	O
haloperidol	haloperidol	NN	B-NP	O	S-drug-AD-2
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
extrapyramidal	extrapyramidal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
catecholamine	catecholamine	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DEMSER	DEMSER	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-drug-EF-2
depressants	depressant	NNS	I-NP	O	E-drug-EF-2
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
MEXITIL	MEXITIL	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP1A2	CYP1A2	NN	I-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
inhibition	inhibition	NN	B-NP	O	O
or	or	CC	I-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
alter	alter	VB	I-VP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
,	,	,	I-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
males	male	NNS	I-NP	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
another	another	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
8	8	CD	B-NP	O	O
extensive	extensive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
n	n	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
poor	poor	JJ	I-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
propafenone	propafenone	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
poor	poor	JJ	I-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
metabolizer	metabolizer	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extensive	extensive	JJ	I-NP	O	O
metabolizer	metabolizer	NN	I-NP	O	O
phenotype	phenotype	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
70	70	CD	I-NP	O	O
%	%	NN	I-NP	O	O
making	make	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
poor	poor	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
extensive	extensive	JJ	I-NP	O	O
metabolizer	metabolizer	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
indistinguishable	indistinguishable	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
crossover	crossover	NN	I-NP	O	O
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propafenone	propafenone	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
phenotype	phenotype	NN	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Addition	Addition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
propafenone	propafenone	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
further	further	JJ	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
changes	change	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
QRS	QRS	NN	B-NP	B-protein	O
,	,	,	O	O	O
QTc	QTc	NN	B-NP	B-protein	O
,	,	,	O	O	O
RR	RR	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
PR	PR	NN	B-NP	B-protein	O
intervals	interval	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
propafenone	propafenone	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mexiletine	mexiletine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
slowly	slowly	RB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
desired	desire	VBN	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
compassionate	compassionate	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
program	program	NN	I-NP	O	O
Mexitil	Mexitil	NN	I-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
employed	employ	VBN	I-NP	O	O
antianginal	antianginal	JJ	I-NP	O	O
,	,	,	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
without	without	IN	B-PP	O	O
observed	observe	VBN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antiarrhythmics	antiarrhythmic	NNS	B-NP	O	S-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
quinidine	quinidine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
propranolol	propranolol	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
added	add	VBN	I-VP	O	O
,	,	,	O	O	O
sometimes	sometimes	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
improved	improve	VBN	B-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
ectopy	ectopy	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
phenobarbital	phenobarbital	NN	I-NP	O	S-drug-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
taken	take	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Mexitil	Mexitil	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
lowered	lower	VBD	B-VP	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Monitoring	Monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Mexitil	Mexitil	NN	B-NP	O	S-brand
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
ineffective	ineffective	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
were	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

ECG	ECG	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
(	(	(	O	O	O
PR	PR	NN	B-NP	B-protein	O
,	,	,	O	O	O
QRS	QRS	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
QT	QT	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
Mexitil	Mexitil	NN	I-NP	O	S-brand
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
or	or	CC	O	O	O
propranolol	propranolol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand-ME-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
,	,	,	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
leave	leave	VB	B-VP	O	O
unchanged	unchanged	JJ	B-NP	O	O
Mexitil	Mexitil	NN	I-NP	O	S-brand
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Mexitil	Mexitil	NN	B-NP	O	S-brand
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
but	but	CC	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug-ME-1
-	-	HYPH	B-NP	O	I-drug-ME-1
aluminum	aluminum	NN	I-NP	O	I-drug-ME-1
hydroxide	hydroxide	NN	I-NP	O	E-drug-ME-1
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
lower	lower	VB	I-VP	O	O
serum	serum	NN	B-NP	B-protein	O
digoxin	digoxin	NN	I-NP	I-protein	S-drug-ME-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mexitil	Mexitil	NN	B-NP	O	S-brand-ME-1
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-ME-2
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
72	72	CD	I-NP	O	O
%	%	NN	I-NP	O	O
mean	mean	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
35	35	CD	I-NP	O	O
-	-	HYPH	O	O	O
136	136	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
point	point	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand
.	.	.	I-NP	O	O
Theophylline	Theophylline	NN	I-NP	O	S-drug-ME-1
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
pre	pre	AFX	O	B-DNA	O
-	-	HYPH	O	O	O
Mexitil	Mexitil	NN	B-NP	O	S-brand
values	value	NNS	I-NP	O	O
within	within	IN	B-PP	O	O
48	48	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
discontinuing	discontinue	VBG	B-VP	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand-ME-2
.	.	.	O	O	O
If	If	IN	B-SBAR	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand-AD-1
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-AD-2
are	be	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
Mexitil	Mexitil	NNP	I-NP	O	S-brand
dose	dose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
changed	change	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
five	five	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
and	and	CC	O	O	O
seven	seven	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Mexitil	Mexitil	NNP	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

Posicor	Posicor	NNP	B-NP	O	S-brand-ME-1
inhibits	inhibit	VBZ	B-VP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
's	's	POS	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
metabolize	metabolize	VB	I-VP	O	O
some	some	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
-	-	HYPH	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
astemizole	astemizole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-ME-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
meaning	mean	VBG	I-VP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
11	11	CD	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
MYCAMINE	MYCAMINE	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
mycophenolate	mycophenolate	NN	I-NP	O	B-drug
mofetil	mofetil	NN	I-NP	O	E-drug
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug
,	,	,	O	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
altered	alter	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
micafungin	micafungin	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
or	or	CC	O	O	O
multiple	multiple	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MYCAMINE	MYCAMINE	NN	B-NP	O	S-brand
on	on	IN	B-PP	O	O
mycophenolate	mycophenolate	NN	B-NP	O	B-drug
mofetil	mofetil	NN	I-NP	O	E-drug
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Sirolimus	Sirolimus	NN	B-NP	O	S-drug-ME-1
AUC	AUC	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Cmax	Cmax	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
MYCAMINE	MYCAMINE	NN	I-NP	O	S-brand-ME-2
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Nifedipine	Nifedipine	NN	B-NP	O	S-drug-ME-1
AUC	AUC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
42	42	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
MYCAMINE	MYCAMINE	NN	I-NP	O	S-brand-ME-2
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug-AD-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
MYCAMINE	MYCAMINE	NN	B-NP	O	S-brand-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
and	and	CC	O	O	O
sirolimus	sirolimus	NN	B-NP	O	S-drug
or	or	CC	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Micafungin	Micafungin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
and	and	CC	O	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
alter	alter	VB	I-VP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
transport	transport	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
Isozymes	Isozyme	NNS	I-NP	I-protein	O
:	:	:	O	O	O
Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
some	some	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
classes	class	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
azole	azole	NN	B-NP	O	B-group-AD-2
antimycotics	antimycotic	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
protease	protease	NN	B-NP	O	B-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group-AD-2
channel	channel	NN	I-NP	O	I-group-AD-2
antagonists	antagonist	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group-AD-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug-ME-1
were	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
orally	orally	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug-ME-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
prolonged	prolong	VBN	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
not	not	RB	O	O	O
studied	study	VBN	B-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
nelfinavir	nelfinavir	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
intense	intense	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
and	and	CC	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
midazolam	midazolam	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
VERSED	VERSED	NNP	B-NP	O	B-brand
Syrup	Syrup	NNP	I-NP	O	E-brand
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
effect	effect	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
.	.	.	O	O	O

Inducers	Inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
Isozymes	Isozyme	NNS	I-NP	I-protein	O
:	:	:	O	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
inducers	inducer	NNS	I-NP	I-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
induce	induce	VBP	B-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
and	and	CC	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
markedly	markedly	RB	I-NP	O	O
decreased	decrease	VBN	I-NP	O	O
C	C	NN	I-NP	O	O
max	max	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
VERSED	VERSED	VBN	B-NP	O	B-brand
Syrup	Syrup	NN	I-NP	O	E-brand
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
and	and	CC	O	O	O
if	if	IN	B-SBAR	O	O
necessary	necessary	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
difficulty	difficulty	NN	I-NP	O	O
in	in	IN	B-PP	O	O
achieving	achieve	VBG	B-VP	O	O
adequate	adequate	JJ	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sedatives	sedative	NNS	I-NP	O	S-group
due	due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
stimulant	stimulant	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methylphenidate	methylphenidate	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VERSED	VERSED	NNP	B-NP	O	B-brand-EF-1
Syrup	Syrup	NNP	I-NP	O	E-brand-EF-1
is	be	VBZ	B-VP	O	O
accentuated	accentuate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
any	any	DT	B-NP	O	O
concomitantly	concomitantly	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
medication	medication	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
depresses	depress	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
narcotics	narcotic	NNS	B-NP	O	S-group-EF-2
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
meperidine	meperidine	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
,	,	,	O	O	O
propofol	propofol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
ketamine	ketamine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
nitrous	nitrous	JJ	B-NP	O	B-drug-EF-2
oxide	oxide	NN	I-NP	O	E-drug-EF-2
,	,	,	O	O	O
secobarbital	secobarbital	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
droperidol	droperidol	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VERSED	VERSED	NNP	B-NP	O	B-brand
Syrup	Syrup	NNP	I-NP	O	E-brand
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
type	type	NN	I-NP	O	O
and	and	CC	I-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
common	common	JJ	B-NP	O	O
premedications	premedication	NNS	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug
,	,	,	O	O	O
scopolamine	scopolamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
glycopyrrolate	glycopyrrolate	NN	B-NP	O	S-drug
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydroxyzine	hydroxyzine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
)	)	)	O	O	O
or	or	CC	O	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ProAmatine	ProAmatine	NN	B-NP	O	S-brand-EF-1
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-group-EF-2
glycosides	glycoside	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
or	or	CC	I-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
bradycardia	bradycardia	NN	B-NP	O	O
,	,	,	O	O	O
A.V	A.V	NN	B-NP	O	O
.	.	.	O	O	O

block	block	NN	B-NP	O	O
or	or	CC	I-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
stimulate	stimulate	VBP	B-VP	O	O
alpha	alpha	SYM	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
adrenergic	adrenergic	JJ	I-NP	I-protein	O
receptors	receptor	NNS	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
phenylephrine	phenylephrine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
pseudoephedrine	pseudoephedrine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
ephedrine	ephedrine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
phenylpropanolamine	phenylpropanolamine	NN	B-NP	O	S-drug-EF-1
or	or	CC	O	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
or	or	CC	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ProAmatine	ProAmatine	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O
Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
ProAmatine	ProAmatine	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
cause	cause	VBP	B-VP	O	O
vasoconstriction	vasoconstriction	NN	B-NP	O	O
.	.	.	O	O	O

ProAmatine	ProAmatine	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
salt	salt	NN	B-NP	O	O
-	-	HYPH	O	O	O
retaining	retain	VBG	B-VP	O	O
steroid	steroid	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fludrocortisone	fludrocortisone	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
)	)	)	O	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
salt	salt	NN	B-NP	O	O
supplementation	supplementation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
supine	supine	NN	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
reducing	reduce	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fludrocortisone	fludrocortisone	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
or	or	CC	O	O	O
decreasing	decrease	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
salt	salt	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
.	.	.	O	O	O

ProAmatine	ProAmatine	NN	B-NP	B-protein	S-brand
.	.	SYM	I-NP	I-protein	O
Alpha	Alpha	NN	I-NP	I-protein	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
adrenergic	adrenergic	JJ	B-NP	O	I-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
prazosin	prazosin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
terazosin	terazosin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
doxazosin	doxazosin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
can	can	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ProAmatine	ProAmatine	NNP	B-NP	O	S-brand-EF-2
.	.	.	I-NP	O	O
Potential	Potential	NNP	I-NP	O	O
for	for	IN	B-PP	O	O
Drug	Drug	NNP	B-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
:	:	:	O	O	O
It	It	PRP	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
supporting	support	VBG	I-NP	O	O
experimental	experimental	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
,	,	,	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
desglymidodrine	desglymidodrine	NN	B-NP	O	S-drug_n-ME-1
(	(	(	O	O	O
a	a	DT	B-NP	O	O
base	base	NN	I-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
active	active	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
base	base	NN	I-NP	O	O
-	-	HYPH	O	O	O
secreting	secrete	VBG	B-VP	O	O
system	system	NN	B-NP	O	O
also	also	RB	B-ADVP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
metformin	metformin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
specific	specific	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
or	or	CC	I-NP	O	O
food	food	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
mifepristone	mifepristone	NN	B-NP	O	S-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
s	s	VBZ	B-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
by	by	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
grapefruit	grapefruit	NN	B-NP	O	O
juice	juice	NN	I-NP	O	O
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
(	(	(	O	O	O
increasing	increase	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mifepristone	mifepristone	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
,	,	,	O	O	O
St	St	NNP	B-NP	O	O
.	.	.	O	O	O

John	John	NNP	B-NP	O	O
s	s	VBZ	B-VP	O	O
Wort	Wort	NNP	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
certain	certain	JJ	B-NP	O	O
anticonvulsants	anticonvulsant	NNS	I-NP	O	S-group-ME-1
(	(	(	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
mifepristone	mifepristone	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
(	(	(	O	O	O
lowering	lower	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mifepristone	mifepristone	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
information	information	NN	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
mifepristone	mifepristone	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
slow	slow	JJ	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mifepristone	mifepristone	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prolonged	prolonged	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
after	after	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
mifepristone	mifepristone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
3A4	3A4	NN	I-NP	I-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
narrow	narrow	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
some	some	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ZAVESCA	ZAVESCA	NN	B-NP	B-protein	S-brand-ME-1
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Cerezyme	Cerezyme	NN	B-NP	B-protein	S-brand-ME-2
by	by	IN	B-PP	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
conclusive	conclusive	JJ	B-ADJP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
studied	study	VBN	B-VP	O	O
and	and	CC	O	O	O
because	because	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
took	take	VBD	B-VP	O	O
variable	variable	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Cerezyme	Cerezyme	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Cerezyme	Cerezyme	NN	B-NP	O	S-brand-AD-1
(	(	(	O	O	O
imiglucerase	imiglucerase	NN	B-NP	B-protein	S-drug-AD-1
)	)	)	O	O	O
and	and	CC	O	O	O
ZAVESCA	ZAVESCA	NN	B-NP	B-protein	S-brand-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
indicated	indicate	VBN	I-VP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-AD-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
depress	depress	VB	I-VP	O	O
plasma	plasma	NN	B-NP	B-protein	O
prothrombin	prothrombin	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group-AD-2
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
downward	downward	JJ	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
bacteriostatic	bacteriostatic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
giving	give	VBG	I-VP	O	O
tetracycline	tetracycline	NN	B-NP	O	B-group-AD-1
class	class	NN	I-NP	O	I-group-AD-1
drugs	drug	NNS	I-NP	O	E-group-AD-1
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-drug-AD-2
.	.	.	O	O	O

Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-ME-1
is	be	VBZ	B-VP	O	O
impaired	impair	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
aluminum	aluminum	NN	B-NP	O	S-drug-ME-2
,	,	,	I-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug-ME-2
or	or	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
preparations	preparation	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	O	S-group-EF-1
and	and	CC	I-NP	O	O
methoxyflurane	methoxyflurane	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-EF-1
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
render	render	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Guanethidine	Guanethidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
minoxidil	minoxidil	NN	B-NP	O	S-drug-EF-1
does	do	VBZ	B-VP	O	O
not	not	RB	O	O	O
itself	itself	PRP	B-NP	O	O
cause	cause	VBP	B-VP	O	O
orthostatic	orthostatic	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-2
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
profound	profound	JJ	B-NP	O	O
orthostatic	orthostatic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
at	at	IN	B-PP	O	O
all	all	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
guanethidine	guanethidine	NN	I-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
well	well	RB	B-ADVP	O	O
before	before	IN	B-SBAR	O	O
minoxidil	minoxidil	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
begun	begin	VBN	I-VP	O	O
.	.	.	O	O	O

Where	Where	WRB	B-ADVP	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
minoxidil	minoxidil	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
started	start	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
should	should	MD	B-VP	O	O
remain	remain	VB	I-VP	O	O
institutionalized	institutionalize	VBN	I-VP	O	O
until	until	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
orthostatic	orthostatic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
no	no	RB	B-ADVP	O	O
longer	longer	RB	I-ADVP	O	O
present	present	JJ	B-ADJP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
learned	learn	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
avoid	avoid	VB	I-VP	O	O
activities	activity	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
provoke	provoke	VBP	B-VP	O	O
them	them	PRP	B-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
pharmacodynamic	pharmacodynamic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
or	or	CC	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Affecting	Affect	VBG	B-VP	O	O
Hepatic	Hepatic	JJ	B-NP	O	O
Metabolism	Metabolism	NN	I-NP	O	O
The	The	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
REMERON	REMERON	NN	B-NP	B-protein	B-brand
SolTab	SolTab	NN	I-NP	I-protein	E-brand
(	(	(	O	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug
)	)	)	O	O	O
Orally	Orally	RB	B-VP	O	O
Disintegrating	Disintegrate	VBG	I-VP	O	O
Tablets	Tablet	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
or	or	CC	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
metab	metab	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
olizing	olize	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
Metabolized	Metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
Inhibit	Inhibit	VBP	B-VP	O	O
Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
Enzymes	Enzyme	NNS	I-NP	I-protein	O
Many	Many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
inhibit	inhibit	VB	B-VP	O	O
various	various	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
2D6	2D6	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
1A2	1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
2D6	2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
1A2	1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
3A4	3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
indication	indication	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
REMERON	REMERON	NNP	B-NP	O	B-brand
SolTab	SolTab	NNP	I-NP	O	E-brand
with	with	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
other	other	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
formally	formally	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
possible	possible	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
make	make	VB	I-VP	O	O
any	any	DT	B-NP	O	O
definitive	definitive	JJ	I-NP	O	O
statements	statement	NNS	I-NP	O	O
about	about	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
REMERON	REMERON	NN	B-NP	B-protein	B-brand
SolTab	SolTab	NN	I-NP	I-protein	E-brand
with	with	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
equivalent	equivalent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
60	60	CD	B-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
minimal	minimal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
motor	motor	NN	I-NP	O	O
skills	skill	NNS	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
REMERON	REMERON	NN	B-NP	O	S-brand-EF-1
were	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-1
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
REMERON	REMERON	NNP	B-NP	O	B-brand-AD-2
SolTab	SolTab	NNP	I-NP	O	E-brand-AD-2
.	.	.	I-NP	O	O
Diazepam	Diazepam	NNP	I-NP	O	S-drug
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
minimal	minimal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
skills	skill	NNS	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
REMERON	REMERON	NN	B-NP	B-protein	S-brand-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
similar	similar	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
REMERON	REMERON	NNP	B-NP	O	B-brand-AD-2
SolTab	SolTab	NNP	I-NP	O	E-brand-AD-2
.	.	.	O	O	O

Mitotane	Mitotane	NNP	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
accelerate	accelerate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
microsomal	microsomal	JJ	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
induction	induction	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
requirements	requirement	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
closely	closely	RB	I-VP	O	O
monitor	monitor	VB	I-VP	O	O
patients	patient	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
requirements	requirement	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
Mitotane	Mitotane	NNP	B-NP	O	S-drug-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
type	type	NN	I-NP	O	I-group-AD-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
Mitotane	Mitotane	NNP	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
susceptible	susceptible	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
induction	induction	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
MIVACRON	MIVACRON	NN	B-NP	O	S-brand
(	(	(	O	O	O
a	a	DT	B-NP	O	O
mixture	mixture	NN	I-NP	O	O
of	of	IN	B-PP	O	O
three	three	CD	B-NP	O	O
stereoisomers	stereoisomer	NNS	I-NP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
following	follow	VBG	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	O
-	-	HYPH	O	O	O
facilitated	facilitate	VBN	B-NP	O	O
tracheal	tracheal	NN	I-NP	O	O
intubation	intubation	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
succinylcholine	succinylcholine	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Prior	Prior	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-1
can	can	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	blocking	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarize	VBG	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Evidence	Evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
from	from	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
before	before	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	O	S-brand
before	before	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
nondepolarizing	nondepolarizing	JJ	I-NP	O	B-group
neuromuscular	neuromuscular	JJ	I-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

Isoflurane	Isoflurane	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
enflurane	enflurane	NN	I-NP	O	S-drug
(	(	(	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nitrous	nitrous	JJ	B-NP	O	B-drug
oxide	oxide	NN	I-NP	O	E-drug
/	/	SYM	B-NP	O	O
oxygen	oxygen	NN	I-NP	O	S-drug
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
1.25	1.25	CD	B-NP	O	O
M.C	M.C	NN	I-NP	O	O
.	.	.	O	O	O

decrease	decrease	VB	B-VP	O	O
the	the	DT	B-NP	O	O
ED50	ED50	NN	I-NP	B-protein	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	B-protein	S-brand
by	by	IN	B-PP	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	I-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CLINICAL	CLINICAL	NN	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
:	:	:	O	O	O
Pharmacodynamics	Pharmacodynamics	NN	B-NP	O	O
and	and	CC	I-NP	O	O
Individualization	Individualization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Dosages	Dosage	NNS	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
effective	effective	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
the	the	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
requirement	requirement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	B-protein	S-brand
by	by	IN	B-PP	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	I-NP	O	O
35	35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	blocking	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	O	S-brand
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
enflurane	enflurane	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
isoflurane	isoflurane	NN	I-NP	O	S-drug
.	.	.	O	O	O

Halothane	Halothane	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
little	little	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
no	no	DT	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ED50	ED50	NN	I-NP	B-protein	O
,	,	,	O	O	O
but	but	CC	O	O	O
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
the	the	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
requirement	requirement	NN	I-NP	O	O
by	by	IN	B-PP	O	O
as	as	RB	B-NP	O	O
much	much	JJ	I-NP	O	O
as	as	IN	I-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarize	VBG	B-NP	O	B-drug-IN-1
agents	agent	NNS	I-NP	O	E-drug-IN-1
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	O	S-brand-IN-1
include	include	VBP	B-VP	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-IN-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
tetracyclines	tetracycline	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
bacitracin	bacitracin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
polymyxins	polymyxin	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
lincomycin	lincomycin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
clindamycin	clindamycin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
colistin	colistin	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-IN-2
colistimethate	colistimethate	NN	I-NP	O	E-drug-IN-2
)	)	)	O	O	O
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	S-group-IN-2
salts	salt	NNS	I-NP	O	O
,	,	,	O	O	O
lithium	lithium	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-IN-2
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	blocking	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	O	S-brand-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
reduce	reduce	VBP	B-VP	O	O
plasma	plasma	NN	B-NP	B-protein	O
cholinesterase	cholinesterase	NN	I-NP	I-protein	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
chronically	chronically	RB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
certain	certain	JJ	B-NP	O	O
monoamine	monoamine	NN	I-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
)	)	)	O	O	O
or	or	CC	O	O	O
by	by	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
irreversibly	irreversibly	RB	B-ADVP	O	O
inhibit	inhibit	VBP	B-VP	O	O
plasma	plasma	NN	B-NP	B-protein	O
cholinesterase	cholinesterase	NN	I-NP	I-protein	O
.	.	.	I-NP	O	O
Resistance	Resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nondepolarizing	nondepolarize	VBG	B-VP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	B-group-EF-1
blocking	block	VBG	I-NP	O	I-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
chronically	chronically	RB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-EF-2
or	or	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-EF-1
or	or	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug-EF-1
therapy	therapy	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MIVACRON	MIVACRON	NN	B-NP	O	S-brand-EF-2
are	be	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
,	,	,	O	O	O
slightly	slightly	RB	B-NP	O	O
shorter	short	JJR	I-NP	O	O
durations	duration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
block	block	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
and	and	CC	O	O	O
infusion	infusion	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
requirements	requirement	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
higher	high	JJR	B-ADJP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
birth	birth	NN	I-NP	O	O
control	control	NN	I-NP	O	O
pills	pill	NNS	I-NP	O	O
-	-	HYPH	B-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group
-	-	HYPH	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
angina	angina	NN	B-NP	O	O
or	or	CC	O	O	O
high	high	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
medicines	medicine	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
pain	pain	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
medicines	medicine	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
given	give	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
injection	injection	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
cisplatin	cisplatin	NN	I-NP	I-protein	S-drug
-	-	HYPH	B-NP	O	O
edrophonium	edrophonium	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
neostigmine	neostigmine	NN	I-NP	O	S-drug
-	-	HYPH	I-NP	O	O
polymyxin	polymyxin	NN	I-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
or	or	CC	I-NP	O	O
bacitracin	bacitracin	NN	I-NP	O	S-drug
-	-	HYPH	I-NP	O	O
local	local	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
procaine	procaine	NN	B-NP	O	S-drug
-	-	HYPH	B-VP	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
-	-	HYPH	O	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Excessive	Excessive	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
diuretic	diuretic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
ACE	ACE	NN	B-NP	O	B-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
started	start	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
UNIVASC	UNIVASC	NNP	B-NP	O	S-brand
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
discontinuing	discontinue	VBG	B-VP	O	O
diuretic	diuretic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
or	or	CC	O	O	O
cautiously	cautiously	RB	B-NP	O	O
increasing	increase	VBG	I-NP	O	O
salt	salt	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
before	before	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
UNIVASC	UNIVASC	NNP	B-NP	O	S-brand
.	.	.	O	O	O
If	If	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
possible	possible	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
starting	start	VBG	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
moexpril	moexpril	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced..	reduced..	NN	B-NP	O	O

Potassium	Potassium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Potassium	Potassium	NN	I-NP	O	B-group
-	-	HYPH	O	O	I-group
Sparing	Spar	VBG	B-VP	O	I-group
Diuretics	Diuretic	NNS	B-NP	O	E-group
:	:	:	O	O	O
UNIVASC	UNIVASC	NNP	B-NP	O	S-brand
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
because	because	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
aldosterone	aldosterone	NN	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	B-group-EF-1
-	-	HYPH	O	O	I-group-EF-1
sparing	spar	VBG	B-VP	O	I-group-EF-1
diuretics	diuretic	NNS	B-NP	O	E-group-EF-1
(	(	(	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
amiloride	amiloride	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
or	or	CC	O	O	O
potassium	potassium	NN	B-NP	O	S-drug-EF-1
supplements	supplement	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Anticoagulants	Anticoagulant	NNS	I-NP	O	S-group
:	:	:	O	O	O
Interaction	Interaction	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
identify	identify	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
or	or	CC	B-PP	O	O
on	on	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ACE	ACE	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-1
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
toxicity	toxicity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Agents	Agent	NNPS	I-NP	O	O
:	:	:	O	O	O
No	No	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
important	important	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
when	when	WRB	B-ADVP	O	O
UNIVASC	UNIVASC	NNP	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

UNIVASC	UNIVASC	NNP	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B-protein	B-group
-	-	HYPH	B-NP	I-protein	I-group
channel	channel	NN	I-NP	I-protein	I-group
-	-	HYPH	B-VP	O	I-group
blocking	block	VBG	B-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
H2	H2	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
cholesterol	cholesterol	NN	B-NP	O	O
-	-	HYPH	O	O	O
lowering	lower	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ASMANEX	ASMANEX	NN	I-NP	O	B-brand
TWISTHALER	TWISTHALER	NN	I-NP	O	E-brand
inhaler	inhaler	NN	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
asthma	asthma	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
unusual	unusual	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mometasone	mometasone	NN	B-NP	O	B-drug-ME-2
furoate	furoate	NN	I-NP	O	E-drug-ME-2
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
.	.	.	O	O	O

Montelukast	Montelukast	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Dose	Dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Once	Once	NNP	I-NP	O	O
Daily	Daily	NNP	I-NP	O	O
Dosed	Dosed	NNP	I-NP	O	O
to	to	TO	B-PP	O	O
Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
Steady	Steady	JJ	I-NP	O	O
State	State	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
(	(	(	O	O	O
predominantly	predominantly	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
1A2	1A2	NN	I-NP	I-protein	O
substrate	substrate	NN	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochromes	cytochrome	NNS	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
2A6	2A6	NN	I-NP	I-protein	O
and	and	CC	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
)	)	)	O	O	O
or	or	CC	B-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
30	30	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
INR	INR	NN	I-NP	O	O
(	(	(	O	O	O
International	International	NNP	B-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
or	or	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
immunoreactive	immunoreactive	JJ	B-NP	B-protein	O
digoxin	digoxin	NN	I-NP	I-protein	S-drug
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
(	(	(	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
)	)	)	O	O	O
or	or	CC	O	O	O
fexofenadine	fexofenadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
carboxylated	carboxylate	VBN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
QTc	QTc	NN	I-NP	B-DNA	O
interval	interval	NN	I-NP	I-DNA	O
following	follow	VBG	B-PP	I-DNA	O
co	co	AFX	B-NP	I-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
60	60	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

Montelukast	Montelukast	NN	B-NP	O	S-drug
at	at	IN	B-PP	O	O
Doses	Dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
Daily	Daily	RB	B-VP	O	O
Dosed	Dose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
Pharmacokinetic	Pharmacokinetic	NNP	B-NP	O	O
Steady	Steady	NNP	I-NP	O	O
State	State	NNP	I-NP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
component	component	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group
containing	contain	VBG	B-VP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
ethinyl	ethinyl	NN	B-NP	O	O
estradiol	estradiol	NN	I-NP	O	S-drug
35	35	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
any	any	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
profiles	profile	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
prednisolone	prednisolone	NN	I-NP	O	S-drug
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	B-NP	O	O
oral	oral	JJ	I-NP	O	O
prednisone	prednisone	NN	I-NP	O	S-drug
or	or	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
prednisolone	prednisolone	NN	I-NP	O	S-drug
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
induces	induce	VBZ	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
reasonable	reasonable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
employ	employ	VB	I-VP	O	O
appropriate	appropriate	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
potent	potent	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-AD-1
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Montelukast	Montelukast	NNP	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
routinely	routinely	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
and	and	CC	O	O	O
chronic	chronic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
asthma	asthma	NN	B-NP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
,	,	,	O	O	O
prednisolone	prednisolone	NN	B-NP	O	S-drug
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
(	(	(	O	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
35	35	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
additional	additional	JJ	B-NP	O	O
specific	specific	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
wide	wide	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
prescribed	prescribe	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
thyroid	thyroid	NN	B-NP	O	B-group
hormones	hormone	NNS	I-NP	O	E-group
,	,	,	O	O	O
sedative	sedative	JJ	B-NP	O	B-group
hypnotics	hypnotic	NNS	I-NP	O	E-group
,	,	,	O	O	O
non	non	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	B-DNA	I-group
steroidal	steroidal	JJ	B-NP	I-DNA	I-group
anti	anti	AFX	I-NP	I-DNA	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
decongestants	decongestant	NNS	B-NP	O	S-group
.	.	.	O	O	O

Phenobarbital	Phenobarbital	NN	B-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
induces	induce	VBZ	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
approximately	approximately	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
reasonable	reasonable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
employ	employ	VB	I-VP	O	O
appropriate	appropriate	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
potent	potent	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-AD-1
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
montelukast	montelukast	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Other	Other	NNP	B-NP	O	O
Central	Central	NNP	I-NP	O	B-group
Nervous	Nervous	NNP	I-NP	O	I-group
System	System	NNP	I-NP	O	I-group
Depressants	Depressant	NNPS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-1
are	be	VBP	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
antihistaminics	antihistaminic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
psychotropic	psychotropic	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	S-group-EF-1
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
respiratory	respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
profound	profound	JJ	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
or	or	CC	I-NP	O	O
coma	coma	NN	I-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Mixed	Mix	VBN	B-NP	O	B-group
Agonist	Agonist	NN	I-NP	O	I-group
/	/	SYM	B-NP	O	I-group
Antagonist	Antagonist	NN	I-NP	O	I-group
Opioid	Opioid	JJ	I-NP	O	I-group
Analgesics	Analgesic	NNS	I-NP	O	E-group
:	:	:	O	O	O
Agonist	Agonist	NN	B-NP	O	B-group-AD-1
/	/	SYM	O	O	I-group-AD-1
antagonist	antagonist	NN	B-NP	O	I-group-AD-1
analgesics	analgesic	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
nalbuphine	nalbuphine	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
butorphanol	butorphanol	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
or	or	CC	O	O	O
buprenorphine	buprenorphine	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
should	should	MD	B-VP	O	O
NOT	NOT	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
proof	proof	NN	I-NP	O	O
opioid	opioid	JJ	I-NP	O	B-group-AD-2
agonist	agonist	NN	I-NP	O	I-group-AD-2
analgesic	analgesic	NN	I-NP	O	E-group-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mixed	mixed	JJ	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
or	or	CC	O	O	O
may	may	MD	B-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Antacids	Antacid	NNS	B-NP	O	S-group
:	:	:	O	O	O
Absorption	Absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Myfortic	Myfortic	JJ	B-NP	O	S-brand-ME-1
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
12	12	CD	B-NP	O	O
stable	stable	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
taking	take	VBG	B-VP	O	O
magnesium	magnesium	NN	B-NP	O	S-drug-ME-2
-	-	HYPH	I-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-ME-2
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-group
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
Cmax	Cmax	NN	I-NP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
t	t	NN	I-NP	O	O
)	)	)	O	O	O
values	value	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
MPA	MPA	NN	B-NP	B-protein	O
were	be	VBD	B-VP	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
37	37	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADJP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
than	than	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
Myfortic	Myfortic	NNP	B-NP	O	S-brand
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
under	under	IN	B-PP	O	O
fasting	fast	VBG	B-VP	O	O
conditions	condition	NNS	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Myfortic	Myfortic	JJ	O	O	S-drug-AD-1
and	and	CC	O	O	O
antacids	antacid	NNS	B-NP	O	S-group-AD-2
not	not	RB	O	O	O
be	be	VB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
studied	study	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
,	,	,	O	O	O
USP	USP	NN	B-NP	B-protein	O
(	(	(	O	O	O
MODIFIED	MODIFIED	NN	B-NP	O	O
)	)	)	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Myfortic	Myfortic	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Acyclovir	Acyclovir	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Ganciclovir	Ganciclovir	NN	I-NP	O	S-drug
:	:	:	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Myfortic	Myfortic	JJ	B-NP	O	S-brand
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
acyclovir	acyclovir	NN	B-NP	O	S-drug
/	/	SYM	B-NP	O	O
ganciclovir	ganciclovir	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
MPAG	MPAG	NN	I-NP	O	S-drug_n
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
coexistence	coexistence	NN	I-NP	O	O
may	may	MD	B-VP	O	O
compete	compete	VB	I-VP	O	O
for	for	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
and	and	CC	O	O	O
further	further	JJ	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
.	.	.	O	O	O

Azathioprine	Azathioprine	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Mycophenolate	Mycophenolate	NN	I-NP	O	B-drug
Mofetil	Mofetil	NN	I-NP	O	E-drug
:	:	:	O	O	O
Given	Give	VBN	B-VP	O	O
that	that	IN	B-SBAR	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
mycophenolate	mycophenolate	NN	I-NP	O	B-drug
mofetil	mofetil	NN	I-NP	O	E-drug
inhibit	inhibit	VBP	B-VP	O	O
purine	purine	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
Myfortic	Myfortic	NNP	B-NP	O	S-brand-AD-1
not	not	RB	O	O	O
be	be	VB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
mycophenolate	mycophenolate	NN	I-NP	O	B-drug-AD-2
mofetil	mofetil	NN	I-NP	O	E-drug-AD-2
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
that	that	IN	B-NP	O	O
Bind	Bind	NNP	B-NP	O	O
Bile	Bile	NNP	I-NP	O	O
Acids	Acids	NNP	I-NP	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
interrupt	interrupt	JJ	B-NP	O	O
enterohepatic	enterohepatic	JJ	I-NP	O	O
recirculation	recirculation	NN	I-NP	O	O
and	and	CC	O	O	O
reduce	reduce	VB	B-VP	O	O
MPA	MPA	NN	B-NP	O	S-drug_n
exposure	exposure	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
mycophenolate	mycophenolate	JJ	B-NP	O	B-drug
mofetil	mofetil	NN	I-NP	O	E-drug
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
administer	administer	VB	I-VP	O	O
Myfortic	Myfortic	JJ	B-ADJP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
enterohepatic	enterohepatic	JJ	B-NP	O	O
recirculation	recirculation	NN	I-NP	O	O
or	or	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
bind	bind	VB	I-VP	O	O
bile	bile	NN	B-NP	O	O
acids	acid	NNS	I-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
example	example	NN	B-NP	O	O
bile	bile	NN	I-NP	O	O
acid	acid	NN	I-NP	O	O
sequestrates	sequestrate	NNS	I-NP	O	O
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
activated	activate	VBN	I-NP	O	B-drug-AD-2
charcoal	charcoal	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Myfortic	Myfortic	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Myfortic	Myfortic	JJ	B-NP	O	S-brand
and	and	CC	I-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
classes	class	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
levonorgesterol	levonorgesterol	NN	I-NP	O	S-drug-ME-1
AUC	AUC	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
mycophenolate	mycophenolate	JJ	B-NP	O	B-drug-ME-2
mofetil	mofetil	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-AD-1
are	be	VBP	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Myfortic	Myfortic	JJ	B-NP	O	S-brand-AD-2
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
additional	additional	JJ	B-NP	O	O
birth	birth	NN	I-NP	O	O
control	control	NN	I-NP	O	O
methods	method	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Live	Live	JJ	B-NP	O	B-group
Vaccines	Vaccine	NNS	I-NP	O	E-group
:	:	:	O	O	O
During	During	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Myfortic	Myfortic	NNP	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
live	live	JJ	B-NP	O	B-group-AD-2
attenuated	attenuate	VBN	I-NP	O	I-group-AD-2
vaccines	vaccine	NNS	I-NP	O	E-group-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advised	advise	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
vaccinations	vaccination	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
.	.	.	O	O	O

Influenza	Influenza	NN	B-NP	O	O
vaccination	vaccination	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
value	value	NN	B-NP	O	O
.	.	.	O	O	O

Prescribers	Prescriber	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
refer	refer	VB	I-VP	O	O
to	to	TO	B-PP	O	O
national	national	JJ	B-NP	O	O
guidelines	guideline	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
influenza	influenza	NN	B-NP	O	O
vaccination	vaccination	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
flora	flora	NN	I-NP	O	O
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
Myfortic	Myfortic	JJ	B-ADJP	O	S-brand
by	by	IN	B-PP	O	O
disrupting	disrupt	VBG	B-VP	O	O
enterohepatic	enterohepatic	JJ	B-NP	O	O
recirculation	recirculation	NN	I-NP	O	O
.	.	.	O	O	O

Interference	Interference	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MPAG	MPAG	NN	B-NP	O	S-drug_n
hydrolysis	hydrolysis	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
less	less	JJR	B-NP	O	O
MPA	MPA	NN	I-NP	O	S-drug_n
available	available	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
.	.	.	O	O	O

Ondansetron	Ondansetron	NN	B-NP	O	S-drug
does	do	VBZ	O	O	O
not	not	RB	O	O	O
itself	itself	PRP	B-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
or	or	CC	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
drug	drug	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzyme	enzyme	NN	B-NP	I-protein	O
system	system	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
cytochrome	cytochrome	NN	I-NP	I-protein	O
P	P	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
450	450	CD	B-NP	I-protein	O
drug	drug	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
metabolizing	metabolize	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
inducers	inducer	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
may	may	MD	B-VP	O	O
change	change	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
hence	hence	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
limited	limited	JJ	B-NP	O	O
available	available	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
Carbamazepine	Carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
Rifampicin	Rifampicin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
rifampicin	rifampicin	NN	B-NP	B-protein	S-drug-ME-1
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
and	and	CC	O	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug-ME-2
blood	blood	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
available	available	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs.1,3	drugs.1,3	NN	I-NP	O	O
Tramadol	Tramadol	NN	I-NP	O	S-drug
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
tramadol	tramadol	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
data	datum	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
2	2	CD	B-NP	O	O
small	small	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tramadol.4,5	tramadol.4,5	NN	B-NP	O	O
Chemotherapy	Chemotherapy	NN	I-NP	O	O
:	:	:	O	O	O
Tumor	Tumor	NN	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
P	P	NN	I-NP	B-protein	O
388	388	CD	I-NP	I-protein	O
mouse	mouse	NN	I-NP	I-protein	O
leukemia	leukemia	NN	I-NP	I-protein	O
model	model	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
,	,	,	O	O	O
carmustine	carmustine	NN	B-NP	O	S-drug
,	,	,	O	O	O
etoposide	etoposide	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
cisplatin	cisplatin	NN	B-NP	B-protein	S-drug
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ondansetron	ondansetron	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
76	76	CD	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
I.V	I.V	NN	B-NP	O	O
.	.	.	O	O	O

ondansetron	ondansetron	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
beta	beta	NN	I-NP	O	B-group-AD-1
adrenergic	adrenergic	JJ	I-NP	O	I-group-AD-1
aerosol	aerosol	NN	I-NP	O	I-group-AD-1
bronchodilators	bronchodilator	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Alupent	Alupent	NN	B-NP	O	S-brand-AD-2
(	(	(	O	O	O
metaproterenol	metaproterenol	NN	B-NP	O	B-drug-AD-2
sulfate	sulfate	NN	I-NP	O	E-drug-AD-2
USP	USP	NN	I-NP	O	O
)	)	)	O	O	O
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Beta	Beta	JJ	B-NP	O	B-group-AD-1
adrenergic	adrenergic	JJ	I-NP	O	I-group-AD-1
agonists	agonist	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-AD-2
oxidase	oxidase	NN	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
or	or	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	NN	B-NP	O	B-group
adrenergic	adrenergic	JJ	I-NP	O	I-group
agonists	agonist	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
.	.	.	O	O	O

Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
30	30	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
weight	weight	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
and	and	CC	O	O	O
40	40	CD	B-NP	O	O
grams	gram	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
approximately	approximately	RB	B-NP	O	O
3	3	CD	I-NP	O	O
glasses	glass	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
wine	wine	NN	B-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
alteration	alteration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
,	,	,	O	O	O
orlistat	orlistat	NN	B-NP	O	S-drug
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
(	(	(	O	O	O
fecal	fecal	JJ	B-NP	O	O
fat	fat	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
orlistat	orlistat	NN	B-NP	O	S-drug
.	.	.	O	O	O

Cyclosporine	Cyclosporine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Preliminary	Preliminary	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
XENICAL	XENICAL	NN	I-NP	O	S-brand
and	and	CC	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand-ME-1
was	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
12	12	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Fat	Fat	NN	B-NP	B-protein	B-group
-	-	HYPH	I-NP	O	I-group
soluble	soluble	JJ	I-NP	O	I-group
Vitamin	Vitamin	NN	I-NP	O	I-group
Supplements	Supplement	NNS	I-NP	O	E-group
and	and	CC	I-NP	O	O
Analogues	Analogue	NNS	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-drug-ME-1
-	-	HYPH	B-NP	O	I-drug-ME-1
carotene	carotene	NN	I-NP	O	E-drug-ME-1
supplement	supplement	NN	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

XENICAL	XENICAL	NN	B-NP	O	S-brand-ME-1
inhibited	inhibit	VBD	B-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-drug-ME-2
E	E	NN	I-NP	O	I-drug-ME-2
acetate	acetate	NN	I-NP	O	E-drug-ME-2
supplement	supplement	NN	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
orlistat	orlistat	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
supplemental	supplemental	JJ	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group
D	D	NN	I-NP	O	E-group
,	,	,	O	O	O
vitamin	vitamin	NN	B-NP	O	B-group
A	A	NN	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
nutritionally	nutritionally	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
derived	derive	VBN	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group
K	K	NN	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Glyburide	Glyburide	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
12	12	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
orlistat	orlistat	NN	B-NP	O	S-drug
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
orlistat	orlistat	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
pharmacodynamics	pharmacodynamic	NNS	I-NP	O	O
(	(	(	O	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
lowering	lower	VBG	I-VP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Nifedipine	Nifedipine	NN	B-NP	O	S-drug
(	(	(	O	O	O
extended	extend	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
17	17	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
(	(	(	O	O	O
extended	extend	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
20	20	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
female	female	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
23	23	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ovulation	ovulation	NN	I-NP	O	O
-	-	HYPH	O	O	O
suppressing	suppress	VBG	B-VP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
12	12	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
300	300	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Pravastatin	Pravastatin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
way	way	NN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
,	,	,	O	O	O
mildly	mildly	RB	B-NP	O	O
hypercholesterolemic	hypercholesterolemic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pravastatin	pravastatin	NN	B-NP	B-protein	S-drug
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
12	12	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
120	120	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
16	16	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
(	(	(	O	O	O
both	both	CC	O	O	O
R	R	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
S	S	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
enantiomers	enantiomer	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
pharmacodynamics	pharmacodynamic	NNS	B-NP	O	O
(	(	(	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	O	O	O
serum	serum	NN	B-NP	B-protein	O
Factor	Factor	NN	I-NP	I-protein	O
VII	VII	CD	I-NP	I-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
undercarboxylated	undercarboxylate	VBN	B-NP	O	O
osteocalcin	osteocalcin	NN	I-NP	B-protein	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
marker	marker	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	O	O
K	K	NN	I-NP	O	O
nutritional	nutritional	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
vitamin	vitamin	NN	B-NP	O	O
K	K	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
tended	tend	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
decline	decline	VB	I-VP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
vitamin	vitamin	NN	B-NP	O	B-group-ME-1
K	K	NN	I-NP	O	E-group-ME-1
absorption	absorption	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand-ME-2
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
stable	stable	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-1
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
XENICAL	XENICAL	NN	B-NP	O	S-brand-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
coagulation	coagulation	NN	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
.	.	.	O	O	O

Tetracycline	Tetracycline	NN	B-NP	O	S-group-EF-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
bacteriostatic	bacteriostatic	JJ	I-NP	O	O
antibiotic	antibiotic	NN	I-NP	O	S-group
,	,	,	O	O	O
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-drug-EF-2
and	and	CC	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
85	85	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
m2	m2	NN	I-NP	B-protein	O
ELOXATIN	ELOXATIN	NN	I-NP	I-protein	S-brand
and	and	CC	O	O	O
infusional	infusional	JJ	B-NP	O	O
5	5	CD	I-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
FU	FU	NN	I-NP	O	E-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
every	every	DT	B-NP	O	O
2	2	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	B-drug-ME-1
-	-	HYPH	I-NP	O	I-drug-ME-1
FU	FU	NN	I-NP	O	E-drug-ME-1
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
130	130	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	B-protein	O
ELOXATIN	ELOXATIN	NN	I-NP	I-protein	S-brand-ME-2
dosed	dose	VBD	B-VP	O	O
every	every	DT	B-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
platinum	platinum	NN	B-NP	O	O
containing	contain	VBG	B-VP	O	O
species	specie	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
primarily	primarily	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
,	,	,	O	O	O
clearance	clearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
;	;	:	O	O	O

although	although	IN	B-SBAR	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
specifically	specifically	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group
Anabolic	Anabolic	JJ	B-NP	O	B-group-EF-1
steroids	steroid	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	S-group
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
desired	desire	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
require	require	VBP	B-VP	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
anabolic	anabolic	JJ	B-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
are	be	VBP	B-VP	O	O
started	start	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
multidose	multidose	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxandrolone	oxandrolone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
as	as	IN	B-PP	O	O
5	5	CD	B-NP	O	O
or	or	CC	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
BID	BID	NN	I-NP	O	O
in	in	IN	B-PP	O	O
15	15	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
S	S	NN	B-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
warfarin	warfarin	NN	I-NP	O	E-drug
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
from	from	IN	B-PP	O	O
26	26	CD	B-NP	O	O
to	to	TO	I-NP	O	O
48	48	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
from	from	IN	B-PP	O	O
4.55	4.55	CD	B-NP	O	O
to	to	TO	I-NP	O	O
12.08	12.08	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
*	*	SYM	B-NP	O	O
hr	hr	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
mL	mL	NN	I-NP	O	O
:	:	:	O	O	O
similar	similar	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
R	R	NN	B-NP	B-protein	B-drug
-	-	HYPH	B-NP	O	I-drug
warfarin	warfarin	NN	I-NP	O	E-drug
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
.	.	.	O	O	O

Microscopic	Microscopic	JJ	B-NP	O	O
hematuria	hematuria	NN	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
/	/	SYM	O	O	O
15	15	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
gingival	gingival	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
/	/	SYM	B-NP	O	O
15	15	CD	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
5.5	5.5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
from	from	IN	B-PP	O	O
6.13	6.13	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1.13	1.13	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
approximately	approximately	RB	B-NP	O	O
80	80	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
85	85	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
a	a	DT	B-NP	O	O
target	target	NN	I-NP	O	O
INR	INR	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1.5	1.5	CD	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
oxandrolone	oxandrolone	NN	B-NP	O	S-drug-AD-1
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
already	already	RB	B-ADVP	O	O
receiving	receive	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
the	the	DT	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
or	or	CC	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
PT	PT	NN	B-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
adjusted	adjust	VBN	B-VP	O	O
as	as	RB	B-ADJP	O	O
necessary	necessary	JJ	I-ADJP	O	O
until	until	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
stable	stable	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
INR	INR	NN	I-NP	O	O
or	or	CC	I-NP	O	O
PT	PT	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
achieved	achieve	VBN	I-VP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
or	or	CC	I-NP	O	O
PT	PT	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-AD-1
dosage	dosage	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
indicated	indicate	VBN	B-VP	O	O
are	be	VBP	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
oxandrolone	oxandrolone	NN	I-NP	O	S-drug-AD-2
dose	dose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
changed	change	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
occult	occult	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
Oxandrolone	Oxandrolone	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group-ME-2
agents	agent	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Adrenal	Adrenal	JJ	B-NP	O	B-group
steroids	steroid	NNS	I-NP	O	E-group
or	or	CC	O	O	O
ACTH	ACTH	NN	B-NP	O	S-drug
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
edema	edema	NN	B-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
adrenal	adrenal	JJ	B-NP	O	B-group
cortical	cortical	JJ	I-NP	O	I-group
steroids	steroid	NNS	I-NP	O	E-group
or	or	CC	O	O	O
ACTH	ACTH	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
edema	edema	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
Anabolic	Anabolic	JJ	B-NP	O	B-drug
steroids	steroid	NNS	I-NP	O	E-drug
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
thyroxine	thyroxine	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
binding	bind	VBG	B-NP	I-protein	O
globulin	globulin	NN	I-NP	I-protein	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
total	total	JJ	I-NP	O	O
T4	T4	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
resin	resin	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
T3	T3	NN	B-NP	O	O
and	and	CC	I-NP	O	O
T4	T4	NN	I-NP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
remain	remain	VBP	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PBI	PBI	NN	B-NP	B-cell_type	O
and	and	CC	O	O	O
radioactive	radioactive	JJ	B-NP	O	O
iodine	iodine	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxybutynin	oxybutynin	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
produce	produce	VBP	B-VP	O	O
dry	dry	JJ	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
,	,	,	O	O	O
constipation	constipation	NN	B-NP	O	O
,	,	,	O	O	O
somnolence	somnolence	NN	B-NP	O	O
(	(	(	O	O	O
drowsiness	drowsiness	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
severity	severity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
concomitantly	concomitantly	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
concern	concern	NN	B-NP	O	O
for	for	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
oxybutynin	oxybutynin	NN	I-NP	O	B-drug
chloride	chloride	NN	I-NP	O	E-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
2	2	CD	I-NP	O	O
fold	fold	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
DITROPAN	DITROPAN	NN	B-NP	O	B-brand-ME-1
XL	XL	NN	I-NP	O	E-brand-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A4	3A4	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
antimycotic	antimycotic	JJ	B-NP	O	B-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
miconazole	miconazole	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
or	or	CC	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group-ME-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
oxybutynin	oxybutynin	NN	B-NP	O	S-drug-ME-2
mean	mean	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
Cmax	Cmax	NN	B-NP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
potential	potential	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
ingestion	ingestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacid	antacid	NN	B-NP	O	S-group
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacid	antacid	NN	B-NP	O	S-group
containing	contain	VBG	B-VP	O	O
aluminum	aluminum	NN	B-NP	O	B-drug
hydroxide	hydroxide	NN	I-NP	O	E-drug
,	,	,	O	O	O
magnesium	magnesium	NN	B-NP	O	B-drug
hydroxide	hydroxide	NN	I-NP	O	E-drug
,	,	,	O	O	O
and	and	CC	O	O	O
simethicone	simethicone	NN	B-NP	O	S-drug
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxybutynin	oxybutynin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
desethyloxybutynin	desethyloxybutynin	NN	I-NP	O	S-drug_n
.	.	.	O	O	O

The	The	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oxycodone	oxycodone	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	B-group-EF-2
depressants..	depressants..	NN	I-NP	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group
depressants	depressant	NNS	I-NP	O	E-group
including	include	VBG	B-PP	O	O
sedatives	sedative	NNS	B-NP	O	S-group
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group
,	,	,	O	O	O
general	general	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group
,	,	,	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
opioids	opioid	NNS	I-NP	O	S-group
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
monoamine	monoamine	NN	B-NP	B-protein	B-group
oxidase	oxidase	NN	I-NP	I-protein	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
)	)	)	O	O	I-group
inhibitors	inhibitor	NNS	B-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
such	such	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
contemplated	contemplate	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Anticholinergics	Anticholinergic	NNS	B-NP	O	S-group-EF-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
opioid	opioid	JJ	B-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
retention	retention	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
severe	severe	JJ	B-NP	O	O
constipation	constipation	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
paralytic	paralytic	JJ	B-NP	O	O
ileus	ileus	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bradycardia	bradycardia	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
oxymorphone	oxymorphone	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
propofol	propofol	NN	B-NP	O	S-drug-EF-2
for	for	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
CNS	CNS	NN	B-NP	B-protein	O
toxicity	toxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
(	(	(	O	O	O
confusion	confusion	NN	B-NP	O	O
,	,	,	O	O	O
disorientation	disorientation	NN	B-NP	O	O
,	,	,	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
,	,	,	O	O	O
apnea	apnea	NN	B-NP	O	O
,	,	,	O	O	O
seizures	seizure	NNS	B-NP	O	O
)	)	)	O	O	O
following	follow	VBG	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
opioid	opioid	JJ	B-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
;	;	:	O	O	O

no	no	DT	B-NP	O	O
clear	clear	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
cut	cut	NN	I-NP	O	O
cause	cause	NN	I-NP	O	O
and	and	CC	O	O	O
effect	effect	NN	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
INVEGA	INVEGA	NNP	B-NP	O	S-brand
to	to	TO	B-PP	O	O
Affect	Affect	NNP	B-NP	O	O
Other	Other	NNP	I-NP	O	O
Drugs	Drugs	NNP	I-NP	O	O
Paliperidone	Paliperidone	NNP	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
paliperidone	paliperidone	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
substantially	substantially	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
/	/	SYM	O	O	O
9	9	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP3A5	CYP3A5	NN	B-NP	B-protein	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
paliperidone	paliperidone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
clearance	clearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Paliperidone	Paliperidone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
inducing	induce	VBG	B-VP	O	O
properties	property	NNS	B-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
paliperidone	paliperidone	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
.	.	.	O	O	O

Paliperidone	Paliperidone	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
mediated	mediate	VBN	I-NP	O	O
transport	transport	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
paliperidone	paliperidone	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
INVEGA	INVEGA	NNP	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
centrally	centrally	RB	I-NP	O	B-group-AD-2
acting	act	VBG	I-NP	O	I-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
and	and	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Paliperidone	Paliperidone	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	O	S-drug-EF-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	B-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
inducing	induce	VBG	B-VP	O	O
orthostatic	orthostatic	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
INVEGA	INVEGA	NNP	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
this	this	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
.	.	.	O	O	O

Potential	Potential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
Affect	Affect	VB	I-VP	O	O
INVEGA	INVEGA	NNP	B-NP	O	S-brand
Paliperidone	Paliperidone	NNP	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
so	so	IN	B-SBAR	O	O
that	that	IN	I-SBAR	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
isozymes	isozyme	NNS	I-NP	B-protein	O
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimally	minimally	RB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
paliperidone	paliperidone	NN	B-NP	O	S-drug
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
in	in	FW	B-PP	O	O
vivo	vivo	FW	B-NP	O	O
studies	study	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
decreased	decrease	VBN	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
isozymes	isozyme	NNS	I-NP	B-protein	O
and	and	CC	O	O	O
they	they	PRP	B-NP	O	O
contribute	contribute	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
only	only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
small	small	JJ	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Pantoprazole	Pantoprazole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
primarily	primarily	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
CYP2C19	CYP2C19	NN	I-NP	O	O
and	and	CC	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
subsequently	subsequently	RB	B-VP	O	O
undergoes	undergo	VBZ	I-VP	O	O
Phase	Phase	NN	B-NP	B-protein	O
II	II	CD	I-NP	I-protein	O
conjugation	conjugation	NN	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
evaluating	evaluate	VBG	B-VP	O	O
possible	possible	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pantoprazole	pantoprazole	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
:	:	:	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
cisapride	cisapride	NN	B-NP	O	S-drug
,	,	,	O	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
,	,	,	O	O	O
caffeine	caffeine	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
(	(	(	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
desmethyldiazepam	desmethyldiazepam	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
,	,	,	O	O	O
piroxicam	piroxicam	NN	B-NP	O	S-drug
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
ethanol	ethanol	NN	B-NP	O	S-drug
,	,	,	O	O	O
glyburide	glyburide	NN	B-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
contraceptive	contraceptive	NN	I-NP	O	S-group
(	(	(	O	O	O
levonorgestrel	levonorgestrel	NN	B-NP	O	S-drug
/	/	SYM	O	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
)	)	)	O	O	O
,	,	,	O	O	O
metoprolol	metoprolol	NN	B-NP	O	S-drug
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	O	S-drug
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
metronidazole	metronidazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
amoxicillin	amoxicillin	NN	B-NP	O	S-drug
.	.	.	O	O	O

Clinically	Clinically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pantoprazole	pantoprazole	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
pantoprazole	pantoprazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
adjustment	adjustment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pantoprazole	pantoprazole	NN	B-NP	O	S-drug
or	or	CC	B-PP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
no	no	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
antacids	antacid	NNS	I-NP	O	S-group
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
postmarketing	postmarketing	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
INR	INR	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
proton	proton	NN	B-NP	O	B-group-EF-1
pump	pump	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
pantoprazole	pantoprazole	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
and	and	CC	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
and	and	CC	O	O	O
even	even	RB	B-ADVP	O	O
death	death	NN	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
proton	proton	NN	B-NP	O	B-group-AD-1
pump	pump	NN	I-NP	O	I-group-AD-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-1
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
concomitantly	concomitantly	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
INR	INR	NN	B-NP	B-protein	O
and	and	CC	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
profound	profound	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
long	long	JJ	I-NP	O	O
lasting	lasting	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
acid	acid	NN	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
,	,	,	O	O	O
pantoprazole	pantoprazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
where	where	WRB	B-ADVP	O	O
gastric	gastric	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
determinant	determinant	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ampicillin	ampicillin	NN	B-NP	O	S-drug-ME-2
esters	ester	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
salts	salt	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NNP	B-NP	O	O
Tests	Test	NNPS	I-NP	O	O
There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
false	false	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
urine	urine	NN	I-NP	O	O
screening	screening	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
tetrahydrocannabinol	tetrahydrocannabinol	NN	B-NP	O	S-drug
(	(	(	O	O	O
THC	THC	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
most	most	JJS	B-NP	O	O
proton	proton	NN	I-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
pantoprazole	pantoprazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

An	An	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
confirmatory	confirmatory	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
verify	verify	VB	I-VP	O	O
positive	positive	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
.	.	.	O	O	O

Paricalcitol	Paricalcitol	NNP	B-NP	O	S-drug_n
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
CYP1A2	CYP1A2	NN	I-NP	B-protein	O
,	,	,	O	O	O
CYP2A6	CYP2A6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2B6	CYP2B6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
CYP2E1	CYP2E1	NN	I-NP	I-protein	O
or	or	CC	O	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
nor	nor	CC	O	O	O
induce	induce	VB	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CYP2B6	CYP2B6	NN	B-NP	B-protein	O
,	,	,	I-NP	O	O
CYP2C9	CYP2C9	NN	I-NP	B-protein	O
or	or	CC	I-NP	O	O
CYP3A	CYP3A	NN	I-NP	B-protein	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
approximately	approximately	RB	B-ADVP	O	O
doubled	double	VBD	B-VP	O	O
paricalcitol	paricalcitol	NN	B-NP	B-protein	S-drug-ME-2
AUC0	AUC0	NN	I-NP	I-protein	O
-	-	HYPH	B-ADVP	O	O
.	.	.	O	O	O
Since	Since	IN	B-SBAR	O	O
paricalcitol	paricalcitol	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
partially	partially	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
le	le	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
3A	3A	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
,	,	,	O	O	O
care	care	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
dosing	dosing	NN	B-NP	O	O
paricalcitol	paricalcitol	NN	I-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
strong	strong	JJ	I-NP	O	O
P450	P450	NN	I-NP	O	O
3A	3A	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
atazanavir	atazanavir	NN	B-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
indinavir	indinavir	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
nefazodone	nefazodone	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
nelfinavir	nelfinavir	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
ritonavir	ritonavir	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
saquinavir	saquinavir	NN	I-NP	O	S-drug-AD-2
,	,	,	I-NP	O	O
telithromycin	telithromycin	NN	I-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
voriconazole	voriconazole	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Zemplar	Zemplar	NNP	B-NP	O	S-brand-AD-1
Capsules	Capsules	NNP	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
iPTH	iPTH	NN	B-NP	O	O
and	and	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
calcium	calcium	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
initiates	initiate	VBZ	B-VP	O	O
or	or	CC	I-VP	O	O
discontinues	discontinue	VBZ	I-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
impair	impair	VBP	B-VP	O	O
intestinal	intestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fat	fat	NN	B-NP	O	B-group-ME-1
-	-	HYPH	B-NP	O	I-group-ME-1
soluble	soluble	JJ	I-NP	O	I-group-ME-1
vitamins	vitamin	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cholestyramine	cholestyramine	NN	B-NP	O	S-drug-ME-M
,	,	,	O	O	O
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Zemplar	Zemplar	NNP	B-NP	O	S-brand-ME-2
Capsules	Capsules	NNP	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
Neulasta	Neulasta	NNP	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neutrophils	neutrophil	NNS	B-NP	B-cell_type	O
;	;	:	O	O	O

patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
Neulasta	Neulasta	NNP	B-NP	O	S-brand-AD-2
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
more	more	RBR	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neutrophil	neutrophil	NN	B-NP	O	O
counts	count	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
18	18	CD	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	O
C	C	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
methadone	methadone	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
PEG	PEG	NN	B-NP	B-protein	B-brand-ME-2
-	-	HYPH	I-NP	O	I-brand-ME-2
Intron	Intron	NN	I-NP	B-DNA	E-brand-ME-2
once	once	RB	B-ADJP	O	O
weekly	weekly	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
methadone	methadone	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
;	;	:	O	O	O

in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
out	out	IN	B-PP	O	O
of	of	IN	B-PP	O	O
18	18	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
methadone	methadone	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
doubled	double	VBD	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
narcotic	narcotic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Acromegalic	Acromegalic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	O
mellitus	mellitus	NN	I-NP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B-protein	S-drug-AD-1
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
oral	oral	JJ	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	S-group-AD-1
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
dose	dose	NN	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
SOMAVERT	SOMAVERT	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
opioids	opioid	NNS	B-NP	O	S-group-ME-1
often	often	RB	B-ADVP	O	O
needed	need	VBD	B-VP	O	O
higher	high	JJR	B-NP	O	O
serum	serum	NN	I-NP	O	O
pegvisomant	pegvisomant	JJ	I-NP	O	S-drug-ME-2
concentrations	concentration	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
appropriate	appropriate	JJ	B-NP	O	O
IGF	IGF	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
not	not	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
opioids	opioid	NNS	B-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

ALIMTA	ALIMTA	NN	B-NP	B-protein	S-brand
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
renally	renally	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	O
filtration	filtration	NN	I-NP	O	O
and	and	CC	O	O	O
tubular	tubular	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
delayed	delay	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ALIMTA	ALIMTA	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
substances	substance	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
tubularly	tubularly	RB	B-VP	O	O
secreted	secrete	VBN	I-VP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
could	could	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
delayed	delay	VBN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ALIMTA	ALIMTA	NN	B-NP	B-protein	S-brand-ME-2
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
qid	qid	NN	I-NP	O	O
)	)	)	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ALIMTA	ALIMTA	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
creatinine	creatinine	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
80	80	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-AD-1
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ALIMTA	ALIMTA	NN	B-NP	B-protein	S-brand-AD-2
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
mild	mild	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
(	(	(	O	O	O
creatinine	creatinine	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
from	from	IN	B-PP	O	O
45	45	CD	B-NP	O	O
to	to	TO	I-NP	O	O
79	79	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
mild	mild	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
should	should	MD	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
taking	take	VBG	I-VP	O	O
NSAIDs	NSAID	NNS	B-NP	O	S-group-AD-1
with	with	IN	B-PP	O	O
short	short	JJ	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
lives	life	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
before	before	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ALIMTA	ALIMTA	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
data	datum	NNS	B-NP	O	O
regarding	regard	VBG	B-VP	O	O
potential	potential	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
ALIMTA	ALIMTA	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group
with	with	IN	B-PP	O	O
longer	long	JJR	B-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
lives	life	NNS	I-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	S-group-AD-1
should	should	MD	B-VP	O	O
interrupt	interrupt	VB	I-VP	O	O
dosing	dosing	NN	B-NP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
before	before	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
ALIMTA	ALIMTA	NN	B-NP	O	S-brand-AD-2
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
NSAID	NSAID	NN	I-NP	O	S-group
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADJP	O	O
myelosuppression	myelosuppression	JJ	I-ADJP	O	O
,	,	,	O	O	O
renal	renal	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
None	None	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYLERT	CYLERT	NN	B-NP	O	S-brand
(	(	(	O	O	O
pemoline	pemoline	NN	B-NP	O	S-drug
)	)	)	O	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
CYLERT	CYLERT	NN	B-NP	B-protein	S-brand
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
drugs	drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
CNS	CNS	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
.	.	.	O	O	O

Decreased	Decrease	VBN	B-NP	O	O
seizure	seizure	NN	I-NP	O	O
threshold	threshold	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
CYLERT	CYLERT	NN	B-NP	O	S-brand-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antiepileptic	antiepileptic	JJ	B-NP	O	B-group-EF-2
medications	medication	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bacteriostatic	bacteriostatic	JJ	B-NP	O	B-group-EF-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
tetracycline	tetracycline	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
bactericidal	bactericidal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
penicillins	penicillin	NNS	B-NP	B-protein	S-group-EF-2
by	by	IN	B-PP	O	O
slowing	slow	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bacterial	bacterial	JJ	B-NP	O	O
growth	growth	NN	I-NP	O	O
.	.	.	O	O	O

Bactericidal	Bactericidal	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
work	work	VBP	B-VP	O	O
most	most	RBS	B-ADVP	O	O
effectively	effectively	RB	I-ADVP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
immature	immature	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
wall	wall	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rapidly	rapidly	RB	B-ADVP	O	O
proliferating	proliferate	VBG	B-VP	O	O
microorganisms	microorganism	NNS	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
well	well	RB	I-VP	O	O
documented	document	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
few	few	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
situations	situation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
'	'	''	O	O	O
'	'	``	B-NP	O	O
static	static	JJ	I-NP	O	O
'	'	''	O	O	O
'	'	``	O	O	O
and	and	CC	O	O	O
'	'	''	O	O	O
'	'	``	O	O	O
cidal	cidal	JJ	B-ADJP	O	O
'	'	''	O	O	O
'	'	POS	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
are	be	VBP	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
selected	select	VBN	B-NP	O	O
circumstances	circumstance	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
such	such	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
adequate	adequate	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antibacterial	antibacterial	JJ	B-NP	O	S-group
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
beginning	begin	VBG	B-VP	O	O
penicillin	penicillin	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
first	first	RB	B-ADVP	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
minimize	minimize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
.	.	.	O	O	O

Penicillin	Penicillin	NN	B-NP	O	S-group-ME-1
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prolonged	prolong	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-ME-2
which	which	WDT	B-NP	O	O
blocks	block	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
penicillins	penicillin	NNS	B-NP	B-protein	S-group
.	.	.	O	O	O

Displacement	Displacement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
penicillin	penicillin	NN	B-NP	B-protein	S-group
from	from	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-DNA	O
protein	protein	NN	I-NP	I-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
will	will	MD	B-VP	O	O
elevate	elevate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	B-protein	O
penicillin	penicillin	NN	I-NP	I-protein	S-group
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
.	.	.	O	O	O

Usage	Usage	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Alcohol	Alcohol	NN	B-NP	O	S-drug
:	:	:	O	O	O
Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
depressants	depressant	NNS	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
currently	currently	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
pentazocine	pentazocine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
prolonged	prolong	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TRENTAL	TRENTAL	NN	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
and	and	CC	B-PP	O	O
without	without	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-2
or	or	CC	O	O	O
platelet	platelet	NN	B-NP	O	B-group-EF-2
aggregation	aggregation	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
Warfarin	Warfarin	NNP	B-NP	O	S-drug
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
more	more	RBR	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
complicated	complicate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
hemorrhage	hemorrhage	NN	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
recent	recent	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
,	,	,	O	O	O
peptic	peptic	JJ	B-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
periodic	periodic	JJ	B-NP	O	O
examinations	examination	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
including	include	VBG	B-PP	O	O
hematocrit	hematocrit	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
hemoglobin	hemoglobin	NN	B-NP	B-protein	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TRENTAL	TRENTAL	NN	B-NP	O	S-brand-ME-1
and	and	CC	I-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug-ME-2
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
their	their	PRP$	B-NP	O	O
theophylline	theophylline	NN	I-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
adjusted	adjust	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

TRENTAL	TRENTAL	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
digitalis	digitalis	NN	B-NP	O	S-group
,	,	,	O	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
antidiabetic	antidiabetic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
antiarrhythmics	antiarrhythmic	NNS	B-NP	O	S-group
,	,	,	O	O	O
without	without	IN	B-PP	O	O
observed	observe	VBN	B-NP	O	O
problems	problem	NNS	I-NP	O	O
.	.	.	O	O	O

Small	Small	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
TRENTAL	TRENTAL	NN	B-NP	O	S-brand
;	;	:	O	O	O

periodic	periodic	JJ	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
indicated	indicate	VBN	B-VP	O	O
,	,	,	O	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Dopamine	Dopamine	NN	B-NP	O	B-group-AD-1
antagonists	antagonist	NNS	I-NP	O	E-group-AD-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
neuroleptics	neuroleptic	NNS	I-NP	O	S-group-AD-1
(	(	(	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-AD-1
,	,	,	O	O	O
butyrophenones	butyrophenone	NNS	B-NP	O	S-group-AD-1
,	,	,	O	O	O
thioxanthines	thioxanthine	NNS	B-NP	O	S-group-AD-1
)	)	)	O	O	O
or	or	CC	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
ordinarily	ordinarily	RB	B-ADVP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Permax	Permax	NN	B-NP	O	S-brand-AD-2
(	(	(	O	O	O
a	a	DT	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	B-group
agonist	agonist	NN	I-NP	O	E-group
)	)	)	O	O	O
;	;	:	O	O	O

these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Permax	Permax	NN	B-NP	O	S-brand
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
pergolide	pergolide	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
90	90	CD	I-NP	O	O
%	%	NN	I-NP	O	O
bound	bind	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
pergolide	pergolide	NN	B-NP	O	B-drug
mesylate	mesylate	NN	I-NP	O	E-drug
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
protein	protein	NN	B-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

Diuretics	Diuretic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
especially	especially	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
started	start	VBD	B-VP	O	O
recently	recently	RB	B-ADVP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
experience	experience	VB	I-VP	O	O
an	an	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ACEON	ACEON	NN	B-NP	O	S-brand-EF-2
Tablets	Tablet	NNS	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotensive	hypotensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
minimized	minimize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
either	either	CC	O	O	O
discontinuing	discontinue	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group-EF-1
or	or	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
salt	salt	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
perindopril	perindopril	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
diuretics	diuretic	NNS	B-NP	O	S-group-AD-1
can	can	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
interrupted	interrupt	VBN	I-VP	O	O
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
supervision	supervision	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
provided	provide	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACEON	ACEON	NNP	B-NP	O	S-brand-AD-2
Tablets	Tablet	NNPS	I-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
two	two	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
until	until	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
another	another	DT	B-NP	O	O
hour	hour	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
perindopril	perindopril	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
and	and	CC	I-NP	O	O
elimination	elimination	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
perindoprilat	perindoprilat	NN	B-NP	O	S-drug_n
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
diuretics	diuretic	NNS	B-NP	O	S-group
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
ACE	ACE	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
.	.	.	O	O	O

Potassium	Potassium	NN	B-NP	O	S-drug
Supplements	Supplement	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
Potassium	Potassium	NN	I-NP	O	B-group
-	-	HYPH	O	O	I-group
Sparing	Spar	VBG	B-VP	O	I-group
Diuretics	Diuretic	NNS	B-NP	O	E-group
:	:	:	O	O	O
ACEON	ACEON	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
aldosterone	aldosterone	NN	B-NP	O	O
production	production	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	O	B-group
-	-	HYPH	O	O	I-group
sparing	spar	VBG	B-VP	O	I-group
diuretics	diuretic	NNS	B-NP	O	E-group
(	(	(	O	O	O
spironolactone	spironolactone	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
amiloride	amiloride	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
triamterene	triamterene	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
others	other	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	O	O
(	(	(	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug
,	,	,	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
,	,	,	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
others	other	NNS	I-NP	O	O
)	)	)	O	O	O
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
frequently	frequently	RB	B-ADVP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	O	S-drug
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
and	and	CC	O	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
ACE	ACE	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
and	and	CC	O	O	O
frequent	frequent	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
diuretic	diuretic	JJ	I-NP	O	S-group
may	may	MD	B-VP	O	O
further	further	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
A	A	DT	B-NP	O	O
controlled	control	VBN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ACEON	ACEON	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
perindopril	perindopril	NN	B-NP	O	S-drug-ME-2
/	/	SYM	B-NP	O	O
perindoprilat	perindoprilat	NN	I-NP	O	S-drug_n-ME-2
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
excluded	exclude	VBN	I-VP	O	O
.	.	.	O	O	O

Gentamicin	Gentamicin	NN	B-NP	O	S-drug
:	:	:	O	O	O
Animal	Animal	NN	B-NP	O	O
data	datum	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
perindopril	perindopril	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
gentamicin	gentamicin	NN	I-NP	O	S-drug-IN-2
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
proceed	proceed	VB	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Food	Food	NN	B-NP	O	O
Interaction	Interaction	NN	I-NP	O	O
:	:	:	O	O	O
Oral	Oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACEON	ACEON	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
food	food	NN	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	O	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
or	or	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
perindopril	perindopril	NN	B-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
fasted	fast	VBN	I-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
biotransformation	biotransformation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
perindopril	perindopril	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
perindoprilat	perindoprilat	NN	B-NP	O	S-drug_n
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
43	43	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
ACE	ACE	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
probably	probably	RB	B-ADJP	O	O
clinically	clinically	RB	I-ADJP	O	O
insignificant	insignificant	JJ	I-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
perindopril	perindopril	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
generally	generally	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
fasting	fast	VBG	I-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-IN-1
with	with	IN	B-PP	O	O
phentermine	phentermine	NN	B-NP	O	B-drug-IN-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-IN-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Vasopressors	Vasopressor	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
metaraminol	metaraminol	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
serious	serious	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-EF-2
anesthesia	anesthesia	NN	I-NP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-VP	O	O
should	should	MD	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
great	great	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
at	at	IN	B-ADVP	O	O
all	all	DT	I-ADVP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-1
pressor	pressor	NN	I-NP	O	I-group-EF-1
amines	amine	NNS	I-NP	O	E-group-EF-1
is	be	VBZ	B-VP	O	O
markedly	markedly	RB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
MAOI	MAOI	NN	B-NP	O	S-group-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
pressor	pressor	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
and	and	CC	O	O	O
used	use	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
due	due	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Vasopressors	Vasopressor	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
metaraminol	metaraminol	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
serious	serious	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
halothane	halothane	NN	B-NP	O	S-drug-EF-2
anesthesia	anesthesia	NN	I-NP	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-VP	O	O
should	should	MD	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
great	great	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
at	at	IN	B-ADVP	O	O
all	all	DT	I-ADVP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
-	-	:	O	O	O
The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-EF-1
pressor	pressor	NN	I-NP	O	I-group-EF-1
amines	amine	NNS	I-NP	O	E-group-EF-1
is	be	VBZ	B-VP	O	O
markedly	markedly	RB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
monoamine	monoamine	NN	B-NP	O	B-group-EF-2
oxidase	oxidase	NN	I-NP	O	I-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
MAOI	MAOI	NN	B-NP	O	S-group-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
pressor	pressor	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
small	small	JJ	B-ADJP	O	O
and	and	CC	O	O	O
used	use	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
due	due	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenergic	adrenergic	JJ	B-NP	O	B-group-EF-1
agents	agent	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Pilocarpine	Pilocarpine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
beta	beta	NN	B-NP	O	B-group-AD-2
adrenergic	adrenergic	JJ	I-NP	O	I-group-AD-2
antagonists	antagonist	NNS	I-NP	O	E-group-AD-2
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
conduction	conduction	NN	B-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
parasympathomimetic	parasympathomimetic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	O	S-drug
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Pilocarpine	Pilocarpine	NN	B-NP	O	S-drug
might	might	MD	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
contributing	contribute	VBG	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
atropine	atropine	NN	B-NP	O	S-drug
,	,	,	O	O	O
inhaled	inhale	VBD	B-VP	O	O
ipratropium	ipratropium	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
either	either	DT	B-NP	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
Sj	Sj	NN	I-NP	B-protein	O
grens	gren	VBZ	B-VP	O	O
efficacy	efficacy	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
:	:	:	O	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
artificial	artificial	JJ	B-NP	O	O
tears	tear	NNS	I-NP	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	S-drug
,	,	,	O	O	O
conjugated	conjugate	VBN	B-NP	O	B-drug
estrogens	estrogen	NNS	I-NP	O	E-drug
,	,	,	O	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
,	,	,	O	O	O
levothyroxine	levothyroxine	NN	B-NP	O	B-drug
sodium	sodium	NN	I-NP	O	E-drug
,	,	,	O	O	O
medroxyprogesterone	medroxyprogesterone	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
,	,	,	O	O	O
multivitamins	multivitamin	NNS	B-NP	O	S-group
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug
,	,	,	O	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
paracetamol	paracetamol	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
prednisone	prednisone	NN	B-NP	O	S-drug
.	.	.	O	O	O

Catecholamine	Catecholamine	NN	B-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	B-group-EF-2
-	-	HYPH	B-PP	O	I-group-EF-2
blocking	block	VBG	B-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
pindolol	pindolol	NN	B-NP	O	S-drug
plus	plus	CC	O	O	O
a	a	DT	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	O
-	-	HYPH	O	O	O
depleting	deplete	VBG	B-VP	O	O
agent	agent	NN	B-NP	O	O
should	should	MD	B-VP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
be	be	VB	B-VP	O	O
closely	closely	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
vertigo	vertigo	RB	B-ADVP	O	O
,	,	,	O	O	O
syncope	syncope	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
postural	postural	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
.	.	.	O	O	O

Pindolol	Pindolol	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug
,	,	,	O	O	O
hydralazine	hydralazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug
without	without	IN	B-PP	O	O
unexpected	unexpected	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Pindolol	Pindolol	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
serum	serum	NN	B-NP	O	O
thioridazine	thioridazine	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

Pindolol	Pindolol	NN	B-NP	O	S-drug
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anaphylactic	anaphylactic	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
:	:	:	O	O	O
While	While	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
anaphylactic	anaphylactic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
allergens	allergen	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
reactive	reactive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
either	either	CC	O	O	O
accidental	accidental	JJ	B-NP	O	O
,	,	,	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
or	or	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	O	S-drug
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
allergic	allergic	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
short	short	JJ	I-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
acting	act	VBG	I-NP	O	I-group-AD-1
beta	beta	NN	I-NP	O	I-group-AD-1
adrenergic	adrenergic	JJ	I-NP	O	I-group-AD-1
aerosol	aerosol	NN	I-NP	O	I-group-AD-1
bronchodilators	bronchodilator	NNS	I-NP	O	E-group-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
MAXAIR	MAXAIR	NN	B-NP	O	B-brand-AD-2
AUTOHALER	AUTOHALER	NN	I-NP	O	E-brand-AD-2
because	because	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

FELDENE	FELDENE	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
highly	highly	RB	B-ADVP	O	O
protein	protein	NN	B-NP	O	O
bound	bind	VBD	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
displace	displace	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
occurred	occur	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
type	type	NN	I-NP	O	I-group
anticoagulants	anticoagulant	NNS	I-NP	O	E-group
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-IN-1
-	-	HYPH	I-NP	O	I-group-IN-1
type	type	NN	I-NP	O	I-group-IN-1
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-IN-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
FELDENE	FELDENE	NN	B-NP	B-DNA	S-brand-IN-2
since	since	IN	B-PP	O	O
marketing	marketing	NN	B-NP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
closely	closely	RB	I-VP	O	O
monitor	monitor	VB	I-VP	O	O
patients	patient	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
requirements	requirement	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
FELDENE	FELDENE	NN	B-NP	O	S-brand-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
type	type	NN	I-NP	O	I-group-AD-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-AD-2
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
piroxicam	piroxicam	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
depressed	depress	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
normal	normal	JJ	I-NP	O	O
values	value	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
FELDENE	FELDENE	NN	B-NP	B-DNA	S-brand-ME-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-2
(	(	(	O	O	O
3900	3900	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
piroxicam	piroxicam	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O
Nonsteroidal	Nonsteroidal	JJ	B-NP	B-DNA	B-group-ME-1
anti	anti	AFX	I-NP	I-DNA	I-group-ME-1
-	-	HYPH	I-NP	O	I-group-ME-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-ME-1
agents	agent	NNS	I-NP	O	E-group-ME-1
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
FELDENE	FELDENE	NNP	B-NP	O	S-brand-ME-1
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
steady	steady	JJ	B-NP	O	O
state	state	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-ME-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
lithium	lithium	NN	I-NP	O	S-drug-AD-1
levels	level	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
initiating	initiate	VBG	B-VP	O	O
,	,	,	I-VP	O	O
adjusting	adjust	VBG	I-VP	O	O
and	and	CC	I-VP	O	O
discontinuing	discontinue	VBG	I-VP	O	O
FELDENE	FELDENE	NN	B-NP	O	S-brand-AD-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
atropine	atropine	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
pralidoxime	pralidoxime	NN	I-NP	O	S-drug-EF-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atropinization	atropinization	NN	B-NP	O	O
(	(	(	O	O	O
flushing	flushing	NN	B-NP	O	O
,	,	,	O	O	O
mydriasis	mydriasis	NN	B-NP	O	O
,	,	,	O	O	O
tachycardia	tachycardia	NN	B-NP	O	O
,	,	,	O	O	O
dryness	dryness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
and	and	CC	I-NP	O	O
nose	nose	NN	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
earlier	earlier	RBR	B-ADVP	O	O
than	than	IN	B-SBAR	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
atropine	atropine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
especially	especially	RB	B-ADJP	O	O
true	true	JJ	I-ADJP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
large	large	JJ	B-ADJP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pralidoxime	pralidoxime	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
delayed	delay	VBN	I-VP	O	O
.	.	.	O	O	O

2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
precautions	precaution	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinesterase	anticholinesterase	NN	B-NP	B-protein	O
poisoning	poisoning	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
bear	bear	VB	I-VP	O	O
directly	directly	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pralidoxime	pralidoxime	NN	B-NP	O	S-drug
:	:	:	O	O	O
since	since	IN	B-SBAR	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-1
are	be	VBP	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anticholinesterases	anticholinesteras	NNS	I-NP	B-protein	S-group-EF-2
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	O
;	;	:	O	O	O

morphine	morphine	NN	B-NP	O	S-drug
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
aminophylline	aminophylline	NN	B-NP	O	S-drug
,	,	,	O	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
phenothiazine	phenothiazine	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
type	type	NN	I-NP	O	I-group
tranquilizers	tranquilizer	NNS	I-NP	O	E-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
organophosphate	organophosphate	NN	B-NP	O	O
poisoning	poisoning	NN	I-NP	O	O
.	.	.	O	O	O

Carbidopa	Carbidopa	NN	B-NP	O	S-drug
/	/	SYM	I-NP	O	O
Levodopa	Levodopa	NN	I-NP	O	S-drug
:	:	SYM	B-NP	O	O
Carbidopa	Carbidopa	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
Levodopa	Levodopa	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

5	5	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Selegiline	Selegiline	NN	B-NP	O	S-drug
:	:	:	O	O	O
In	In	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
11	11	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
selegiline	selegiline	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Amantadine	Amantadine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
amantadine	amantadine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
54	54	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
organic	organic	JJ	B-NP	O	O
bases	base	NNS	I-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cationic	cationic	JJ	I-NP	O	O
transport	transport	NN	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug-ME-2
AUC	AUC	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
half	half	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Probenecid	Probenecid	NN	B-NP	O	S-drug
:	:	:	O	O	O
Probenecid	Probenecid	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
organic	organic	JJ	B-NP	O	O
acids	acid	NNS	I-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aruonic	aruonic	JJ	I-NP	O	O
transporter	transporter	NN	I-NP	O	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
noticeably	noticeably	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
eliminated	eliminate	VBN	B-VP	O	O
via	via	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
:	:	:	O	O	O
Population	Population	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
secreted	secrete	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cationic	cationic	JJ	I-NP	O	O
transport	transport	NN	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
diltiazem	diltiazem	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
triamterene	triamterene	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
quinine	quinine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
those	those	DT	B-NP	O	O
secreted	secrete	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anionic	anionic	JJ	I-NP	O	O
transport	transport	NN	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
cephalosporins	cephalosporin	NNS	B-NP	O	S-group-ME-1
,	,	,	O	O	O
penicillins	penicillin	NNS	B-NP	B-protein	S-group-ME-1
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
and	and	CC	O	O	O
chlorpropamide	chlorpropamide	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
little	little	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

CYP	CYP	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Inhibitors	Inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
elimination	elimination	NN	I-NP	O	O
because	because	IN	B-SBAR	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appreciably	appreciably	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
enzymes	enzyme	NNS	I-NP	B-protein	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
or	or	CC	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Pramipexole	Pramipexole	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
CYPIA2	CYPIA2	NN	I-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2CI9	CYP2CI9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2EI	CYP2EI	NN	B-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
Ki	Ki	NN	I-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
uM	uM	NN	I-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
will	will	MD	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
CYP	CYP	NN	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
at	at	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
observed	observe	VBN	B-VP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
tid	tid	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Dopamine	Dopamine	NN	B-NP	O	B-group
antagonists	antagonist	NNS	I-NP	O	E-group
:	:	:	O	O	O
Since	Since	IN	B-SBAR	O	O
pramipexole	pramipexole	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
dopamine	dopamine	NN	I-NP	O	B-group
agonist	agonist	NN	I-NP	O	E-group
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
dopamine	dopamine	NN	B-NP	O	B-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
neuroleptics	neuroleptic	NNS	I-NP	O	S-group-EF-1
(	(	(	O	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
butyrophenones	butyrophenone	NNS	B-NP	O	S-group-EF-1
,	,	,	O	O	O
thioxanthenes	thioxanthene	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
or	or	CC	O	O	O
metoclopramide	metoclopramide	NN	B-NP	O	S-group-EF-1
,	,	,	O	O	O
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MIRAPEX	MIRAPEX	NN	B-NP	B-protein	S-brand-EF-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
MIRAPEX	MIRAPEX	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
its	its	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
gastric	gastric	JJ	B-NP	O	O
emptying	emptying	NN	I-NP	O	O
,	,	,	O	O	O
SYMLIN	SYMLIN	NN	B-NP	O	S-brand-AD-1
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
and	and	CC	O	O	O
agents	agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
slow	slow	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nutrients	nutrient	NNS	B-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
alpha	alpha	NN	B-NP	O	B-group-AD-2
glucosidase	glucosidase	NN	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

SYMLIN	SYMLIN	NN	B-NP	B-protein	S-brand
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
delay	delay	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitantly	concomitantly	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
orally	orally	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
agent	agent	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
determinant	determinant	NN	I-NP	O	O
of	of	IN	B-PP	O	O
effectiveness	effectiveness	NN	B-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
analgesics	analgesic	NNS	B-NP	O	S-group-AD-1
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
or	or	CC	O	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
SYMLIN	SYMLIN	NN	B-NP	O	S-brand-AD-2
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfonylureas	sulfonylurea	NNS	B-NP	O	S-group
or	or	CC	I-NP	O	O
biguanides	biguanide	NNS	I-NP	O	S-group
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SYMLIN	SYMLIN	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

No	No	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SYMLIN	SYMLIN	NN	B-NP	B-protein	S-brand
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

Mixing	Mixing	NNP	B-NP	O	O
SYMLIN	SYMLIN	NNP	I-NP	O	S-brand
and	and	CC	I-NP	O	O
Insulin	Insulin	NNP	I-NP	O	S-drug
The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
SYMLIN	SYMLIN	NN	B-NP	B-protein	S-brand-ME-1
were	be	VBD	B-VP	O	O
altered	alter	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
mixed	mix	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
,	,	,	I-NP	O	O
NPH	NPH	NN	I-NP	B-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
70	70	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
30	30	CD	I-NP	O	O
premixed	premixe	VBN	I-NP	O	O
formulations	formulation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
recombinant	recombinant	JJ	B-NP	B-protein	O
human	human	JJ	I-NP	I-protein	B-drug-ME-2
insulin	insulin	NN	I-NP	I-protein	E-drug-ME-2
immediately	immediately	RB	B-ADJP	O	O
prior	prior	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
injection	injection	NN	B-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
SYMLIN	SYMLIN	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
mixed	mix	VBN	I-VP	O	O
and	and	CC	O	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
separately	separately	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
listed	list	VBN	B-VP	O	O
below	below	IN	B-PP	O	O
are	be	VBP	B-VP	O	O
potentially	potentially	RB	B-ADJP	O	O
clinically	clinically	RB	I-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-1
,	,	,	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
rifampin	rifampin	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
require	require	VB	I-VP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group-ME-2
dose	dose	NN	I-NP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
and	and	CC	O	O	O
thus	thus	RB	B-ADVP	O	O
decrease	decrease	VB	B-VP	O	O
their	their	PRP$	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
steroid	steroid	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Corticosteroids	Corticosteroid	NNS	B-NP	O	S-group-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-ME-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
could	could	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
salicylate	salicylate	NN	I-NP	O	S-group
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
or	or	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylate	salicylate	NN	B-NP	O	S-group-EF-1
toxicity	toxicity	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
corticosteroid	corticosteroid	NN	B-NP	O	S-group-EF-2
is	be	VBZ	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
cautiously	cautiously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-AD-2
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
hypoprothrombinemia	hypoprothrombinemia	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-1
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
is	be	VBZ	B-VP	O	O
variable	variable	JJ	B-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
enhanced	enhance	VBN	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
diminished	diminish	VBN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-1
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
coagulation	coagulation	NN	B-NP	O	O
indices	index	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
maintain	maintain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Anticholinesterases	Anticholinesteras	NNS	B-NP	B-protein	S-group
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
and	and	CC	I-NP	O	O
anticholinesterase	anticholinesterase	NN	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
since	since	IN	B-SBAR	O	O
anticholinesterases	anticholinesteras	NNS	B-NP	B-protein	S-group-ME-1
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
breakdown	breakdown	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	B-drug-ME-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

Antimyasthenics	Antimyasthenics	DT	B-NP	O	O
Concurrent	Concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	B-drug
hydrochloride	hydrochloride	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
antimyasthenics	antimyasthenic	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
myasthenia	myasthenia	NN	B-NP	O	O
gravis	gravis	NN	I-NP	O	O
due	due	IN	B-PP	O	O
to	to	TO	I-PP	O	O
antagonism	antagonism	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antimyasthenics	antimyasthenic	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
skeletal	skeletal	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
.	.	.	O	O	O

Temporary	Temporary	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antimyasthenics	antimyasthenic	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Also	Also	RB	B-NP	O	O
antimyasthenics	antimyasthenic	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
anticholinesterase	anticholinesterase	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

CNS	CNS	NN	B-NP	O	B-group
depressant	depressant	NN	I-NP	O	E-group
medications	medication	NNS	I-NP	O	O
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
and	and	CC	O	O	O
CNS	CNS	NN	B-NP	O	B-group-EF-2
depressant	depressant	NN	I-NP	O	I-group-EF-2
medications	medication	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
additive	additive	JJ	B-NP	O	O
depressant	depressant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Hyaluronidase	Hyaluronidase	NN	B-NP	O	S-drug
:	:	:	O	O	O
Hyaluronidase	Hyaluronidase	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
diffusion	diffusion	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	B-drug-ME-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
onset	onset	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Neuromuscular	Neuromuscular	JJ	B-NP	O	B-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	O	B-drug
chloride	chloride	NN	I-NP	O	E-drug
)	)	)	O	O	O
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
and	and	CC	O	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	B-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
prolongation	prolongation	NN	B-NP	O	O
or	or	CC	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
.	.	.	O	O	O

Sulfonamides	Sulfonamide	NNS	B-NP	O	S-group
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	B-drug-EF-1
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-EF-1
and	and	CC	I-NP	O	O
sulfonamides	sulfonamide	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antibacterial	antibacterial	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sulfonamide	sulfonamide	NN	I-NP	O	S-group
.	.	.	O	O	O

Acetazolamide	Acetazolamide	NN	B-NP	O	S-drug
:	:	:	O	O	O
Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetazolamide	acetazolamide	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
procaine	procaine	NN	I-NP	O	B-drug-ME-2
hydrochloride	hydrochloride	NN	I-NP	O	E-drug-ME-2
may	may	MD	B-VP	O	O
extend	extend	VB	I-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	O	S-drug
.	.	.	O	O	O

To	To	TO	B-VP	O	O
minimize	minimize	VB	I-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
depression	depression	NN	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
,	,	,	O	O	O
narcotics	narcotic	NNS	B-NP	O	S-group
,	,	,	O	O	O
hypotensive	hypotensive	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
or	or	CC	I-NP	O	O
phenothiazines	phenothiazine	NNS	I-NP	O	S-group
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Ethyl	Ethyl	NN	B-NP	O	B-drug
alcohol	alcohol	NN	I-NP	O	E-drug
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
since	since	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
Antabuse	Antabuse	NN	I-NP	O	O
(	(	(	O	O	O
disulfiram	disulfiram	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
Matulane	Matulane	NNP	B-NP	O	S-brand-AD-1
exhibits	exhibit	VBZ	B-VP	O	O
some	some	DT	B-NP	O	O
monoamine	monoamine	NN	I-NP	B-protein	O
oxidase	oxidase	NN	I-NP	I-protein	O
inhibitory	inhibitory	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-AD-2
antidepressant	antidepressant	JJ	I-NP	O	E-group-AD-2
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
amitriptyline	amitriptyline	NN	B-NP	O	B-drug-AD-2
HCl	HCl	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
imipramine	imipramine	NN	B-NP	O	B-drug-AD-2
HCl	HCl	NN	I-NP	O	E-drug-AD-2
)	)	)	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
foods	food	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
tyramine	tyramine	NN	I-NP	O	S-drug_n-AD-2
content	content	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
wine	wine	NN	B-NP	O	O
,	,	,	O	O	O
yogurt	yogurt	NN	B-NP	O	O
,	,	,	O	O	O
ripe	ripe	NN	B-NP	O	O
cheese	cheese	NN	I-NP	O	O
and	and	CC	I-NP	O	O
bananas	bananas	NN	I-NP	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
common	common	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
many	many	JJ	B-NP	O	O
hydrazine	hydrazine	NN	I-NP	O	B-group
derivatives	derivative	NNS	I-NP	O	E-group
is	be	VBZ	B-VP	O	O
hemolysis	hemolysis	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Heinz	Heinz	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Ehrlich	Ehrlich	NNP	I-NP	O	O
inclusion	inclusion	NN	I-NP	O	O
bodies	body	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
erythrocytes	erythrocyte	NNS	B-NP	B-cell_type	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
cross	cross	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
resistance	resistance	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
chemotherapeutic	chemotherapeutic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
radiotherapy	radiotherapy	NN	B-NP	O	O
or	or	CC	I-NP	O	O
steroids	steroid	NNS	I-NP	O	S-group
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
.	.	.	O	O	O

Thiazide	Thiazide	NN	B-NP	O	B-group-EF-1
diuretics	diuretic	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
accentuate	accentuate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
orthostatic	orthostatic	JJ	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

Antihypertensive	Antihypertensive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
guanethidine	guanethidine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
related	relate	VBN	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
counteracted	counteract	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-EF-2
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
phenothiazines	phenothiazine	NNS	B-NP	O	S-group-ME-2
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
requirements	requirement	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DIPRIVAN	DIPRIVAN	NN	B-NP	O	S-brand-EF-1
Injectable	Injectable	JJ	I-NP	O	O
Emulsion	Emulsion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
intramuscular	intramuscular	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
premedication	premedication	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
narcotics	narcotic	NNS	B-NP	O	S-group-EF-2
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
morphine	morphine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
meperidine	meperidine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
fentanyl	fentanyl	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

and	and	CC	O	O	O
combinations	combination	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
opioids	opioid	NNS	B-NP	O	S-group
and	and	CC	I-NP	O	O
sedatives	sedative	NNS	I-NP	O	S-group
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
benzodiazepines	benzodiazepine	NNS	B-NP	O	S-group
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group
,	,	,	O	O	O
chloral	chloral	JJ	B-NP	O	B-drug
hydrate	hydrate	NN	I-NP	O	E-drug
,	,	,	O	O	O
droperidol	droperidol	NN	B-NP	O	S-drug
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DIPRIVAN	DIPRIVAN	NN	B-NP	O	S-brand
Injectable	Injectable	JJ	I-NP	O	O
Emulsion	Emulsion	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
systolic	systolic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mean	mean	VB	B-VP	O	O
arterial	arterial	JJ	B-NP	O	O
pressures	pressure	NNS	I-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
maintenance	maintenance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
or	or	CC	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DIPRIVAN	DIPRIVAN	NN	B-NP	O	S-brand-AD-1
Injectable	Injectable	JJ	I-NP	O	O
Emulsion	Emulsion	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
desired	desire	VBN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
or	or	CC	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
supplemental	supplemental	JJ	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	B-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
nitrous	nitrous	JJ	B-NP	O	B-drug-AD-2
oxide	oxide	NN	I-NP	O	E-drug-AD-2
or	or	CC	I-NP	O	O
opioids	opioid	NNS	I-NP	O	S-group-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
inhalational	inhalational	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
isoflurane	isoflurane	NN	B-NP	O	S-drug
,	,	,	O	O	O
enflurane	enflurane	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
halothane	halothane	NN	B-NP	O	S-drug
)	)	)	O	O	O
during	during	IN	B-PP	O	O
maintenance	maintenance	NN	B-NP	O	O
with	with	IN	B-PP	O	O
DIPRIVAN	DIPRIVAN	NN	B-NP	O	S-brand
Injectable	Injectable	JJ	I-NP	O	O
Emulsion	Emulsion	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
extensively	extensively	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
inhalational	inhalational	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
sedative	sedative	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
cardiorespiratory	cardiorespiratory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DIPRIVAN	DIPRIVAN	NN	B-NP	O	S-brand
Injectable	Injectable	JJ	I-NP	O	O
Emulsion	Emulsion	NN	I-NP	O	O
.	.	.	O	O	O

DIPRIVAN	DIPRIVAN	NN	B-NP	O	S-brand
Injectable	Injectable	JJ	I-NP	O	O
Emulsion	Emulsion	NN	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
onset	onset	NN	B-NP	O	O
,	,	,	O	O	O
intensity	intensity	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
duration	duration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
commonly	commonly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	B-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
nondepolarizing	nondepolarizing	JJ	B-NP	O	B-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
used	use	VBN	I-NP	O	O
premedications	premedication	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
or	or	CC	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
,	,	,	O	O	O
inhalational	inhalational	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
analgesic	analgesic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
local	local	JJ	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
CNS	CNS	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
depressant	depressant	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
CNS	CNS	NN	I-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
with	with	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
medicinal	medicinal	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
slow	slow	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concomitantly	concomitantly	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Should	Should	MD	O	O	O
this	this	DT	B-NP	O	O
occur	occur	VB	B-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
pharmacologic	pharmacologic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
occurrences	occurrence	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
propoxyphene	propoxyphene	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group
,	,	,	O	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group
,	,	,	O	O	O
or	or	CC	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Sever	Sever	RB	B-NP	O	O
neurologic	neurologic	JJ	I-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
coma	coma	NN	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
.	.	.	O	O	O

MAO	MAO	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group-EF-1
adrenergic	adrenergic	JJ	I-NP	O	I-group-EF-1
blockers	blocker	NNS	I-NP	O	E-group-EF-1
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pseudoephedrine	pseudoephedrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Sympathomimetics	Sympathomimetic	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
mecamylamine	mecamylamine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
veratrum	veratrum	NN	I-NP	O	B-group-EF-2
alkaloids	alkaloid	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Pyrimethamine	Pyrimethamine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
sulfonamides	sulfonamide	NNS	B-NP	O	S-group
,	,	,	O	O	O
quinine	quinine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
antimalarials	antimalarial	NNS	I-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
folate	folate	JJ	B-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
develop	develop	NN	I-NP	O	O
,	,	,	O	O	O
pyrimethamine	pyrimethamine	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

Folinic	Folinic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
(	(	(	O	O	O
leucovorin	leucovorin	NN	B-NP	O	S-drug
)	)	)	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
until	until	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
hematopoiesis	hematopoiesis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
restored	restore	VBN	I-VP	O	O
.	.	.	O	O	O

Mild	Mild	JJ	B-NP	O	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
lorazepam	lorazepam	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
pyrimethamine	pyrimethamine	NN	I-NP	O	S-drug-EF-2
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug
:	:	:	O	O	O
Cholestyramine	Cholestyramine	NN	B-NP	O	S-drug-MU-1
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
and	and	CC	I-NP	O	O
enterohepatic	enterohepatic	JJ	I-NP	O	O
cycling	cycling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
raloxifene	raloxifene	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
EVISTA	EVISTA	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
coadministration	coadministration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EVISTA	EVISTA	NN	B-NP	B-protein	S-brand
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
under	under	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
EVISTA	EVISTA	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
Highly	Highly	RB	I-NP	B-protein	O
Protein	Protein	NN	I-NP	I-protein	O
-	-	HYPH	I-NP	O	O
Bound	Bound	NN	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Raloxifene	Raloxifene	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
95	95	CD	I-NP	O	O
%	%	NN	I-NP	O	O
bound	bind	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
raloxifene	raloxifene	NN	B-NP	O	S-drug
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
EVISTA	EVISTA	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
protein	protein	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
bound	bind	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
clofibrate	clofibrate	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
and	and	CC	O	O	O
diazoxide	diazoxide	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

See	See	VB	B-VP	O	O
also	also	RB	B-ADVP	O	O
CLINICAL	CLINICAL	JJ	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NN	I-NP	O	O
,	,	,	O	O	O
Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
TRITEC	TRITEC	NN	B-NP	B-protein	S-brand-ME-1
with	with	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
ranitidine	ranitidine	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
57	57	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
bismuth	bismuth	NN	I-NP	O	O
trough	trough	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
14	14	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxy	hydroxy	NN	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
clarithromycin	clarithromycin	NN	I-NP	O	E-drug_n
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
(	(	(	O	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylate	salicylate	NN	B-NP	O	S-group
absorption	absorption	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
unimportant	unimportant	JJ	I-ADJP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antacid	antacid	NN	B-NP	O	S-group-ME-1
(	(	(	O	O	O
170	170	CD	B-NP	O	O
mEq	mEq	NN	I-NP	O	O
)	)	)	O	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
28	28	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bismuth	bismuth	NN	B-NP	O	O
from	from	IN	B-PP	O	O
TRITEC	TRITEC	NN	B-NP	B-cell_type	S-brand-ME-2
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
insignificant	insignificant	JJ	I-ADJP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
information	information	NN	B-NP	O	O
on	on	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ranitidine	ranitidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
refer	refer	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
ZANTAC	ZANTAC	NN	I-NP	B-DNA	S-brand
package	package	NN	I-NP	I-DNA	O
insert	insert	NN	I-NP	I-DNA	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-ME-1
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
retapamulin	retapamulin	NN	B-NP	O	S-drug
geometric	geometric	JJ	I-NP	O	O
mean	mean	JJ	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	O	O	O
24	24	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Cmax	Cmax	NN	B-NP	B-protein	O
by	by	IN	B-PP	O	O
81	81	CD	B-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
topical	topical	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
retapamulin	retapamulin	NN	B-NP	O	S-drug-ME-2
ointment	ointment	NN	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
abraded	abrade	VBN	I-NP	O	O
skin	skin	NN	I-NP	O	O
of	of	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
adult	adult	JJ	I-NP	O	O
males	male	NNS	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
low	low	JJ	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
retapamulin	retapamulin	NN	B-NP	B-protein	S-drug
following	follow	VBG	B-PP	O	O
topical	topical	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
dosage	dosage	NN	B-NP	O	O
adjustments	adjustment	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
retapamulin	retapamulin	NN	B-NP	B-protein	S-drug
are	be	VBP	B-VP	O	O
unnecessary	unnecessary	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
P450	P450	NN	I-NP	B-protein	O
inhibition	inhibition	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
following	follow	VBG	B-PP	O	O
topical	topical	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ALTABAX	ALTABAX	NN	B-NP	B-protein	S-brand
,	,	,	O	O	O
retapamulin	retapamulin	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
substrates	substrate	NNS	I-NP	I-protein	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ALTABAX	ALTABAX	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
topical	topical	JJ	I-NP	O	O
products	product	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
of	of	IN	B-PP	O	O
skin	skin	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Retavase	Retavase	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cardioactive	cardioactive	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
bleeding	bleeding	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group-EF-1
K	K	NN	I-NP	O	I-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
,	,	,	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
abciximab	abciximab	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
if	if	IN	B-SBAR	O	O
administered	administer	VBN	B-VP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
or	or	CC	B-PP	O	O
after	after	IN	I-PP	O	O
Retavase	Retavase	NN	B-NP	O	S-brand-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug
B2	B2	NN	I-NP	O	E-drug
(	(	(	O	O	O
Riboflavin	Riboflavin	NN	B-NP	O	S-drug
)	)	)	O	O	O
:	:	:	O	O	O
Alcohol	Alcohol	NN	B-NP	O	S-drug-ME-1
-	-	HYPH	B-NP	O	O
impairs	impair	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
riboflavin	riboflavin	NN	B-NP	O	S-drug-ME-2

Probenecid	Probenecid	NN	B-NP	O	S-drug-ME-1
-	-	HYPH	I-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
riboflavin	riboflavin	NN	B-NP	O	S-drug-ME-2
;	;	:	O	O	O

requirements	requirement	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
riboflavin	riboflavin	NN	B-NP	B-protein	S-drug-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
probenecid	probenecid	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	O	S-drug
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
cimetidine	cimetidine	NN	I-NP	O	S-drug
use	use	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rimantadine	rimantadine	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rimantadine	rimantadine	NN	B-NP	O	B-drug-ME-1
HCl	HCl	NN	I-NP	O	E-drug-ME-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
one	one	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Cimetidine	Cimetidine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
four	four	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
total	total	JJ	I-NP	O	O
rimantadine	rimantadine	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
adults	adult	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
total	total	JJ	I-NP	O	O
rimantadine	rimantadine	NN	I-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	O	S-drug
:	:	:	O	O	O
Rimantadine	Rimantadine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
,	,	,	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
13	13	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
12	12	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
day	day	NN	B-NP	O	O
11	11	CD	I-NP	O	O
,	,	,	O	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
(	(	(	O	O	O
650	650	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
four	four	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
started	start	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
continued	continue	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rimantadine	rimantadine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
11	11	CD	B-NP	O	O
and	and	CC	I-NP	O	O
13	13	CD	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
with	with	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug-ME-1
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AUC	AUC	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
rimantadine	rimantadine	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
11	11	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand
:	:	:	O	O	O
Rimantadine	Rimantadine	NN	B-NP	O	B-drug
HCl	HCl	NN	I-NP	O	E-drug
,	,	,	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
twice	twice	RB	B-VP	O	O
daily	daily	RB	I-VP	O	O
fro	fro	VB	I-VP	O	O
13	13	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
12	12	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
day	day	NN	B-NP	O	O
11	11	CD	I-NP	O	O
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
(	(	(	O	O	O
650	650	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
four	four	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
started	start	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
continued	continue	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rimantadine	rimantadine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
11	11	CD	B-NP	O	O
and	and	CC	I-NP	O	O
13	13	CD	I-NP	O	O
.	.	.	O	O	O

Peak	Peak	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rimantadine	rimantadine	NN	B-NP	O	S-drug-ME-1
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
approximately	approximately	RB	B-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	I-PP	O	O
presence	presence	NN	I-PP	O	O
of	of	IN	I-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Effect	Effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Exelon	Exelon	NN	B-NP	O	S-brand
(	(	(	O	O	O
rivastigmine	rivastigmine	NN	B-NP	O	B-drug
tartrate	tartrate	NN	I-NP	O	E-drug
)	)	)	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Metabolism	Metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
:	:	:	O	O	O
Rivastigmine	Rivastigmine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
hydrolysis	hydrolysis	NN	B-NP	O	O
by	by	IN	B-PP	O	O
esterases	esteras	NNS	B-NP	B-protein	O
.	.	.	O	O	O

Minimal	Minimal	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
isoenzymes	isoenzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
metabolized	metabolize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
expected	expect	VBN	I-VP	O	O
:	:	:	O	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
/	/	SYM	B-VP	O	O
5	5	CD	B-NP	O	O
,	,	,	O	O	O
CYP2E1	CYP2E1	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C9	CYP2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
rivastigmine	rivastigmine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Exelon	Exelon	NNP	B-NP	O	S-brand
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Other	Other	JJ	B-NP	O	O
Drugs	Drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Metabolism	Metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Exelon	Exelon	NNP	B-NP	O	S-brand
:	:	:	O	O	O
Drugs	Drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
inhibit	inhibit	VBP	I-VP	O	O
CYP450	CYP450	NN	B-NP	B-protein	O
metabolism	metabolism	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rivastigmine	rivastigmine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Single	Single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rivastigmine	rivastigmine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Population	Population	NN	B-NP	O	O
PK	PK	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
database	database	NN	I-NP	O	O
of	of	IN	B-PP	O	O
625	625	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rivastigmine	rivastigmine	NN	B-NP	O	S-drug
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influenced	influence	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
commonly	commonly	RB	B-NP	O	O
prescribed	prescribe	VBN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
antacids	antacid	NNS	B-NP	O	S-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
77	77	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
antihypertensives	antihypertensive	NNS	B-NP	O	S-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
72	72	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
75	75	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
antidiabetics	antidiabetic	NNS	B-NP	O	S-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
21	21	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
nonsteroidal	nonsteroidal	JJ	B-ADJP	O	B-group
anti	anti	AFX	B-NP	O	I-group
-	-	HYPH	I-NP	O	I-group
inflammatory	inflammatory	JJ	I-NP	O	I-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
79	79	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
estrogens	estrogen	NNS	B-NP	O	S-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
70	70	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
salicylate	salicylate	NN	B-NP	O	B-group
analgesics	analgesic	NNS	I-NP	O	E-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
177	177	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
antianginals	antianginal	NNS	B-NP	O	S-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
35	35	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
15	15	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Anticholinergics	Anticholinergic	NNS	B-NP	O	S-group
:	:	:	O	O	O
Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
their	their	PRP$	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
,	,	,	O	O	O
cholinesterase	cholinesterase	NN	B-NP	O	B-group-IN-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-IN-1
have	have	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group-IN-2
medications	medication	NNS	I-NP	O	E-group-IN-2
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Cholinomimetics	Cholinomimetic	NNS	B-NP	O	S-group
and	and	CC	O	O	O
Other	Other	JJ	B-NP	O	O
Cholinesterase	Cholinesterase	NN	I-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
:	:	:	O	O	O
A	A	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
cholinesterase	cholinesterase	NN	B-NP	O	B-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
are	be	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
similar	similar	JJ	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	B-group-EF-2
blocking	block	VBG	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
or	or	CC	O	O	O
cholinergic	cholinergic	JJ	B-NP	O	B-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
bethanechol	bethanechol	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZEMURON	ZEMURON	NN	B-NP	B-DNA	S-brand
(	(	(	O	O	O
rocuronium	rocuronium	NN	B-NP	O	B-drug
bromide	bromide	NN	I-NP	O	E-drug
)	)	)	O	O	O
Injection	Injection	NN	B-NP	O	O
before	before	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
,	,	,	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
attenuating	attenuate	VBG	B-VP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
ZEMURON	ZEMURON	NN	B-NP	B-DNA	S-brand-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
until	until	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
from	from	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ZEMURON	ZEMURON	NN	B-NP	O	S-brand
0.6	0.6	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
T	T	NN	B-NP	B-DNA	O
1	1	CD	I-NP	I-DNA	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
36	36	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
14	14	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
57	57	CD	I-NP	O	O
,	,	,	I-NP	O	O
n	n	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
vs	v	NNS	B-NP	O	O
.	.	.	O	O	O

28	28	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
(	(	(	O	O	O
17	17	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
51	51	CD	I-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
without	without	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
documenting	document	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZEMURON	ZEMURON	NN	B-NP	B-DNA	S-brand
before	before	IN	B-PP	O	O
or	or	CC	I-PP	O	O
after	after	IN	I-PP	O	O
other	other	JJ	B-NP	O	O
nondepolarizing	nondepolarizing	JJ	I-NP	O	B-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
other	other	JJ	B-NP	O	O
nondepolarizing	nondepolarizing	JJ	I-NP	O	B-group
muscle	muscle	NN	I-NP	O	I-group
relaxants	relaxant	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
succession	succession	NN	B-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
None	None	NN	B-NP	O	O
known	know	VBN	B-VP	O	O
.	.	.	O	O	O

Ropivacaine	Ropivacaine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
local	local	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	S-group-AD-2
or	or	CC	I-NP	O	O
agents	agent	NNS	I-NP	O	O
structurally	structurally	RB	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
amide	amide	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
type	type	NN	I-NP	O	I-group
local	local	JJ	I-NP	O	I-group
anesthetics	anesthetic	NNS	I-NP	O	E-group
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
additive	additive	JJ	B-ADJP	O	O
.	.	.	O	O	O

Cytochrome	Cytochrome	NN	B-NP	B-protein	O
P4501A2	P4501A2	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3	3	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
hydroxy	hydroxy	NN	I-NP	O	I-drug_n
ropivacaine	ropivacaine	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ropivacaine	ropivacaine	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
during	during	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
bid	bid	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP1A2	CYP1A2	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P4501A2	P4501A2	NN	I-NP	I-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-IN-1
,	,	,	O	O	O
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Ropivacaine	Ropivacaine	NNP	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
can	can	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
Ropivacaine	Ropivacaine	NNP	B-NP	O	S-drug
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
ropivacaine	ropivacaine	NN	I-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
.	.	.	O	O	O

Possible	Possible	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP1A2	CYP1A2	NN	B-NP	B-protein	O
via	via	IN	B-PP	O	O
competitive	competitive	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
imipramine	imipramine	NN	I-NP	O	S-drug
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
potent	potent	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
bid	bid	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ropivacaine	ropivacaine	NN	B-NP	O	S-drug
infusion	infusion	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
)	)	)	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
in	in	FW	B-PP	O	O
-	-	HYPH	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ropivacaine	ropivacaine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

An	An	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
gemfibrozil	gemfibrozil	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rosiglitazone	rosiglitazone	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rosiglitazone	rosiglitazone	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
or	or	CC	O	O	O
an	an	DT	B-NP	O	O
inducer	inducer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP2C8	CYP2C8	NN	B-NP	B-protein	O
is	be	VBZ	B-VP	O	O
started	start	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
stopped	stop	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
rosiglitazone	rosiglitazone	NN	B-NP	O	S-drug
,	,	,	O	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
needed	need	VBN	I-VP	O	O
based	base	VBN	B-VP	O	O
upon	upon	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
contra	contra	AFX	O	O	O
-	-	HYPH	O	O	O
indicated	indicate	VBN	B-VP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
Vasoconstrictive	Vasoconstrictive	JJ	I-NP	O	O
ergot	ergot	NN	I-NP	O	B-group
alkaloids	alkaloid	NNS	I-NP	O	E-group
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administrations	administration	NNS	I-NP	O	O
not	not	RB	O	O	O
recommended	recommend	VBD	B-VP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
Terfenadine	Terfenadine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
astemizole	astemizole	NN	I-NP	O	S-drug
:	:	:	O	O	O
Certain	Certain	JJ	B-NP	O	O
macrolides	macrolide	NNS	I-NP	O	S-group-IN-1
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-IN-2
and	and	CC	I-NP	O	O
astemizole	astemizole	NN	I-NP	O	S-drug-IN-2
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	O
,	,	,	O	O	O
typically	typically	RB	B-ADVP	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	IN	I-NP	O	O
pointe	pointe	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
a	a	DT	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
roxithromycin	roxithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
roxithromycin	roxithromycin	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-2
or	or	CC	I-NP	O	O
astemizole	astemizole	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

-	-	HYPH	B-NP	O	O
Cisapride	Cisapride	NN	I-NP	O	S-drug
,	,	,	O	O	O
pimozide	pimozide	NN	B-NP	O	S-drug-ME-1
:	:	:	O	O	O
Other	Other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
cisapride	cisapride	NN	B-NP	O	S-drug-ME-1
or	or	CC	I-NP	O	O
pimozide	pimozide	NN	I-NP	O	S-drug
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolised	metabolise	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	B-protein	O
CYP3A	CYP3A	NN	I-NP	I-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrythmias	arrythmia	NNS	I-NP	O	O
(	(	(	O	O	O
typically	typically	RB	B-ADVP	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	IN	I-NP	O	O
pointe	pointe	NN	I-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increase	increase	NN	B-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
serum	serum	NN	I-NP	O	O
level	level	NN	I-NP	O	O
subsequent	subsequent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
isozyme	isozyme	NN	I-NP	B-protein	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
some	some	DT	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group-ME-2
antibacterials	antibacterial	NNS	I-NP	O	E-group-ME-2
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
a	a	DT	I-NP	O	O
risk	risk	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
verified	verify	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
roxithromycin	roxithromycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
combination	combination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
roxithromycin	roxithromycin	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Nasal	Nasal	JJ	B-NP	O	O
Spray	Spray	NN	I-NP	O	O
:	:	:	O	O	O
Formal	Formal	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
designed	design	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
drug	drug	NN	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Calcitonin	Calcitonin	NN	B-NP	B-protein	B-drug
(	(	(	O	O	I-drug
salmon	salmon	NN	B-NP	O	I-drug
)	)	)	O	O	E-drug
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
done	do	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Calcitonin	Calcitonin	NN	B-NP	B-protein	B-drug
(	(	(	I-NP	O	I-drug
salmon	salmon	NN	I-NP	O	I-drug
)	)	)	I-NP	O	E-drug
nasal	nasal	JJ	I-NP	O	O
spray	spray	NN	I-NP	O	O
ingredients	ingredient	NNS	I-NP	O	O
.	.	.	O	O	O

Currently	Currently	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Calcitonin	Calcitonin	NN	B-NP	B-protein	B-drug
(	(	(	O	O	I-drug
salmon	salmon	NN	B-NP	O	I-drug
)	)	)	O	O	E-drug
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diphosphonates	diphosphonate	NNS	B-NP	O	S-group
in	in	IN	B-PP	O	O
postmenopausal	postmenopausal	JJ	B-NP	O	O
osteoporosis	osteoporosis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
;	;	:	O	O	O

however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Paget	Paget	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
Disease	Disease	NN	I-NP	O	O
prior	prior	JJ	I-NP	O	O
diphosphonate	diphosphonate	NN	I-NP	O	S-group-EF-1
use	use	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
resorptive	resorptive	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Calcitonin	Calcitonin	NN	B-NP	B-protein	B-drug-EF-2
(	(	(	O	O	I-drug-EF-2
salmon	salmon	NN	B-NP	O	I-drug-EF-2
)	)	)	O	O	E-drug-EF-2
nasal	nasal	JJ	B-NP	O	O
spray	spray	NN	I-NP	O	O
.	.	.	O	O	O

Salicylates	Salicylate	NNS	B-NP	O	S-group
antagonize	antagonize	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
uricosuric	uricosuric	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
.	.	.	O	O	O
drugs	drug	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
gout	gout	NN	B-NP	O	O
.	.	.	O	O	O

ASPIRIN	ASPIRIN	NNP	B-NP	O	S-brand-EF-1
AND	AND	CC	I-NP	O	O
OTHER	OTHER	NNP	I-NP	O	O
SALICYLATE	SALICYLATE	NNP	I-NP	O	B-group-EF-1
DRUGS	DRUGS	NNP	I-NP	O	E-group-EF-1
WILL	WILL	NNP	I-NP	O	O
BE	BE	NNP	I-NP	O	O
ADDITIVE	ADDITIVE	NNP	I-NP	O	O
TO	TO	TO	B-PP	O	O
DISALCID	DISALCID	NNP	B-NP	O	S-brand-EF-2
AND	AND	CC	I-NP	O	O
MAY	MAY	NNP	I-NP	O	O
INCREASE	INCREASE	NN	I-NP	O	O
PLASMA	PLASMA	NN	I-NP	O	O
CONCENTRATIONS	CONCENTRATIONS	NNS	I-NP	O	O
OF	OF	IN	B-PP	O	O
SALICYLIC	SALICYLIC	NN	B-NP	O	B-drug
ACID	ACID	NN	I-NP	O	E-drug
TO	TO	TO	B-PP	O	O
TOXIC	TOXIC	NN	B-NP	O	O
LEVELS	LEVELS	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
foods	food	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
raise	raise	VBP	B-VP	O	O
urine	urine	NN	B-NP	O	O
pH	pH	NN	I-NP	O	O
will	will	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
salicylic	salicylic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
lowering	lower	VBG	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
;	;	:	O	O	O

acidifying	acidify	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
foods	food	NNS	I-NP	O	O
will	will	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
increase	increase	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Salicylates	Salicylate	NNS	B-NP	O	S-group-EF-1
given	give	VBN	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
predispose	predispose	VB	I-VP	O	O
to	to	TO	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

Salicylates	Salicylate	NNS	B-NP	O	S-group-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	B-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sulfonylurea	sulfonylurea	NN	I-NP	O	O
class	class	NN	I-NP	O	O
.	.	.	O	O	O

Salicylate	Salicylate	NNP	B-NP	O	S-group-ME-1
competes	compete	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
protein	protein	NN	B-NP	B-DNA	O
binding	binding	NN	I-NP	I-DNA	O
sites	site	NNS	I-NP	I-DNA	O
,	,	,	O	O	O
notably	notably	RB	B-ADVP	O	O
penicillin	penicillin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
thiopental	thiopental	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
thyroxine	thyroxine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
triiodothyronine	triiodothyronine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
sulfinpyrazone	sulfinpyrazone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
and	and	CC	O	O	O
possibly	possibly	RB	B-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group-ME-2
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Salicylate	Salicylate	NNP	I-NP	O	S-group
competes	compete	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
thyroid	thyroid	NN	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
for	for	IN	B-PP	O	O
binding	binding	NN	B-NP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reflected	reflect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
depressed	depressed	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
T4	T4	NN	I-NP	O	O
value	value	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
;	;	:	O	O	O

thyroid	thyroid	NN	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
basal	basal	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
Leukine	Leukine	NN	B-NP	O	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
fully	fully	RB	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
myeloproliferative	myeloproliferative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Leukine	Leukine	NN	B-NP	O	S-brand-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
lithium	lithium	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	S-group-EF-2
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
scopolamine	scopolamine	NN	B-NP	O	S-drug
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
decreased	decrease	VBN	B-NP	O	O
gastric	gastric	JJ	I-NP	O	O
motility	motility	NN	I-NP	O	O
and	and	CC	O	O	O
delayed	delay	VBD	B-VP	O	O
gastric	gastric	JJ	B-NP	O	O
emptying	emptying	NN	I-NP	O	O
.	.	.	O	O	O

Scopolamine	Scopolamine	NN	B-NP	O	S-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
care	care	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
causing	cause	VBG	B-VP	O	O
CNS	CNS	NN	B-NP	B-protein	O
effects	effect	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
sedatives	sedative	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
tranquilizers	tranquilizer	NNS	B-NP	O	S-group-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Special	Special	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
paid	pay	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
potential	potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
having	have	VBG	B-VP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
;	;	:	O	O	O

e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
belladonna	belladonna	NN	I-NP	O	B-group
alkaloids	alkaloid	NNS	I-NP	O	E-group
,	,	,	O	O	O
antihistamines	antihistamine	NNS	B-NP	O	S-group
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
meclizine	meclizine	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
muscle	muscle	NN	B-NP	O	B-group
relaxants	relaxant	NNS	I-NP	O	E-group
.	.	.	O	O	O

Laboratory	Laboratory	NNP	B-NP	O	O
Test	Test	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Scopolamine	Scopolamine	NNP	I-NP	O	S-drug
will	will	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastric	gastric	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Barbiturates	Barbiturate	NNS	B-NP	O	S-group-IN-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-IN-2
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group-IN-2
,	,	,	O	O	O
quinidine	quinidine	NN	B-NP	O	S-group-IN-2
,	,	,	O	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-IN-2
,	,	,	O	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	B-group-IN-2
blockers	blocker	NNS	I-NP	O	E-group-IN-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stupor	stupor	NN	B-NP	O	O
,	,	,	O	O	O
muscular	muscular	JJ	B-NP	O	O
rigidity	rigidity	NN	I-NP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
agitation	agitation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
elevated	elevate	VBN	B-NP	O	O
temperature	temperature	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
selegiline	selegiline	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
meperidine	meperidine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Symptoms	Symptom	NNS	B-NP	O	O
usually	usually	RB	B-ADVP	O	O
resolve	resolve	VBP	B-VP	O	O
over	over	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
typical	typical	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meperidine	meperidine	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
MAOIs	MAOI	NNS	I-NP	B-protein	S-group-IN-2
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
serious	serious	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
severe	severe	JJ	B-NP	O	O
agitation	agitation	NN	I-NP	O	O
,	,	,	O	O	O
hallucinations	hallucination	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Severe	Severe	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
ELDEPRYL	ELDEPRYL	NN	B-NP	O	S-brand-EF-2
and	and	CC	O	O	O
selective	selective	JJ	B-NP	O	B-group-EF-1
serotonin	serotonin	NN	I-NP	O	I-group-EF-1
reuptake	reuptake	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
and	and	CC	O	O	O
ELDEPRYL	ELDEPRYL	NN	B-NP	O	S-brand-EF-2
.	.	.	O	O	O

One	One	CD	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
crisis	crisis	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
selegiline	selegiline	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
sympathomimetic	sympathomimetic	JJ	I-NP	O	B-group-EF-2
medication	medication	NN	I-NP	O	E-group-EF-2
(	(	(	O	O	O
ephedrine	ephedrine	NN	B-NP	O	S-drug-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	O	S-drug
:	:	:	O	O	O
There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
,	,	,	O	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
mean	mean	JJ	B-NP	O	O
peak	peak	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
(	(	(	O	O	O
Cmax	Cmax	NN	B-NP	O	O
,	,	,	O	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
sitagliptin	sitagliptin	NN	I-NP	O	S-drug-ME-2
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
appropriately	appropriately	RB	B-ADVP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
JANUVIA	JANUVIA	NN	I-NP	O	S-brand
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Additives	Additive	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
incompatible	incompatible	JJ	B-ADJP	O	O
;	;	:	O	O	O

norepinephrine	norepinephrine	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
dobutamine	dobutamine	NN	I-NP	O	S-drug-IN-1
are	be	VBP	B-VP	O	O
incompatible	incompatible	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug-IN-2
bicarbonate	bicarbonate	NN	I-NP	O	E-drug-IN-2
solution	solution	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	B-drug
bicarbonate	bicarbonate	NN	I-NP	O	E-drug
to	to	TO	B-PP	O	O
parenteral	parenteral	JJ	B-NP	O	O
solutions	solution	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
calcium	calcium	NN	B-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
where	where	WRB	B-ADVP	O	O
compatibility	compatibility	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
previously	previously	RB	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Precipitation	Precipitation	NN	B-NP	O	O
or	or	CC	I-NP	O	O
haze	haze	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
sodium	sodium	NN	B-NP	O	O
bicarbonate	bicarbonate	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
calcium	calcium	NN	I-NP	O	O
admixtures	admixture	NNS	I-NP	O	O
.	.	.	O	O	O

NOTE	NOTE	NN	B-NP	O	O
:	:	:	O	O	O
Do	Do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
use	use	VB	I-VP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
contains	contain	VBZ	B-VP	O	O
precipitate	precipitate	JJ	B-ADJP	O	O
.	.	.	O	O	O

Additives	Additive	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
incompatible	incompatible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Consult	Consult	NN	B-NP	O	O
with	with	IN	B-PP	O	O
pharmacist	pharmacist	NN	B-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
introducing	introduce	VBG	B-VP	O	O
additives	additive	NNS	B-NP	O	O
,	,	,	O	O	O
use	use	VBP	B-VP	O	O
aseptic	aseptic	JJ	B-NP	O	O
technique	technique	NN	I-NP	O	O
,	,	,	O	O	O
mix	mix	NN	B-NP	O	O
thoroughly	thoroughly	RB	B-ADVP	O	O
and	and	CC	O	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
store	store	VB	I-VP	O	O
.	.	.	O	O	O

Do	Do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
exceed	exceed	VB	I-VP	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VESIcare	VESIcare	NNP	B-NP	O	S-brand-AD-1
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-2
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Congenital	Congenital	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
Acquired	Acquire	VBN	I-NP	O	O
QT	QT	NN	I-NP	O	O
Prolongation	Prolongation	NN	I-NP	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
solifenacin	solifenacin	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
in	in	IN	B-PP	O	O
76	76	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
prolonging	prolonging	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
less	less	JJR	B-ADVP	O	O
with	with	IN	B-PP	O	O
solifenacin	solifenacin	NN	B-NP	O	S-drug
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
maximum	maximum	NN	I-NP	O	O
recommended	recommend	VBN	B-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
solifenacin	solifenacin	NN	B-NP	O	S-drug
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
as	as	RB	B-ADJP	O	O
large	large	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
moxifloxacin	moxifloxacin	NN	I-NP	O	S-drug
at	at	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
observation	observation	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
decisions	decision	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
prescribe	prescribe	VB	I-VP	O	O
VESIcare	VESIcare	NNP	B-NP	O	S-brand
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
QT	QT	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
or	or	CC	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
medications	medication	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

Excessive	Excessive	JJ	B-NP	O	O
glucocorticoid	glucocorticoid	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
will	will	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
growth	growth	NN	I-NP	O	O
-	-	HYPH	O	O	O
promoting	promote	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	B-drug
GH	GH	NN	I-NP	O	E-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ACTH	ACTH	NN	B-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
glucocorticoid	glucocorticoid	NN	I-NP	O	S-group
-	-	HYPH	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
carefully	carefully	RB	B-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
an	an	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
growth	growth	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Nutropin	Nutropin	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
glucocorticoid	glucocorticoid	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
growth	growth	NN	I-NP	O	O
-	-	HYPH	O	O	O
promoting	promote	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Nutropin	Nutropin	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	S-group
replacement	replacement	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
glucocorticoid	glucocorticoid	NN	I-NP	O	S-group
dose	dose	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
adjusted	adjust	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Nutropin	Nutropin	NN	B-NP	O	S-brand
s	s	VBZ	B-VP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Limited	Limit	VBN	B-NP	O	O
published	publish	VBN	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
GH	GH	NN	B-NP	O	S-drug-ME-1
treatment	treatment	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	O	O
CP450	CP450	NN	B-NP	B-protein	O
)	)	)	O	O	O
mediated	mediate	VBD	B-VP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug-ME-2
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
GH	GH	NN	B-NP	O	S-drug-ME-1
administration	administration	NN	I-NP	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CP450	CP450	NN	B-NP	B-protein	O
liver	liver	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
sex	sex	NN	B-NP	O	B-group-ME-2
steroids	steroid	NNS	I-NP	O	E-group-ME-2
,	,	,	O	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	S-group-ME-2
,	,	,	O	O	O
cyclosporin	cyclosporin	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
when	when	WRB	B-ADVP	O	O
GH	GH	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CP450	CP450	NN	B-NP	B-protein	O
liver	liver	NN	I-NP	I-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
NEXAVAR	NEXAVAR	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
/	/	SYM	B-NP	O	O
eliminated	eliminate	VBN	B-VP	O	O
predominantly	predominantly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
UGT1A1	UGT1A1	NN	I-NP	B-protein	O
pathway	pathway	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	I-NP	O	O
irinotecan	irinotecan	NN	I-NP	O	S-drug-AD-2
)	)	)	O	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
NEXAVAR	NEXAVAR	NN	B-NP	O	S-brand-ME-1
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
21	21	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AUC	AUC	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
NEXAVAR	NEXAVAR	NN	B-NP	B-protein	S-brand-AD-2
.	.	.	O	O	O

Sorafenib	Sorafenib	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
CYP2B6	CYP2B6	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2C8	CYP2C8	NN	I-NP	B-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
with	with	IN	B-PP	O	O
Ki	Ki	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
?	?	.	I-NP	O	O
M	M	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2B6	CYP2B6	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2C8	CYP2C8	NN	I-NP	B-protein	O
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
co	co	AFX	O	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
NEXAVAR	NEXAVAR	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
substrates	substrate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2B6	CYP2B6	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
CYP2C8	CYP2C8	NN	I-NP	B-protein	O
with	with	IN	B-PP	O	O
NEXAVAR	NEXAVAR	NN	B-NP	B-protein	S-brand
.	.	.	O	O	O

Zidovudine	Zidovudine	NN	B-NP	O	S-drug-EF-1
competitively	competitively	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stavudine	stavudine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	O	S-drug-AD-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ZERIT	ZERIT	NN	B-NP	B-protein	S-brand-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stavudine	stavudine	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
relevant	relevant	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
ribavirin	ribavirin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
;	;	:	O	O	O

therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stavudine	stavudine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
either	either	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Streptase	Streptase	NNP	B-NP	O	S-brand
,	,	,	O	O	O
Streptokinase	Streptokinase	NNP	B-NP	B-protein	S-drug
,	,	,	O	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
well	well	RB	B-ADJP	O	O
studied	study	VBN	I-ADJP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Anticoagulants	Anticoagulants	NNP	B-NP	O	S-group
and	and	CC	O	O	O
Antiplatelet	Antiplatelet	NNP	B-NP	O	B-group
Agents	Agent	NNPS	I-NP	O	E-group
-	-	HYPH	O	O	O
-	-	HYPH	O	B-protein	O
Streptase	Streptase	NNP	B-NP	I-protein	S-brand-EF-1
,	,	,	O	O	O
Streptokinase	Streptokinase	NNP	B-NP	B-protein	S-drug-EF-1
,	,	,	O	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
antiplatelet	antiplatelet	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
and	and	CC	O	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
bleeding	bleed	VBG	I-VP	O	O
complications	complication	NNS	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
MI	MI	NN	I-NP	O	O
,	,	,	O	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
not	not	RB	O	O	O
otherwise	otherwise	RB	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
Streptokinase	Streptokinase	NNP	B-NP	O	S-drug
(	(	(	O	O	O
see	see	VB	B-VP	O	O
below	below	IN	B-PP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Anticoagulation	Anticoagulation	NN	B-NP	O	O
and	and	CC	I-NP	O	O
Antiplatelets	Antiplatelet	NNS	I-NP	O	S-group
After	After	IN	B-PP	O	O
Treatment	Treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
Myocardial	Myocardial	JJ	B-NP	O	O
Infarction	Infarction	NN	I-NP	O	O
-	-	HYPH	O	O	O
-	-	SYM	B-NP	O	O
In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
infarction	infarction	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reinfarction	reinfarction	NN	B-NP	O	O
and	and	CC	I-NP	O	O
stroke	stroke	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand-EF-1
to	to	TO	B-PP	O	O
Streptokinase	Streptokinase	NNP	B-NP	B-protein	S-drug-EF-2
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
minimal	minimal	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
minor	minor	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
(	(	(	O	O	O
3.9	3.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
3.1	3.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O

ZANOSAR	ZANOSAR	NN	B-NP	B-protein	S-brand
may	may	MD	B-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
additive	additive	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cytotoxic	cytotoxic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Streptozocin	Streptozocin	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
severe	severe	JJ	B-NP	O	O
bone	bone	NN	I-NP	O	O
marrow	marrow	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
;	;	:	O	O	O

a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	O	S-drug-AD-1
dosage	dosage	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ZANOSAR	ZANOSAR	NN	B-NP	B-protein	S-brand-AD-2
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
streptozocin	streptozocin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
case	case	NN	I-NP	O	O
to	to	TO	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
streptozocin	streptozocin	NN	I-NP	O	S-drug
cytotoxicity	cytotoxicity	NN	I-NP	O	O
.	.	.	O	O	O

CHEMET	CHEMET	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug
supplements	supplement	NNS	I-NP	O	O
;	;	:	O	O	O

interactions	interaction	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
systematically	systematically	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CHEMET	CHEMET	NN	B-NP	O	S-brand-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
chelation	chelation	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
CaNa	CaNa	NN	B-NP	B-protein	B-drug-AD-2
2	2	CD	I-NP	I-protein	I-drug-AD-2
EDTA	EDTA	NN	I-NP	I-protein	E-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Tests	Test	VBZ	B-VP	O	O
Interaction	Interaction	NN	B-NP	O	O
:	:	:	O	O	O
Succimer	Succimer	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
succimer	succimer	NN	B-NP	O	S-drug
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
false	false	JJ	B-NP	O	O
positive	positive	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
ketones	ketone	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
using	use	VBG	B-VP	O	O
nitroprusside	nitroprusside	NN	B-NP	O	O
reagents	reagent	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Ketostix	Ketostix	NNP	B-NP	O	O
and	and	CC	O	O	O
falsely	falsely	RB	B-VP	O	O
decreased	decrease	VBD	I-VP	O	O
measurements	measurement	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
uric	uric	JJ	I-NP	O	O
acid	acid	NN	I-NP	O	O
and	and	CC	I-NP	O	O
CPK	CPK	NN	I-NP	B-protein	O
.	.	.	O	O	O

Sulfamethizole	Sulfamethizole	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
uricosurics	uricosuric	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
thiazides	thiazide	NNS	B-NP	O	S-group
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
sulfonylurea	sulfonylurea	NN	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
(	(	(	O	O	O
decreased	decrease	VBN	B-VP	O	O
renal	renal	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
(	(	(	O	O	O
decreased	decrease	VBN	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
certain	certain	JJ	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group
,	,	,	O	O	O
primarily	primarily	RB	B-NP	O	O
thiazides	thiazide	NNS	I-NP	O	S-group
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombopenia	thrombopenia	NN	B-NP	O	O
with	with	IN	B-PP	O	O
purpura	purpura	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
prolong	prolong	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	B-protein	S-group
warfarin	warfarin	NN	I-NP	I-protein	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
kept	keep	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mind	mind	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
Gantanol	Gantanol	NN	B-NP	O	S-brand
is	be	VBZ	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
already	already	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
coagulation	coagulation	NN	I-NP	O	O
time	time	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reassessed	reassess	VBN	I-VP	O	O
.	.	.	O	O	O

Sulfamethoxazole	Sulfamethoxazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

At	At	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1.6	1.6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
g	g	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug-ME-1
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
corresponding	corresponding	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
one	one	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alert	alert	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Sulfonamides	Sulfonamide	NNS	B-NP	O	S-group-ME-1
can	can	MD	B-VP	O	O
also	also	RB	I-VP	O	O
displace	displace	VB	I-VP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
from	from	IN	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
protein	protein	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	O	O
binding	bind	VBG	B-NP	B-DNA	O
sites	site	NNS	I-NP	I-DNA	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
free	free	JJ	B-NP	O	O
methotrexate	methotrexate	NN	I-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Jaff	Jaff	NNP	I-NP	O	O
alkaline	alkaline	NN	I-NP	O	O
picrate	picrate	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
for	for	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
overestimations	overestimation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
about	about	IN	B-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
folic	folic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
those	those	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
daily	daily	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug
2	2	CD	I-NP	O	O
g	g	NN	I-NP	O	O
and	and	CC	O	O	O
weekly	weekly	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
7.5	7.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
15	15	CD	B-NP	O	O
rheumatoid	rheumatoid	JJ	I-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
.	.	.	O	O	O

Daily	Daily	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug
2	2	CD	I-NP	O	O
g	g	NN	I-NP	O	O
(	(	(	O	O	O
maximum	maximum	NN	B-NP	O	O
3	3	CD	I-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
weekly	weekly	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
7.5	7.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
maximum	maximum	NN	B-NP	O	O
15	15	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
to	to	TO	B-PP	O	O
310	310	CD	B-NP	O	O
rheumatoid	rheumatoid	JJ	I-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
52	52	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-NP	O	O
nausea	nausea	NN	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
drug	drug	NN	B-NP	O	O
administered	administer	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sulfasalazine	sulfasalazine	NN	B-NP	O	S-drug
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
body	body	NN	B-NP	O	O
fluids	fluid	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
laboratory	laboratory	JJ	B-NP	O	O
test	test	NN	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
.	.	.	O	O	O

REFERENCES	REFERENCES	NNP	B-NP	O	O
7.Farr	7.Farr	NNP	I-NP	O	O
M	M	NNP	I-NP	O	O
,	,	,	O	O	O
et	et	FW	B-ADVP	O	O
al	al	FW	I-ADVP	O	O
.	.	.	O	O	O

Immunodeficiencies	Immunodeficiency	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
sulphasalazine	sulphasalazine	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
arthritis	arthritis	NN	I-NP	O	O
.	.	.	O	O	O

British	British	NNP	B-NP	O	O
Jnl	Jnl	NNP	I-NP	O	O
Rheum	Rheum	NNP	I-NP	O	O
1991	1991	CD	I-NP	O	O
;	;	:	O	O	O
30	30	CD	B-NP	O	O
:	:	:	O	O	O
413	413	CD	B-NP	O	O
-	-	:	O	O	O
417	417	CD	B-NP	O	O
.	.	.	O	O	O

Sulfoxone	Sulfoxone	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
uricosurics	uricosuric	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
thiazides	thiazide	NNS	B-NP	O	S-group
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
sulfonylurea	sulfonylurea	NN	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
(	(	(	O	O	O
increased	increase	VBN	B-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
(	(	(	O	O	O
decreased	decrease	VBN	B-VP	O	O
renal	renal	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
(	(	(	O	O	O
decreased	decrease	VBN	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
)	)	)	O	O	O
.	.	.	O	O	O

Ergot	Ergot	NN	B-NP	O	S-group
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
prolonged	prolonged	JJ	B-NP	O	O
vasospastic	vasospastic	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
theoretical	theoretical	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additive	additive	JJ	B-ADJP	O	O
,	,	,	O	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ergotamine	ergotamine	NN	B-NP	O	S-drug-AD-1
-	-	HYPH	B-VP	O	O
containing	contain	VBG	I-VP	O	O
or	or	CC	O	O	O
ergot	ergot	NN	B-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
type	type	NN	I-NP	O	I-group-AD-1
medications	medication	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
like	like	IN	B-PP	O	O
dihydroergotamine	dihydroergotamine	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
methysergide	methysergide	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
and	and	CC	O	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-AD-2
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

MAO	MAO	NN	B-NP	B-protein	B-group-ME-1
-	-	HYPH	I-NP	O	I-group-ME-1
A	A	NN	I-NP	O	I-group-ME-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-ME-1
reduce	reduce	VBP	B-VP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-ME-2
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
significantly	significantly	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
systemic	systemic	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	B-drug-AD-1
succinate	succinate	NN	I-NP	O	E-drug-AD-1
tablets	tablet	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
MAO	MAO	NN	B-NP	B-protein	B-group-AD-2
-	-	HYPH	B-NP	O	I-group-AD-2
A	A	NN	I-NP	O	I-group-AD-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O
Selective	Selective	JJ	B-NP	O	B-group-EF-1
serotonin	serotonin	NN	I-NP	O	I-group-EF-1
reuptake	reuptake	NN	I-NP	O	I-group-EF-1
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-1
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	S-group-EF-1
)	)	)	O	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
fluvoxamine	fluvoxamine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
sertraline	sertraline	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
rarely	rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
weakness	weakness	NN	B-NP	O	O
,	,	,	O	O	O
hyperreflexia	hyperreflexia	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
incoordination	incoordination	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
concomitant	concomitant	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	B-protein	S-group-AD-2
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
,	,	,	O	O	O
appropriate	appropriate	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
advised	advise	VBN	I-VP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
SUTENT	SUTENT	NN	B-NP	O	S-brand-ME-1
with	with	IN	B-PP	O	O
strong	strong	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
atazanavir	atazanavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nefazodone	nefazodone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
nelfinavir	nelfinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
ritonavir	ritonavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
saquinavir	saquinavir	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
telithromycin	telithromycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
voriconizole	voriconizole	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increases	increase	VBZ	I-VP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Grapefruit	Grapefruit	NN	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
SUTENT	SUTENT	NN	B-NP	O	S-brand
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
SUTENT	SUTENT	NN	B-NP	O	S-brand-ME-1
with	with	IN	B-PP	O	O
inducers	inducer	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug-ME-2
,	,	,	O	O	O
rifapentin	rifapentin	NN	B-NP	B-protein	S-drug-ME-2
,	,	,	O	O	O
phenobarbital	phenobarbital	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
St.	St.	NNP	B-NP	O	O
Johns	Johns	NNP	I-NP	O	O
Wort	Wort	NNP	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

St	St	NN	B-NP	O	O
.	.	.	O	O	O

Johns	Johns	NNP	B-NP	O	O
Wort	Wort	NNP	I-NP	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
SUTENT	SUTENT	NN	B-NP	O	S-brand
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
unpredictably	unpredictably	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
SUTENT	SUTENT	NN	B-NP	O	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
take	take	VB	I-VP	O	O
St	St	NNP	B-NP	O	O
.	.	.	O	O	O

Johns	Johns	NNP	B-NP	O	O
Wort	Wort	NNP	I-NP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

SUTENT	SUTENT	NN	B-NP	O	S-brand
dose	dose	NN	I-NP	O	O
modification	modification	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
inducers	inducer	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
eye	eye	NN	I-NP	O	O
drops	drop	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
medications	medication	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
acetylcholine	acetylcholine	NN	B-NP	O	B-drug-EF-1
chloride	chloride	NN	I-NP	O	E-drug-EF-1
(	(	(	O	O	O
Miochol	Miochol	NN	B-NP	O	S-brand-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
carbachol	carbachol	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
Carboptic	Carboptic	NNP	B-NP	O	S-brand-EF-1
,	,	,	O	O	O
Isopto	Isopto	NNP	B-NP	O	B-brand-EF-1
Carbachol	Carbachol	NNP	I-NP	O	E-brand-EF-1
)	)	)	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
suprofen	suprofen	NN	B-NP	O	S-drug-EF-2
ophthalmic	ophthalmic	JJ	B-ADJP	O	O
.	.	.	O	O	O

Drug	Drug	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
FLOMAX	FLOMAX	NN	B-NP	O	S-brand
capsules	capsule	NNS	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
alpha	alpha	SYM	I-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
adrenergic	adrenergic	JJ	B-NP	O	I-group
blocking	block	VBG	I-NP	O	I-group
agents	agent	NNS	I-NP	O	E-group
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
interactions	interaction	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
expected	expect	VBN	I-VP	O	O
and	and	CC	O	O	O
FLOMAX	FLOMAX	NN	B-NP	O	S-brand-AD-1
capsules	capsule	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
NOT	NOT	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
alpha	alpha	SYM	I-NP	O	B-group-AD-2
-	-	HYPH	I-NP	O	I-group-AD-2
adrenergic	adrenergic	JJ	I-NP	O	I-group-AD-2
blocking	block	VBG	I-NP	O	I-group-AD-2
agents	agent	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
FLOMAX	FLOMAX	NN	I-NP	O	S-brand
capsules	capsule	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
significant	significant	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
tamsulosin	tamsulosin	NN	B-NP	O	B-drug
HCI	HCI	NN	I-NP	O	E-drug
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
FLOMAX	FLOMAX	NN	B-NP	O	S-brand-AD-1
capsules	capsule	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.4	0.4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
limited	limited	JJ	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
tamsulosin	tamsulosin	NN	B-NP	O	B-drug
HCI	HCI	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
inconclusive	inconclusive	JJ	B-ADJP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
FLOMAX	FLOMAX	NN	I-NP	O	S-brand-AD-2
capsules	capsule	NNS	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valproic	valproic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
oral	oral	JJ	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
temozolomide	temozolomide	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
5	5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
implication	implication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Severe	Severe	JJ	B-NP	O	O
Hepatic	Hepatic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
Renal	Renal	JJ	I-NP	O	O
Impairment	Impairment	NN	I-NP	O	O
Caution	Caution	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
TEMODAR	TEMODAR	NN	B-NP	O	S-brand
Capsules	Capsule	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
renal	renal	JJ	I-NP	O	O
impairment	impairment	NN	I-NP	O	O
.	.	.	O	O	O

Formal	Formal	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TNKase	TNKase	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
studied	study	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TNKase	TNKase	NN	B-NP	B-protein	S-brand
were	be	VBD	B-VP	O	O
routinely	routinely	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand
.	.	.	O	O	O

Anticoagulants	Anticoagulant	NNS	B-NP	O	S-group-EF-1
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group-EF-1
K	K	NN	I-NP	O	I-group-EF-1
antagonists	antagonist	NNS	I-NP	O	E-group-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
acetylsalicylic	acetylsalicylic	JJ	B-NP	O	B-drug-EF-1
acid	acid	NN	I-NP	O	E-drug-EF-1
,	,	,	O	O	O
dipyridamole	dipyridamole	NN	B-NP	O	S-drug-EF-1
,	,	,	O	O	O
and	and	CC	O	O	O
GP	GP	NN	B-NP	B-protein	O
IIb	IIb	NN	I-NP	I-protein	O
/	/	SYM	B-VP	O	O
IIIa	IIIa	NN	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
if	if	IN	B-SBAR	O	O
administered	administer	VBN	B-VP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
after	after	IN	B-SBAR	O	O
TNKase	TNKase	NN	B-NP	B-protein	S-brand-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
During	During	IN	B-PP	O	O
TNKase	TNKase	NN	B-NP	B-protein	S-brand
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
results	result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
coagulation	coagulation	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
measures	measure	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
fibrinolytic	fibrinolytic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
unreliable	unreliable	JJ	B-ADJP	O	O
unless	unless	IN	B-SBAR	O	O
specific	specific	JJ	B-NP	O	O
precautions	precaution	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
taken	take	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
artifacts	artifact	NNS	I-NP	O	O
.	.	.	O	O	O

Tenecteplase	Tenecteplase	NN	B-NP	B-protein	S-drug
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
that	that	IN	B-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
in	in	IN	B-PP	O	O
pharmacologic	pharmacologic	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
remains	remain	VBZ	B-VP	O	O
active	active	JJ	B-ADJP	O	O
under	under	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
can	can	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
degradation	degradation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fibrinogen	fibrinogen	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
removed	remove	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
analysis	analysis	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
34	34	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
,	,	,	O	O	O
therapeutically	therapeutically	RB	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
sodium	sodium	NN	B-NP	O	B-drug-ME-1
salicylate	salicylate	NN	I-NP	O	E-drug-ME-1
and	and	CC	O	O	O
sulfamethizole	sulfamethizole	NN	B-NP	B-protein	S-drug-ME-1
displaced	displace	VBD	B-VP	I-protein	O
protein	protein	NN	B-NP	I-protein	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-NP	O	O
teniposide	teniposide	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
fresh	fresh	JJ	B-NP	O	O
human	human	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
significant	significant	JJ	I-NP	O	O
extent	extent	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
extremely	extremely	RB	I-NP	O	O
high	high	JJ	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
teniposide	teniposide	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	B-protein	O
proteins	protein	NNS	I-NP	I-protein	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
binding	binding	NN	B-NP	O	O
could	could	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
substantial	substantial	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
potentiation	potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
administering	administer	VBG	B-VP	O	O
VUMON	VUMON	NN	B-NP	B-protein	S-brand
(	(	(	O	O	O
teniposide	teniposide	NN	B-NP	O	S-drug
injection	injection	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
teniposide	teniposide	NN	B-NP	O	S-drug
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
slightly	slightly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
intracellular	intracellular	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-1
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
teniposide	teniposide	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
liver	liver	NN	I-NP	I-cell_type	O
microsomes	microsome	NNS	I-NP	I-cell_type	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
terbinafine	terbinafine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tolbutamide	tolbutamide	NN	B-NP	O	S-drug
,	,	,	O	O	O
ethinylestradiol	ethinylestradiol	NN	B-NP	O	S-drug
,	,	,	O	O	O
ethoxycoumarin	ethoxycoumarin	NN	B-NP	B-protein	S-drug_n
,	,	,	O	O	O
and	and	CC	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
terbinafine	terbinafine	NN	B-NP	O	S-drug
inhibits	inhibit	VBZ	B-VP	O	O
CYP2D6	CYP2D6	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
for	for	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
predominantly	predominantly	RB	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	B-protein	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
,	,	,	O	O	O
-	-	HYPH	B-NP	O	O
blockers	blocker	NNS	I-NP	O	O
,	,	,	O	O	O
selective	selective	JJ	B-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	B-protein	S-group
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
monoamine	monoamine	NN	B-NP	O	B-group
oxidase	oxidase	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	I-group
(	(	(	O	O	I-group
MAO	MAO	NN	B-NP	O	I-group
-	-	HYPH	O	O	I-group
Is	Be	VBZ	O	O	I-group
)	)	)	O	O	I-group
Type	Type	NN	B-NP	O	I-group
B	B	NN	I-NP	O	E-group
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
window	window	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
conducted	conduct	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteer	volunteer	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
terbinafine	terbinafine	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antipyrine	antipyrine	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Terbinafine	Terbinafine	NN	B-NP	O	S-drug-ME-1
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Terbinafine	Terbinafine	NN	B-NP	O	S-drug-ME-1
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
increase	increase	NN	B-NP	O	O
or	or	CC	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concomitantly	concomitantly	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
oral	oral	JJ	B-NP	O	O
terbinafine	terbinafine	NN	I-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
LAMISIL	LAMISIL	NN	B-NP	O	S-brand
Tablets	Tablet	NNS	I-NP	O	O
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Terbinafine	Terbinafine	NN	B-NP	O	S-drug-ME-1
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
100	100	CD	B-NP	O	O
%	%	NN	I-NP	O	O
by	by	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CyP450	CyP450	NN	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
inducer	inducer	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
by	by	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CyP450	CyP450	NN	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

Terbinafine	Terbinafine	NN	B-NP	O	S-drug
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
information	information	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
classes	class	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
:	:	:	O	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
,	,	,	O	O	O
hormone	hormone	NN	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
,	,	,	O	O	O
hypoglycemics	hypoglycemic	NNS	B-NP	O	S-group
,	,	,	O	O	O
theophyllines	theophylline	NNS	B-NP	O	S-drug
,	,	,	O	O	O
phenytoins	phenytoin	NNS	B-NP	O	S-drug
,	,	,	O	O	O
thiazide	thiazide	NN	B-NP	O	B-group
diuretics	diuretic	NNS	I-NP	O	E-group
,	,	,	O	O	O
beta	beta	NN	B-NP	O	B-group
blockers	blocker	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
calcium	calcium	NN	B-NP	O	B-group
channel	channel	NN	I-NP	O	I-group
blockers	blocker	NNS	I-NP	O	E-group
.	.	.	O	O	O

Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Spontaneous	Spontaneous	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
recommended	recommend	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-EF-2
demonstrate	demonstrate	VBP	B-VP	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
and	and	CC	O	O	O
rare	rare	JJ	B-NP	O	O
serious	serious	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O

death	death	NN	B-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ventricular	ventricular	JJ	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	IN	B-PP	O	O
pointes	pointe	NNS	B-NP	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
markedly	markedly	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Presence	Presence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
unchanged	unchanged	JJ	B-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
statistically	statistically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
and	and	CC	I-NP	O	O
QTc	QTc	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Itraconazole	Itraconazole	NN	B-NP	O	S-drug
:	:	:	O	O	O
Torsades	Torsades	FW	B-NP	O	O
de	de	FW	I-NP	O	O
pointes	pointes	FW	I-NP	O	O
and	and	CC	O	O	O
elevated	elevated	JJ	B-NP	O	O
parent	parent	NN	I-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug
levels	level	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
and	and	CC	B-PP	O	O
from	from	IN	B-PP	O	O
foreign	foreign	JJ	B-NP	B-cell_type	O
post	post	AFX	I-NP	I-cell_type	O
-	-	HYPH	I-NP	O	O
marketing	market	VBG	B-VP	O	O
sources	source	NNS	B-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
death	death	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
foreign	foreign	JJ	O	B-cell_type	O
post	post	AFX	O	I-cell_type	O
-	-	HYPH	O	O	O
marketing	market	VBG	B-VP	O	O
sources	source	NNS	B-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	I-PP	O	O
the	the	DT	B-NP	O	O
chemical	chemical	JJ	I-NP	O	O
similarity	similarity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
azole	azole	NN	I-NP	O	B-group-AD-1
-	-	HYPH	I-NP	O	I-group-AD-1
type	type	NN	I-NP	O	I-group-AD-1
antifungal	antifungal	JJ	I-NP	O	I-group-AD-1
agents	agent	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
metronidazole	metronidazole	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
and	and	CC	O	O	O
miconazole	miconazole	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
to	to	TO	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
pending	pende	VBG	B-PP	O	O
full	full	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Macrolides	Macrolide	NNS	B-NP	O	S-group
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
clarithromycin	clarithromycin	NN	I-NP	O	S-drug-ME-1
can	can	MD	B-VP	O	O
exert	exert	VB	I-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
erythromycin	erythromycin	NN	B-NP	O	O
measurably	measurably	RB	B-ADVP	O	O
decreases	decrease	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
terfenadine	terfenadine	NN	I-NP	O	S-drug
acid	acid	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
still	still	RB	B-ADVP	O	O
under	under	IN	B-PP	O	O
investigation	investigation	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
spontaneous	spontaneous	JJ	I-NP	O	O
accounts	account	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
torsades	torsade	NNS	B-NP	O	O
de	de	IN	B-PP	O	O
pointes	pointe	NNS	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
troleandomycin	troleandomycin	NN	I-NP	O	S-drug
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
troleandomycin	troleandomycin	NN	B-NP	O	S-drug-AD-2
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
:	:	:	O	O	O
Pending	Pende	VBG	B-VP	O	O
full	full	JJ	B-NP	O	O
characterization	characterization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
macrolide	macrolide	NN	I-NP	O	B-group-AD-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-AD-2
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
potential	potential	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
terfenadine	terfenadine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
azithromycin	azithromycin	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
progress	progress	NN	B-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
testolactone	testolactone	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
anticoagulants	anticoagulant	NNS	I-NP	O	S-group-EF-2
;	;	:	O	O	O

monitor	monitor	NN	B-NP	O	O
and	and	CC	I-NP	O	O
adjust	adjust	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	S-group
dosage	dosage	NN	I-NP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
:	:	:	O	O	O
Physiologic	Physiologic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
testolactone	testolactone	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
estradiol	estradiol	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
radioimmunoassays	radioimmunoassay	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
calcium	calcium	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
24	24	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
urinary	urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
creatine	creatine	NN	B-NP	O	O
and	and	CC	O	O	O
17	17	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
ketosteroids	ketosteroid	NNS	I-NP	O	O
.	.	.	O	O	O

Thalidomide	Thalidomide	NN	B-NP	O	S-drug-EF-1
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug
,	,	,	O	O	O
chlorpromazine	chlorpromazine	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
reserpine	reserpine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Peripheral	Peripheral	JJ	B-NP	O	O
Neuropathy	Neuropathy	NN	I-NP	O	O
:	:	:	O	O	O
Medications	Medication	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
thalidomide	thalidomide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
Contraceptives	Contraceptive	NNS	I-NP	O	S-group
:	:	:	O	O	O
In	In	IN	B-PP	O	O
10	10	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
ethinyl	ethinyl	NN	I-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
1.0	1.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norethindrone	norethindrone	NN	B-NP	O	B-drug
acetate	acetate	NN	I-NP	O	E-drug
and	and	CC	O	O	O
75	75	CD	B-NP	O	O
g	g	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethinyl	ethinyl	NN	B-NP	O	B-drug
estradiol	estradiol	NN	I-NP	O	E-drug
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
and	and	CC	O	O	O
without	without	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	O	S-drug
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
to	to	TO	B-PP	O	O
steady	steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Important	Important	JJ	B-NP	O	O
Non	Non	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Thalidomide	Thalidomide	NNP	I-NP	O	S-drug
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
Drugs	Drugs	NNP	I-NP	O	O
That	That	NNP	I-NP	O	O
Interfere	Interfere	NNP	I-NP	O	O
with	with	IN	B-PP	O	O
Hormonal	Hormonal	NNP	B-NP	O	B-group
Contraceptives	Contraceptive	NNPS	I-NP	O	E-group
:	:	:	O	O	O
Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-group
-	-	HYPH	B-NP	O	I-group
protease	protease	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
,	,	,	O	O	O
griseofulvin	griseofulvin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
modafinil	modafinil	NN	B-NP	O	S-drug
,	,	,	O	O	O
penicillins	penicillin	NNS	B-NP	B-protein	S-group
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug
,	,	,	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug
,	,	,	O	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
,	,	,	O	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
certain	certain	JJ	B-NP	O	O
herbal	herbal	JJ	I-NP	O	O
supplements	supplement	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
St	St	NNP	B-NP	O	O
.	.	.	O	O	O

John	John	NNP	B-NP	O	B-drug_n-EF-1
's	's	POS	B-NP	O	I-drug_n-EF-1
Wort	Wort	NN	I-NP	O	E-drug_n-EF-1
with	with	IN	B-PP	O	O
hormonal	hormonal	JJ	B-NP	O	B-group-EF-2
contraceptive	contraceptive	JJ	I-NP	O	I-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contraception	contraception	NN	I-NP	O	O
and	and	CC	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
one	one	CD	I-NP	O	O
month	month	NN	I-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
women	woman	NNS	B-NP	O	O
requiring	require	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
use	use	VB	I-VP	O	O
two	two	CD	B-NP	O	O
OTHER	OTHER	NN	I-NP	O	O
effective	effective	JJ	B-ADJP	O	O
or	or	CC	O	O	O
highly	highly	RB	B-NP	O	O
effective	effective	JJ	I-NP	O	O
methods	method	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
contraception	contraception	NN	B-NP	O	O
or	or	CC	O	O	O
abstain	abstain	VB	B-VP	O	O
from	from	IN	B-PP	O	O
heterosexual	heterosexual	JJ	B-NP	O	O
sexual	sexual	JJ	I-NP	O	O
contact	contact	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
thalidomide	thalidomide	NN	B-NP	O	S-drug
.	.	.	O	O	O

Thiabendazole	Thiabendazole	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
compete	compete	VB	I-VP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
theophylline	theophylline	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
for	for	IN	B-PP	O	O
sites	site	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
metabolism	metabolism	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
elevating	elevate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiabendazole	thiabendazole	NN	B-NP	O	S-drug-AD-1
and	and	CC	I-NP	O	O
xanthine	xanthine	NN	I-NP	O	B-group-AD-2
derivatives	derivative	NNS	I-NP	O	E-group-AD-2
is	be	VBZ	B-VP	O	O
anticipated	anticipate	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
reduce	reduce	VB	B-VP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
under	under	IN	B-PP	O	O
careful	careful	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
supervision	supervision	NN	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
Vitamin	Vitamin	NN	B-NP	O	B-drug-IN-1
B1	B1	NN	I-NP	O	E-drug-IN-1
(	(	(	O	O	O
Thiamine	Thiamine	NN	B-NP	O	S-drug-IN-1
)	)	)	O	O	O
:	:	:	O	O	O
Loop	Loop	NNP	B-NP	O	B-group-IN-2
Diuretics	Diuretics	NNP	I-NP	O	E-group-IN-2
,	,	,	O	O	O
Oral	Oral	NNP	B-NP	O	O
Contraceptives	Contraceptives	NNP	I-NP	O	S-group-IN-2
,	,	,	O	O	O
Stavudine	Stavudine	NN	B-NP	O	S-drug-IN-2
,	,	,	O	O	O
Tricyclic	Tricyclic	JJ	B-NP	O	B-group-IN-2
Antidepressants	Antidepressant	NNS	I-NP	O	E-group-IN-2

Phenothiazines	Phenothiazine	NNS	B-NP	O	S-group-EF-1
are	be	VBP	B-VP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
potentiating	potentiate	VBG	B-VP	O	O
CNS	CNS	NN	B-NP	O	B-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
anesthetics	anesthetic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
opiates	opiate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
etc	etc	FW	B-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
atropine	atropine	NN	B-NP	O	S-drug
and	and	CC	O	O	O
phosphorous	phosphorous	JJ	B-NP	O	B-drug_n
insecticides	insecticide	NNS	I-NP	O	E-drug_n
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
usually	usually	RB	B-ADVP	O	O
complete	complete	JJ	B-ADJP	O	O
cross	cross	AFX	O	O	O
-	-	HYPH	O	O	O
resistance	resistance	NN	B-NP	O	O
between	between	IN	B-PP	O	O
PURINETHOL	PURINETHOL	NN	B-NP	O	S-brand-EF-1
(	(	(	O	O	O
mercaptopurine	mercaptopurine	NN	B-NP	O	S-drug-EF-1
)	)	)	O	O	O
and	and	CC	O	O	O
TABLOID	TABLOID	NN	B-NP	O	S-brand-EF-2
brand	brand	NN	I-NP	O	O
Thioguanine	Thioguanine	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
aminosalicylate	aminosalicylate	NN	B-NP	O	B-group-ME-1
derivatives	derivative	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
olsalazine	olsalazine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
mesalazine	mesalazine	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
or	or	CC	O	O	O
sulphasalazine	sulphasalazine	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
inhibit	inhibit	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
TPMT	TPMT	NN	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
thioguanine	thioguanine	NN	I-NP	O	S-drug-ME-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Interactions	Interaction	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
ZADAXIN	ZADAXIN	NN	B-NP	B-protein	S-brand
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
fully	fully	RB	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
ZADAXIN	ZADAXIN	NN	B-NP	B-protein	S-brand-AD-1
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
immunomodulating	immunomodulating	JJ	I-NP	O	B-group-AD-2
drugs	drug	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

ZADAXIN	ZADAXIN	NN	B-NP	B-protein	S-brand
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
mixed	mix	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Prothrombin	Prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
tigecycline	tigecycline	NN	B-NP	O	S-drug-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antibacterial	antibacterial	JJ	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-EF-2
may	may	MD	B-VP	O	O
render	render	VB	I-VP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group
less	less	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SKELID	SKELID	NN	B-NP	O	S-brand-ME-1
is	be	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
80	80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
by	by	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
calcium	calcium	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
SKELID	SKELID	NN	I-NP	O	S-brand
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
by	by	IN	B-PP	O	O
some	some	DT	B-NP	O	O
aluminum	aluminum	NN	I-NP	O	S-drug-ME-1
-	-	HYPH	B-NP	O	O
or	or	CC	I-NP	O	O
magnesium	magnesium	NN	I-NP	O	S-drug-ME-1
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
antacids	antacid	NNS	B-NP	O	S-drug
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
SKELID	SKELID	NN	B-NP	O	S-brand-ME-2
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	O	S-brand-ME-1
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
bioavailability	bioavailability	NN	B-NP	O	O
of	of	IN	B-PP	O	O
SKELID	SKELID	NN	B-NP	O	S-brand-ME-2
by	by	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
taken	take	VBN	B-VP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
SKELID	SKELID	NN	B-NP	O	S-brand
.	.	.	O	O	O

The	The	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SKELID	SKELID	NN	B-NP	O	S-brand-ME-1
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
fold	fold	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	O	S-drug-ME-2
but	but	CC	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
modified	modify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
SKELID	SKELID	NN	B-NP	O	S-brand
coadministration	coadministration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
tiludronate	tiludronate	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
displace	displace	VB	I-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
binding	bind	VBG	I-NP	O	O
site	site	NN	I-NP	O	O
on	on	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
.	.	.	O	O	O

SPIRIVA	SPIRIVA	NN	B-NP	B-protein	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
COPD	COPD	NN	B-NP	O	O
without	without	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
include	include	VBP	B-VP	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	B-group
bronchodilators	bronchodilator	NNS	I-NP	O	E-group
,	,	,	O	O	O
methylxanthines	methylxanthine	NNS	B-NP	O	S-group
,	,	,	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
inhaled	inhale	VBN	I-NP	O	O
steroids	steroid	NNS	I-NP	O	S-group
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
co	co	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SPIRIVA	SPIRIVA	NN	B-NP	B-protein	S-brand-AD-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	S-group-AD-2
containing	contain	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
ipratropium	ipratropium	NN	B-NP	O	S-drug-AD-2
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

AGGRASTAT	AGGRASTAT	NN	B-NP	O	S-brand
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
background	background	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	O	S-brand
and	and	CC	I-NP	O	O
heparin	heparin	NN	I-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AGGRASTAT	AGGRASTAT	NN	B-NP	O	S-brand-EF-1
,	,	,	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug-EF-2
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-2
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bleeding	bleed	VBG	B-VP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
heparin	heparin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O

In	In	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TOBI	TOBI	NNP	B-NP	O	S-brand
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
TOBI	TOBI	NN	B-NP	B-protein	S-brand-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
dornase	dornase	NN	B-NP	O	B-drug-EF-2
alfa	alfa	NN	I-NP	O	E-drug-EF-2
(	(	(	O	O	O
PULMOZYME	PULMOZYME	NN	B-NP	B-protein	S-brand-EF-2
,	,	,	O	O	O
Genentech	Genentech	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
(	(	(	O	O	B-group-EF-2
beta	beta	SYM	O	O	I-group-EF-2
)	)	)	O	O	I-group-EF-2
-	-	HYPH	B-NP	O	I-group-EF-2
agonists	agonist	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
inhaled	inhale	VBD	B-VP	O	O
corticosteroids	corticosteroid	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
other	other	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
pseudomonal	pseudomonal	JJ	I-NP	O	I-group-EF-2
antibiotics	antibiotic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
parenteral	parenteral	JJ	B-NP	O	O
aminoglycosides	aminoglycoside	NNS	I-NP	O	S-group-EF-2
demonstrated	demonstrate	VBD	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
experience	experience	NN	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
population	population	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
whole	whole	NN	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
sequential	sequential	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TOBI	TOBI	NN	B-NP	B-protein	S-brand
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
neurotoxic	neurotoxic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
ototoxic	ototoxic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
diuretics	diuretic	NNS	I-NP	O	S-group-EF-1
can	can	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	S-group-EF-2
toxicity	toxicity	NN	I-NP	O	O
by	by	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
antibiotic	antibiotic	JJ	B-NP	O	S-group
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
.	.	.	O	O	O

TOBI	TOBI	NN	B-NP	B-protein	S-brand-AD-1
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ethacrynic	ethacrynic	JJ	B-NP	O	B-drug-AD-2
acid	acid	NN	I-NP	O	E-drug-AD-2
,	,	,	O	O	O
furosemide	furosemide	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
urea	urea	NN	B-NP	O	S-drug-AD-2
,	,	,	O	O	O
or	or	CC	O	O	O
mannitol	mannitol	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-protein	O
plasma	plasma	NN	I-NP	I-protein	O
proteins	protein	NNS	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
tolmetin	tolmetin	NN	B-NP	O	S-drug
,	,	,	O	O	O
and	and	CC	O	O	O
tolmetin	tolmetin	NN	B-NP	B-protein	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
prothrombin	prothrombin	NN	I-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
TOLECTIN	TOLECTIN	NN	I-NP	O	S-brand-EF-1
and	and	CC	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug-EF-2
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
caution	caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
TOLECTIN	TOLECTIN	NN	B-NP	B-protein	S-brand-AD-1
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	S-group-AD-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
sulfonylureas	sulfonylureas	NN	B-NP	O	S-group
or	or	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B-protein	S-drug
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
TOLECTIN	TOLECTIN	NN	B-NP	B-protein	S-brand
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
hypoglycemic	hypoglycemic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
TOLECTIN	TOLECTIN	NN	B-NP	B-protein	S-brand-AD-1
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

TOLECTIN	TOLECTIN	NN	B-NP	B-protein	S-brand-ME-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	B-group-ME-1
anti	anti	AFX	I-NP	O	I-group-ME-1
-	-	HYPH	I-NP	O	I-group-ME-1
inflammatory	inflammatory	JJ	I-NP	O	I-group-ME-1
drugs	drug	NNS	I-NP	O	E-group-ME-1
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
enhancing	enhance	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	O	S-drug
.	.	.	O	O	O

Laboratory	Laboratory	NN	B-NP	O	O
Tests	Test	NNS	I-NP	O	O
Because	Because	IN	B-SBAR	O	O
serious	serious	JJ	B-NP	O	O
GI	GI	NN	I-NP	O	O
tract	tract	NN	I-NP	O	O
ulceration	ulceration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
without	without	IN	B-PP	O	O
warning	warn	VBG	B-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
follow	follow	VB	I-VP	O	O
chronically	chronically	RB	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ulceration	ulceration	NN	B-NP	O	O
and	and	CC	O	O	O
bleeding	bleed	VBG	B-VP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
inform	inform	VB	I-VP	O	O
them	them	PRP	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

CYP3A4	CYP3A4	NN	B-NP	B-protein	O
Inhibitors	Inhibitor	NNS	I-NP	O	O
:	:	:	O	O	O
Ketoconazole	Ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
,	,	,	O	O	O
significantly	significantly	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tolterodine	tolterodine	NN	B-NP	O	S-drug-ME-2
when	when	WRB	B-ADVP	O	O
coadministered	coadministere	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
poor	poor	JJ	B-NP	O	O
metabolizers	metabolizer	NNS	I-NP	O	O
(	(	(	O	O	O
see	see	VB	B-VP	O	O
CLINICAL	CLINICAL	NNP	B-NP	O	O
PHARMACOLOGY	PHARMACOLOGY	NNP	I-NP	O	O
,	,	,	O	O	O
Variability	Variability	NNP	B-NP	O	O
in	in	IN	B-PP	O	O
Metabolism	Metabolism	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interactions	Interactions	NNP	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-AD-1
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
other	other	JJ	B-NP	O	O
azole	azole	NN	I-NP	O	B-group-AD-1
antifungals	antifungal	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
miconazole	miconazole	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
or	or	CC	O	O	O
macrolide	macrolide	NN	B-NP	O	B-group-AD-1
antibiotics	antibiotic	NNS	I-NP	O	E-group-AD-1
(	(	(	O	O	O
eg	eg	FW	B-NP	O	O
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-AD-1
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	O	S-drug-AD-1
)	)	)	O	O	O
or	or	CC	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-AD-1
or	or	CC	I-NP	O	O
vinblastine	vinblastine	NN	I-NP	O	S-drug-AD-1
,	,	,	O	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DETROL	DETROL	NN	B-NP	O	B-brand-AD-2
LA	LA	NN	I-NP	O	E-brand-AD-2
is	be	VBZ	B-VP	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
tolterodine	tolterodine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
HERCEPTIN	HERCEPTIN	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug-ME-1
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
HERCEPTIN	HERCEPTIN	NN	B-NP	B-protein	S-brand-ME-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
two	two	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
HERCEPTIN	HERCEPTIN	NN	B-NP	O	S-brand
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
human	human	JJ	I-NP	O	O
primate	primate	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1.5	1.5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
HERCEPTIN	HERCEPTIN	NN	B-NP	O	S-brand
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Trilostane	Trilostane	NN	B-NP	O	S-drug-IN-1
may	may	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
aminoglutethimide	aminoglutethimide	NN	B-NP	O	S-drug-IN-2
or	or	CC	I-NP	O	O
mitotane	mitotane	NN	I-NP	O	S-drug-IN-2
(	(	(	O	O	O
causing	cause	VBG	B-VP	O	O
too	too	RB	B-NP	O	O
great	great	JJ	I-NP	O	O
a	a	DT	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adrenal	adrenal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Trimethoprim	Trimethoprim	NN	B-NP	O	S-drug-ME-1
may	may	MD	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Trimethoprim	Trimethoprim	NNP	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-2
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
by	by	IN	B-PP	O	O
51	51	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug-ME-2
metabolic	metabolic	JJ	I-NP	O	O
clearance	clearance	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
administering	administer	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
,	,	,	O	O	O
one	one	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alert	alert	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
trimetrexate	trimetrexate	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
P450	P450	NN	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
induce	induce	VBP	B-VP	O	O
or	or	CC	I-VP	O	O
inhibit	inhibit	VBP	I-VP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
metabolizing	metabolize	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
elicit	elicit	VB	I-VP	O	O
important	important	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
alter	alter	VB	I-VP	O	O
trimetrexate	trimetrexate	NN	B-NP	O	S-drug
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Agents	Agent	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
coadministered	coadministere	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
trimetrexate	trimetrexate	NN	B-NP	O	S-drug-EF-1
in	in	IN	B-PP	O	O
AIDS	AIDS	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
indications	indication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
elicit	elicit	VB	I-VP	O	O
this	this	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
include	include	VBP	B-VP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
rifampin	rifampin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
rifabutin	rifabutin	NN	B-NP	B-protein	S-drug-EF-2
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
fluconazole	fluconazole	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
perfusion	perfusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	O	O
rat	rat	NN	I-NP	O	O
liver	liver	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
cimetidine	cimetidine	NN	B-NP	O	S-drug-ME-1
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
trimetrexate	trimetrexate	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
acetaminophen	acetaminophen	NN	B-NP	O	S-drug
altered	alter	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
trimetrexate	trimetrexate	NN	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
possibly	possibly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
competing	compete	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
sulfate	sulfate	NN	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
rat	rat	NN	I-NP	O	O
liver	liver	NN	I-NP	O	O
model	model	NN	I-NP	O	O
,	,	,	O	O	O
nitrogen	nitrogen	NN	B-NP	O	O
substituted	substitute	VBD	B-VP	O	O
imidazole	imidazole	NN	B-NP	O	B-group-ME-1
drugs	drug	NNS	I-NP	O	E-group-ME-1
(	(	(	O	O	O
clotrimazole	clotrimazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
miconazole	miconazole	NN	B-NP	O	S-drug-ME-1
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
potent	potent	JJ	B-ADJP	O	O
,	,	,	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	B-NP	O	O
competitive	competitive	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
trimetrexate	trimetrexate	NN	B-NP	O	S-drug-ME-2
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
medicated	medicate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
trimetrexate	trimetrexate	NN	I-NP	O	S-drug
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
.	.	.	O	O	O

Triprolidine	Triprolidine	NN	B-NP	O	S-drug-EF-1
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
the	the	DT	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-group-EF-2
nervous	nervous	JJ	I-NP	O	I-group-EF-2
system	system	NN	I-NP	O	I-group-EF-2
depressants	depressant	NNS	I-NP	O	E-group-EF-2
including	include	VBG	B-PP	O	O
alcohol	alcohol	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
barbiturates	barbiturate	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
hypnotics	hypnotic	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
narcotic	narcotic	JJ	B-NP	O	B-group-EF-2
analgesics	analgesic	NNS	I-NP	O	E-group-EF-2
,	,	,	O	O	O
sedatives	sedative	NNS	B-NP	O	S-group-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
tranquillisers	tranquilliser	NNS	B-NP	O	S-group-EF-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	B-group-EF-1
drugs	drug	NNS	I-NP	O	E-group-EF-1
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
atropine	atropine	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
tricyclic	tricyclic	JJ	B-NP	O	B-group-EF-1
antidepressants	antidepressant	NNS	I-NP	O	E-group-EF-1
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triprolidine	triprolidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

Triprolidine	Triprolidine	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
effect	effect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Sanctura	Sanctura	NNP	B-NP	O	S-brand-EF-1
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
that	that	WDT	B-NP	O	O
produce	produce	VBP	B-VP	O	O
dry	dry	JJ	B-NP	O	O
mouth	mouth	NN	I-NP	O	O
,	,	,	O	O	O
constipation	constipation	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
severity	severity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Anticholinergic	Anticholinergic	JJ	B-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
may	may	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
some	some	DT	B-NP	O	O
concomitantly	concomitantly	RB	I-NP	O	O
administered	administer	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
anticholinergic	anticholinergic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
.	.	.	O	O	O

Drugs	Drug	NNS	B-NP	O	O
Eliminated	Eliminate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Active	Active	JJ	B-NP	O	O
Tubular	Tubular	JJ	I-NP	O	O
Secretion	Secretion	NN	I-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
studies	study	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Sanctura	Sanctura	NNP	B-NP	O	S-brand
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
,	,	,	O	O	O
Sanctura	Sanctura	NNP	B-NP	O	S-brand-ME-1
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O
digoxin	digoxin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
procainamide	procainamide	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
pancuronium	pancuronium	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
morphine	morphine	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
metformin	metformin	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
tenofovir	tenofovir	NN	B-NP	O	S-drug-ME-2
)	)	)	O	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NNP	B-NP	O	O
of	of	IN	B-PP	O	O
Sanctura	Sanctura	NNP	B-NP	O	S-brand
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Sanctura	Sanctura	NNP	B-NP	O	S-brand
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
coadministered	coadministere	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
due	due	IN	B-PP	O	O
to	to	TO	I-PP	O	O
competition	competition	NN	B-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
such	such	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Laboratory	Laboratory	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Test	Test	NN	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
Interactions	Interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
Sanctura	Sanctura	NNP	B-NP	O	S-brand
and	and	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	O	S-drug-EF-1
and	and	CC	O	O	O
anesthetic	anesthetic	JJ	B-NP	O	B-group-EF-2
agents	agent	NNS	I-NP	O	E-group-EF-2
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
erythema	erythema	NN	B-NP	O	O
and	and	CC	I-NP	O	O
histamine	histamine	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
flushing	flushing	NN	I-NP	O	O
and	and	CC	I-NP	O	O
anaphylactoid	anaphylactoid	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Concurrent	Concurrent	JJ	B-ADJP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
sequential	sequential	JJ	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
topical	topical	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
/	/	SYM	I-NP	O	O
or	or	CC	O	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
amphotericin	amphotericin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
,	,	,	O	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	S-group
,	,	,	O	O	O
bacitracin	bacitracin	NN	B-NP	O	S-drug
,	,	,	O	O	O
polymyxin	polymyxin	NN	B-NP	O	B-drug
B	B	NN	I-NP	O	E-drug
,	,	,	O	O	O
colistin	colistin	NN	B-NP	O	S-drug
,	,	,	O	O	O
viomycin	viomycin	NN	B-NP	O	S-drug
,	,	,	O	O	O
or	or	CC	O	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
indicated	indicate	VBN	B-VP	O	O
,	,	,	O	O	O
requires	require	VBZ	B-VP	O	O
careful	careful	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
published	publish	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
2002	2002	CD	B-NP	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
vigabatrin	vigabatrin	NN	B-NP	O	S-drug-ME-1
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
1984	1984	CD	B-NP	O	O
,	,	,	O	O	O
Drs	Drs	NNP	B-NP	O	O
Rimmer	Rimmer	NNP	I-NP	O	O
and	and	CC	O	O	O
Richens	Richens	NNP	B-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
University	University	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Wales	Wales	NNP	B-NP	O	O
reported	report	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
administering	administer	VBG	B-VP	O	O
vigabatrin	vigabatrin	NN	B-NP	O	S-drug-ME-1
with	with	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug-ME-2
lowered	lower	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	O	S-drug
concentration	concentration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	O	S-drug
falls	fall	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
within	within	IN	B-PP	O	O
five	five	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
experiment	experiment	NN	I-NP	O	O
published	publish	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
1989	1989	CD	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
two	two	CD	I-NP	O	O
scientists	scientist	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
tried	try	VBD	B-VP	O	O
and	and	CC	O	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
elucidate	elucidate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
behind	behind	RB	B-ADVP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Vindesine	Vindesine	NN	B-NP	O	S-drug-IN-1
can	can	MD	B-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
categories	category	NNS	I-NP	O	O
:	:	:	O	O	O
-	-	HYPH	B-NP	O	O
Blood	Blood	NN	I-NP	O	O
dyscrasia	dyscrasia	NN	I-NP	O	O
:	:	:	O	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
unpredictable	unpredictable	JJ	B-NP	O	O
myelotoxicity	myelotoxicity	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Bone	Bone	NN	I-NP	O	O
marrow	marrow	NN	I-NP	O	O
depressants	depressant	NNS	I-NP	O	O
:	:	:	O	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
predictable	predictable	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
related	relate	VBN	B-NP	O	O
myelotoxicity	myelotoxicity	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
Radiation	Radiation	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
marrow	marrow	NN	B-NP	O	O
depression	depression	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Neurotoxic	Neurotoxic	JJ	I-NP	O	O
medications	medication	NNS	I-NP	O	O
:	:	:	O	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
neurologic	neurologic	JJ	B-NP	B-protein	O
toxicity	toxicity	NN	I-NP	I-protein	O
-	-	HYPH	O	I-protein	O
Phenytoin	Phenytoin	NN	B-NP	I-protein	S-drug-IN-2
:	:	:	O	O	O
can	can	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
seizure	seizure	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Live	Live	JJ	I-NP	O	B-group-IN-2
virus	virus	NN	I-NP	O	I-group-IN-2
vaccines	vaccine	NNS	I-NP	O	E-group-IN-2
:	:	:	O	O	O
may	may	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
replication	replication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vaccine	vaccine	NN	I-NP	O	S-drug
virus	virus	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vaccination	vaccination	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decrease	decrease	VB	B-VP	O	O
patient	patient	NN	B-NP	O	O
's	's	POS	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
vaccine	vaccine	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Mitomycin	Mitomycin	NN	I-NP	O	B-drug-IN-2
-	-	HYPH	I-NP	O	I-drug-IN-2
C	C	NN	I-NP	O	E-drug-IN-2
:	:	:	O	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
shortness	shortness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
breath	breath	NN	B-NP	O	O
and	and	CC	I-NP	O	O
bronchospasm	bronchospasm	NN	I-NP	O	O
-	-	HYPH	O	O	O
Killed	Kill	VBN	B-NP	O	B-group-IN-2
virus	virus	NN	I-NP	O	I-group-IN-2
vaccines	vaccine	NNS	I-NP	O	E-group-IN-2
:	:	:	O	O	O
may	may	MD	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
patient	patient	NN	B-NP	O	O
's	's	POS	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
vaccine	vaccine	NN	I-NP	O	S-group

Drug	Drug	NNP	B-NP	O	O
Interactions	Interaction	NNPS	I-NP	O	O
:	:	:	O	O	O
Women	Woman	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
contraceptives	contraceptive	NNS	I-NP	O	S-group-ME-1
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
vitamin	vitamin	NN	I-NP	O	B-group-ME-2
A	A	NN	I-NP	O	E-group-ME-2
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Limited	Limit	VBN	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
ascorbic	ascorbic	JJ	B-NP	O	B-drug-ME-1
acid	acid	NN	I-NP	O	E-drug-ME-1
may	may	MD	B-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
intensity	intensity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bishydroxycoumarin	bishydroxycoumarin	NN	B-NP	O	S-drug-ME-2
.	.	.	O	O	O

Coumarin	Coumarin	NN	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
Derivative	Derivative	JJ	I-NP	O	I-group
Anticoagulants	Anticoagulant	NNS	I-NP	O	E-group
:	:	:	O	O	O
Prolongation	Prolongation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prothrombin	prothrombin	NN	B-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
PT	PT	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
International	International	NNP	B-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
(	(	(	O	O	O
INR	INR	NN	B-NP	B-protein	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ZOLINZA	ZOLINZA	NN	B-NP	B-protein	S-brand-EF-1
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
coumarin	coumarin	NN	B-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
derivative	derivative	JJ	I-NP	O	I-group-EF-2
anticoagulants	anticoagulant	NNS	I-NP	O	E-group-EF-2
.	.	.	O	O	O

Physicians	Physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
carefully	carefully	RB	I-VP	O	O
monitor	monitor	VB	I-VP	O	O
PT	PT	NN	B-NP	O	O
and	and	CC	I-NP	O	O
INR	INR	NN	I-NP	B-protein	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
concurrently	concurrently	RB	B-VP	O	O
administered	administer	VBN	I-VP	O	O
ZOLINZA	ZOLINZA	NN	B-NP	O	S-brand-AD-1
and	and	CC	I-NP	O	O
coumarin	coumarin	NN	I-NP	O	B-group-AD-2
derivatives	derivative	NNS	I-NP	O	E-group-AD-2
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
HDAC	HDAC	NN	I-NP	O	B-group
Inhibitors	Inhibitor	NNS	I-NP	O	E-group
Severe	Severe	JJ	B-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	O
and	and	CC	O	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZOLINZA	ZOLINZA	NN	B-NP	B-protein	S-brand-EF-1
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
HDAC	HDAC	NN	I-NP	O	B-group-EF-2
inhibitors	inhibitor	NNS	I-NP	O	E-group-EF-2
(	(	(	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	NN	I-NP	O	O
,	,	,	O	O	O
valproic	valproic	JJ	B-NP	O	B-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
)	)	)	O	O	O
.	.	.	O	O	O

Monitor	Monitor	NN	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
count	count	NN	I-NP	O	O
every	every	DT	B-NP	O	O
2	2	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
2	2	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

Metabotropic	Metabotropic	JJ	B-NP	O	O
glutamate	glutamate	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
5	5	CD	B-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
protects	protect	VBZ	B-VP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
noradrenergic	noradrenergic	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
degeneration	degeneration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
MPTP	MPTP	NN	B-NP	B-protein	S-drug_n
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
.	.	.	O	O	O

Degeneration	Degeneration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
nigrostriatal	nigrostriatal	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
noradrenergic	noradrenergic	JJ	B-NP	B-cell_type	O
neurons	neuron	NNS	I-NP	I-cell_type	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
locus	locus	NN	I-NP	O	O
coeruleus	coeruleus	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
important	important	JJ	B-NP	O	O
pathological	pathological	JJ	I-NP	O	O
features	feature	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
urgent	urgent	JJ	I-NP	O	O
need	need	NN	I-NP	O	O
to	to	TO	B-VP	O	O
develop	develop	VB	I-VP	O	O
therapies	therapy	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
slow	slow	VBP	B-VP	O	O
down	down	RP	B-PRT	O	O
the	the	DT	B-NP	O	O
progression	progression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurodegeneration	neurodegeneration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
tested	test	VBD	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
highly	highly	RB	I-NP	O	O
specific	specific	JJ	I-NP	O	O
metabotropic	metabotropic	JJ	I-NP	O	O
glutamate	glutamate	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
5	5	CD	B-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
[	[	(	O	O	I-drug_n
(	(	(	O	O	I-drug_n
2	2	CD	B-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,3	1,3	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
thiazol	thiazol	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
yl	yl	NN	I-NP	O	I-drug_n
)	)	)	O	O	I-drug_n
ethynyl	ethynyl	NN	B-NP	O	I-drug_n
]	]	)	O	O	I-drug_n
pyridine	pyridine	NN	B-NP	O	E-drug_n
,	,	,	O	O	O
reduces	reduce	VBZ	B-VP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
noradrenergic	noradrenergic	JJ	I-NP	O	O
neuronal	neuronal	JJ	I-NP	O	O
loss	loss	NN	I-NP	O	O
in	in	IN	B-PP	O	O
monkeys	monkey	NNS	B-NP	O	O
rendered	render	VBD	B-VP	O	O
parkinsonian	parkinsonian	NN	B-NP	O	O
by	by	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

Weekly	Weekly	RB	B-NP	O	O
intramuscular	intramuscular	JJ	I-NP	O	O
1	1	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
injections	injection	NNS	I-NP	O	O
(	(	(	O	O	O
0.2	0.2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.5	0.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3	3	CD	B-NP	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
[	[	(	O	O	I-drug_n
(	(	(	O	O	I-drug_n
2	2	CD	B-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,3	1,3	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
thiazol	thiazol	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
yl	yl	NN	I-NP	O	I-drug_n
)	)	)	O	O	I-drug_n
ethynyl	ethynyl	NN	B-NP	O	I-drug_n
]	]	)	O	O	I-drug_n
pyridine	pyridine	NN	B-NP	O	E-drug_n
or	or	CC	I-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
until	until	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	O
motor	motor	NN	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
experimental	experimental	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	B-protein	E-drug_n
/	/	SYM	B-NP	I-protein	O
3	3	CD	I-NP	I-protein	B-drug_n
-	-	HYPH	O	O	I-drug_n
[	[	(	O	O	I-drug_n
(	(	(	O	O	I-drug_n
2	2	CD	B-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,3	1,3	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
thiazol	thiazol	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
yl	yl	NN	I-NP	O	I-drug_n
)	)	)	O	O	I-drug_n
ethynyl	ethynyl	NN	B-NP	O	I-drug_n
]	]	)	O	O	I-drug_n
pyridine	pyridine	NN	B-NP	O	E-drug_n
versus	versus	IN	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
/	/	SYM	I-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
21	21	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
1	1	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
/	/	SYM	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
displayed	display	VBD	B-VP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1	1	CD	I-NP	O	B-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
methyl	methyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
4	4	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
phenyl	phenyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
tetrahydropyridine	tetrahydropyridine	NN	I-NP	B-protein	E-drug_n-EF-1
/	/	SYM	B-NP	I-protein	O
3	3	CD	I-NP	I-protein	B-drug_n-EF-2
-	-	HYPH	O	O	I-drug_n-EF-2
[	[	(	O	O	I-drug_n-EF-2
(	(	(	O	O	I-drug_n-EF-2
2	2	CD	B-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
methyl	methyl	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
1,3	1,3	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
thiazol	thiazol	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
4	4	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
yl	yl	NN	I-NP	O	I-drug_n-EF-2
)	)	)	O	O	I-drug_n-EF-2
ethynyl	ethynyl	NN	B-NP	O	I-drug_n-EF-2
]	]	)	B-NP	O	I-drug_n-EF-2
pyridine	pyridine	NN	I-NP	O	E-drug_n-EF-2
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
behavioural	behavioural	JJ	I-NP	O	O
observations	observation	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
positron	positron	NN	I-NP	O	O
emission	emission	NN	I-NP	O	O
tomography	tomography	NN	I-NP	O	O
dopamine	dopamine	NN	I-NP	O	O
transporter	transporter	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
with	with	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
mortem	mortem	NN	I-NP	O	O
stereological	stereological	JJ	I-NP	O	O
counts	count	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
midbrain	midbrain	NN	B-NP	B-protein	O
dopaminergic	dopaminergic	JJ	I-NP	I-protein	O
neurons	neuron	NNS	I-NP	I-protein	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
striatal	striatal	JJ	B-NP	O	O
intensity	intensity	NN	I-NP	O	O
measurements	measurement	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	O
transporter	transporter	NN	I-NP	O	O
and	and	CC	O	O	O
tyrosine	tyrosine	NN	B-NP	O	O
hydroxylase	hydroxylase	NN	I-NP	O	O
immunoreactivity	immunoreactivity	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
all	all	DT	B-ADVP	O	O
significantly	significantly	RB	I-ADVP	O	O
higher	high	JJR	I-ADVP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
methyl	methyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
4	4	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
phenyl	phenyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
tetrahydropyridine	tetrahydropyridine	NN	I-NP	B-protein	E-drug_n-EF-1
/	/	SYM	B-NP	I-protein	O
3	3	CD	I-NP	I-protein	B-drug_n-EF-2
-	-	HYPH	O	O	I-drug_n-EF-2
[	[	(	O	O	I-drug_n-EF-2
(	(	(	O	O	I-drug_n-EF-2
2	2	CD	B-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
methyl	methyl	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
1,3	1,3	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
thiazol	thiazol	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
4	4	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
yl	yl	NN	I-NP	O	I-drug_n-EF-2
)	)	)	O	O	I-drug_n-EF-2
ethynyl	ethynyl	NN	B-NP	O	I-drug_n-EF-2
]	]	)	B-NP	O	I-drug_n-EF-2
pyridine	pyridine	NN	I-NP	O	E-drug_n-EF-2
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
/	/	SYM	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
3	3	CD	I-NP	O	B-drug_n-EF-1
-	-	HYPH	O	O	I-drug_n-EF-1
[	[	(	O	O	I-drug_n-EF-1
(	(	(	O	O	I-drug_n-EF-1
2	2	CD	B-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
methyl	methyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
1,3	1,3	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
thiazol	thiazol	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
4	4	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
yl	yl	NN	I-NP	O	I-drug_n-EF-1
)	)	)	O	O	I-drug_n-EF-1
ethynyl	ethynyl	NN	B-NP	O	I-drug_n-EF-1
]	]	)	O	O	I-drug_n-EF-1
pyridine	pyridine	NN	B-NP	O	E-drug_n-EF-1
treatment	treatment	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1	1	CD	I-NP	O	B-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
methyl	methyl	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
4	4	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
phenyl	phenyl	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n-EF-2
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	B-protein	O
neurons	neuron	NNS	I-NP	I-protein	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
locus	locus	NN	I-NP	O	O
coeruleus	coeruleus	NN	I-NP	O	O
and	and	CC	O	O	O
adjoining	adjoin	VBG	B-VP	O	O
A5	A5	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
A7	A7	NN	I-NP	B-protein	O
noradrenaline	noradrenaline	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	B-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
/	/	SYM	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
almost	almost	RB	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tyrosine	tyrosine	NN	B-NP	B-protein	O
hydroxylase	hydroxylase	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
locus	locus	NN	B-NP	O	O
coeruleus	coeruleus	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
A5	A5	NN	I-NP	B-protein	O
/	/	SYM	I-NP	O	O
A7	A7	NN	I-NP	B-protein	O
noradrenaline	noradrenaline	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuronal	neuronal	JJ	B-NP	O	O
loss	loss	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	B-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
methyl	methyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
4	4	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
phenyl	phenyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
tetrahydropyridine	tetrahydropyridine	NN	I-NP	B-protein	E-drug_n-EF-1
/	/	SYM	B-NP	I-protein	O
3	3	CD	I-NP	I-protein	B-drug_n-EF-2
-	-	HYPH	O	O	I-drug_n-EF-2
[	[	(	O	O	I-drug_n-EF-2
(	(	(	O	O	I-drug_n-EF-2
2	2	CD	B-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
methyl	methyl	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
1,3	1,3	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
thiazol	thiazol	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
4	4	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
yl	yl	NN	I-NP	O	I-drug_n-EF-2
)	)	)	O	O	I-drug_n-EF-2
ethynyl	ethynyl	NN	B-NP	O	I-drug_n-EF-2
]	]	)	B-NP	O	I-drug_n-EF-2
pyridine	pyridine	NN	I-NP	O	E-drug_n-EF-2
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
chronic	chronic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
metabotropic	metabotropic	JJ	I-NP	O	O
glutamate	glutamate	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
5	5	CD	B-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	B-drug_n-EF-1
-	-	HYPH	O	O	I-drug_n-EF-1
[	[	(	O	O	I-drug_n-EF-1
(	(	(	O	O	I-drug_n-EF-1
2	2	CD	B-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
methyl	methyl	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
1,3	1,3	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
thiazol	thiazol	NN	I-NP	O	I-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
4	4	CD	I-NP	O	I-drug_n-EF-1
-	-	HYPH	I-NP	O	I-drug_n-EF-1
yl	yl	NN	I-NP	O	I-drug_n-EF-1
)	)	)	I-NP	O	I-drug_n-EF-1
ethynyl	ethynyl	NN	I-NP	O	I-drug_n-EF-1
]	]	)	I-NP	O	I-drug_n-EF-1
pyridine	pyridine	NN	I-NP	O	E-drug_n-EF-1
,	,	,	O	O	O
significantly	significantly	RB	B-VP	O	O
reduces	reduce	VBZ	I-VP	O	O
1	1	CD	B-NP	O	B-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
methyl	methyl	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
4	4	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
phenyl	phenyl	NN	I-NP	O	I-drug_n-EF-2
-	-	HYPH	B-NP	O	I-drug_n-EF-2
1,2,3,6	1,2,3,6	CD	I-NP	O	I-drug_n-EF-2
-	-	HYPH	I-NP	O	I-drug_n-EF-2
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n-EF-2
toxicity	toxicity	NN	I-NP	O	O
towards	towards	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
noradrenergic	noradrenergic	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
human	human	JJ	I-NP	O	O
primates	primate	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabotropic	metabotropic	JJ	B-NP	O	O
glutamate	glutamate	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
5	5	CD	B-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
strategy	strategy	NN	I-NP	O	O
to	to	TO	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
degeneration	degeneration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
catecholaminergic	catecholaminergic	JJ	B-NP	B-protein	O
neurons	neuron	NNS	I-NP	I-protein	O
in	in	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	B-protein	O
inhibition	inhibition	NN	I-NP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug
(	(	(	O	O	O
LBH589	LBH589	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
orally	orally	RB	I-NP	O	O
active	active	JJ	I-NP	O	O
histone	histone	NN	I-NP	B-protein	B-group
deacetylase	deacetylase	NN	I-NP	I-protein	I-group
inhibitor	inhibitor	NN	I-NP	O	E-group
.	.	.	O	O	O

Panobinostat	Panobinostat	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
partly	partly	RB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	B-protein	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP3A	CYP3A	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
panobinostat	panobinostat	NN	I-NP	O	S-drug
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
wash	wash	VB	B-VP	O	O
-	-	HYPH	O	O	O
out	out	RP	B-PRT	O	O
period	period	NN	B-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
9	9	CD	I-NP	O	O
,	,	,	O	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
day	day	NN	B-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
panobinostat	panobinostat	NN	I-NP	O	S-drug
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
co	co	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Panobinostat	Panobinostat	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
agent	agent	NN	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
15	15	CD	I-NP	O	O
and	and	CC	O	O	O
onward	onward	RB	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	O	S-drug-ME-1
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
1.6	1.6	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
1.8	1.8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
C	C	NN	B-NP	O	O
(	(	(	O	O	O
max	max	NN	B-NP	B-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
AUC	AUC	NN	B-NP	O	O
of	of	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug-ME-2
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
substantial	substantial	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
T	T	NN	B-NP	O	O
(	(	(	O	O	O
max	max	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
half	half	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
carrying	carry	VBG	B-VP	O	O
CYP3A5	CYP3A5	NN	B-NP	B-protein	O
*	*	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
*	*	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
and	and	CC	I-NP	O	O
CYP3A5	CYP3A5	NN	I-NP	B-protein	O
*	*	SYM	B-NP	O	O
3	3	CD	I-NP	O	O
/	/	SYM	O	O	O
*	*	SYM	O	B-DNA	O
3	3	CD	B-NP	I-DNA	O
alleles	allele	NNS	I-NP	I-DNA	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Most	Most	RBS	B-NP	O	O
frequently	frequently	RB	I-NP	O	O
reported	report	VBN	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-ADJP	O	O
related	relate	VBN	I-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
asymptomatic	asymptomatic	JJ	B-NP	O	O
hypophosphatemia	hypophosphatemia	NN	I-NP	O	O
(	(	(	O	O	O
64	64	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
urine	urine	NN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
suggested	suggest	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	O
phosphate	phosphate	NN	I-NP	O	O
wasting	wasting	NN	I-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
feasible	feasible	JJ	B-ADJP	O	O
as	as	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug
PK	PK	NN	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
relevant	relevant	JJ	I-ADJP	O	O
.	.	.	O	O	O

Considering	Consider	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
variability	variability	NN	I-NP	O	O
in	in	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
following	follow	VBG	B-PP	O	O
enzyme	enzyme	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
fact	fact	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
chronic	chronic	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
close	close	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
panobinostat	panobinostat	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
moxifloxacin	moxifloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
lomefloxacin	lomefloxacin	NN	I-NP	O	S-drug
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Moxifloxacin	Moxifloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
lomefloxacin	lomefloxacin	NN	I-NP	O	S-drug
are	be	VBP	B-VP	O	O
fluoroquinolone	fluoroquinolone	NN	B-NP	O	B-group
antibiotics	antibiotic	NNS	I-NP	O	E-group
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
treating	treat	VBG	B-VP	O	O
urinary	urinary	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
infections	infection	NNS	I-NP	O	O
.	.	.	O	O	O

Fluoroquinolones	Fluoroquinolone	NNS	B-NP	O	S-group
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
interactions	interaction	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
active	active	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
gastro	gastro	NN	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
.	.	.	O	O	O

Being	Be	VBG	B-VP	O	O
moxifloxacin	moxifloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
lomefloxacin	lomefloxacin	NN	I-NP	O	O
fluoroquinolones	fluoroquinolone	NNS	I-NP	O	S-group
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
with	with	IN	B-PP	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug
,	,	,	O	O	O
gelusil	gelusil	NN	B-NP	O	S-brand
,	,	,	O	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
multi	multi	JJ	B-NP	O	B-group
minerals	mineral	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
neutral	neutral	JJ	B-NP	O	O
,	,	,	I-NP	O	O
acidic	acidic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
basic	basic	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
both	both	CC	B-PP	O	O
at	at	IN	B-PP	O	O
room	room	NN	B-NP	O	O
temperature	temperature	NN	I-NP	O	O
and	and	CC	O	O	O
37	37	CD	B-NP	O	O
C	C	JJ	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dissolution	dissolution	NN	B-NP	O	O
medium	medium	NN	I-NP	O	O
simulating	simulate	VBG	B-VP	O	O
various	various	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
environments	environment	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
pH	pH	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
elucidate	elucidate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
response	response	NN	I-NP	O	O
of	of	IN	B-PP	O	O
moxifloxacin	moxifloxacin	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
lomefloxacin	lomefloxacin	NN	I-NP	O	S-drug
after	after	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administered	administer	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
temperature	temperature	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
Shimadzu	Shimadzu	NN	I-NP	O	O
HPLC	HPLC	NN	I-NP	O	O
system	system	NN	I-NP	O	O
with	with	IN	B-PP	O	O
PDA	PDA	NN	B-NP	O	O
detector	detector	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
interaction	interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
fluoroquinolones	fluoroquinolone	NNS	I-NP	O	S-group
was	be	VBD	B-VP	O	O
more	more	JJR	B-ADVP	O	O
at	at	IN	B-PP	O	O
37	37	CD	B-NP	O	O
C	C	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
at	at	IN	B-PP	O	O
room	room	NN	B-NP	O	O
temperature	temperature	NN	I-NP	O	O
.	.	.	O	O	O

Moxifloxacin	Moxifloxacin	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
Lomefloxacin	Lomefloxacin	NN	I-NP	O	S-drug-ME-1
reacts	react	VBZ	B-VP	O	O
faster	faster	RBR	B-ADVP	O	O
with	with	IN	B-PP	O	O
sucralfate	sucralfate	NN	B-NP	O	S-drug-ME-2
and	and	CC	I-NP	O	O
gelusil	gelusil	NN	I-NP	O	S-brand-ME-2
in	in	IN	B-PP	O	O
acidic	acidic	JJ	B-NP	O	O
media	medium	NNS	I-NP	O	O
whereas	whereas	IN	B-ADVP	O	O
with	with	IN	B-PP	O	O
erythromycin	erythromycin	NN	B-NP	O	S-drug-ME-2
in	in	IN	B-PP	O	O
basic	basic	JJ	B-NP	O	O
media	medium	NNS	I-NP	O	O
and	and	CC	O	O	O
multi	multi	AFX	B-NP	O	B-group-ME-2
-	-	HYPH	I-NP	O	I-group-ME-2
minerals	mineral	NNS	B-NP	O	E-group-ME-2
in	in	IN	B-PP	O	O
neutral	neutral	JJ	B-NP	O	O
media	medium	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
ensures	ensure	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluoroquinolones	fluoroquinolone	NNS	B-NP	O	S-group
with	with	IN	B-PP	O	O
selected	select	VBN	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
administrations	administration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
.	.	.	O	O	O

Exposure	Exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
oral	oral	JJ	B-NP	O	O
S	S	NN	I-NP	O	B-drug-EF-1
-	-	HYPH	O	O	I-drug-EF-1
ketamine	ketamine	NN	B-NP	O	E-drug-EF-1
is	be	VBZ	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
but	but	CC	O	O	O
greatly	greatly	RB	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ticlopidine	ticlopidine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
examined	examine	VBD	B-VP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
S	S	NN	I-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
ketamine	ketamine	NN	I-NP	O	E-drug
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
)	)	)	O	O	O
2B6	2B6	NN	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
ticlopidine	ticlopidine	NN	I-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
CYP3A	CYP3A	NN	I-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
randomized	randomize	VBN	B-VP	O	O
,	,	,	O	O	O
blinded	blind	VBN	B-VP	O	O
,	,	,	O	O	O
crossover	crossover	NN	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
11	11	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
ingested	ingest	VBD	B-VP	O	O
0.2	0.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
S	S	NN	I-NP	O	B-drug
-	-	HYPH	B-NP	O	I-drug
ketamine	ketamine	NN	I-NP	O	E-drug
after	after	IN	B-PP	O	O
pretreatments	pretreatment	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
ticlopidine	ticlopidine	NN	I-NP	O	S-drug
(	(	(	O	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
periods	period	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
intervals	interval	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Ticlopidine	Ticlopidine	NN	B-NP	O	S-drug-ME-1
treatment	treatment	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
extrapolated	extrapolate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
infinity	infinity	NN	B-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	O	O	O
)	)	)	O	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug-ME-2
by	by	IN	B-PP	O	O
2.4	2.4	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
fold	fold	RB	B-ADVP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
treatment	treatment	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
S	S	NN	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
ketamine	ketamine	NN	I-NP	O	E-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norketamine	norketamine	NN	B-NP	O	S-drug_n
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	O	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
ketamine	ketamine	NN	B-NP	O	S-drug
AUC	AUC	NN	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	O	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ticlopidine	ticlopidine	NN	I-NP	O	S-drug
(	(	(	O	O	O
P	P	NN	B-NP	O	O
&	&	CC	I-NP	O	O
lt	lt	NN	I-NP	O	O
;	;	:	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
itraconazole	itraconazole	NN	B-NP	O	S-drug
phases	phase	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.006	0.006	CD	B-NP	O	O
)	)	)	O	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ticlopidine	ticlopidine	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
itraconazole	itraconazole	NN	I-NP	O	S-drug
phases	phase	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
areas	area	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
curves	curve	NNS	I-NP	O	O
(	(	(	O	O	O
self	self	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
reported	report	VBN	I-NP	O	O
drowsiness	drowsiness	NN	I-NP	O	O
and	and	CC	I-NP	O	O
performance	performance	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
phase	phase	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
S	S	NN	B-NP	O	B-drug-AD-1
-	-	HYPH	B-NP	O	I-drug-AD-1
ketamine	ketamine	NN	I-NP	O	E-drug-AD-1
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ticlopidine	ticlopidine	NN	B-NP	O	S-drug-AD-2
.	.	.	O	O	O

Determinants	Determinant	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
DZNep	DZNep	NN	B-NP	B-protein	S-drug_n
induced	induce	VBD	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	B-cell_line	O
myeloma	myeloma	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
3	3	CD	I-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
Deazaneplanocin	Deazaneplanocin	NN	I-NP	O	I-drug_n
A	A	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
DZNep	DZNep	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
S	S	NN	B-NP	O	O
-	-	HYPH	O	O	O
adenosylhomocysteine	adenosylhomocysteine	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
AdoHcy	AdoHcy	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
hydrolase	hydrolase	NN	B-NP	I-protein	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
antitumor	antitumor	JJ	B-NP	O	O
activities	activity	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
broad	broad	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
solid	solid	JJ	B-NP	O	O
tumors	tumor	NNS	I-NP	O	O
and	and	CC	O	O	O
acute	acute	JJ	B-NP	O	O
myeloid	myeloid	JJ	I-NP	O	O
leukemia	leukemia	NN	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
its	its	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	B-cell_line	O
myeloma	myeloma	NN	I-NP	I-cell_line	O
(	(	(	O	I-cell_line	O
MM	MM	NN	B-NP	I-cell_line	O
)	)	)	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
and	and	CC	O	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
500	500	CD	B-NP	O	O
nM	nM	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
potently	potently	RB	B-ADVP	O	O
inhibited	inhibit	VBD	B-VP	O	O
growth	growth	NN	B-NP	O	O
and	and	CC	O	O	O
induced	induce	VBD	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
of	of	IN	B-PP	O	O
8	8	CD	B-NP	O	O
MM	MM	NN	I-NP	B-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

RNA	RNA	NN	B-NP	O	O
from	from	IN	B-PP	O	O
un	un	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	B-VP	O	O
and	and	CC	O	O	O
DZNep	DZNep	NN	B-NP	B-cell_line	S-drug_n
treated	treat	VBN	B-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
was	be	VBD	B-VP	O	O
profiled	profile	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Affymetrix	Affymetrix	NN	B-NP	O	O
HG	HG	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
U133	U133	NN	I-NP	O	O
Plus	Plus	NN	I-NP	O	O
2.0	2.0	CD	I-NP	O	O
microarray	microarray	NN	I-NP	O	O
and	and	CC	O	O	O
genes	gene	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
significance	significance	NN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microarray	microarray	NN	B-NP	O	O
(	(	(	O	O	O
SAM	SAM	NN	B-NP	O	O
)	)	)	O	O	O
testing	testing	NN	B-NP	O	O
.	.	.	O	O	O

ALOX5	ALOX5	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
the	the	DT	O	O	O
most	most	RBS	B-ADVP	O	O
down	down	RB	I-ADVP	O	O
-	-	HYPH	B-NP	B-DNA	O
regulated	regulate	VBN	I-NP	I-DNA	O
gene	gene	NN	I-NP	I-DNA	O
(	(	(	O	O	O
5.8	5.8	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
sensitive	sensitive	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
expressed	express	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
level	level	NN	I-NP	O	O
in	in	IN	B-PP	O	O
resistant	resistant	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
corroborated	corroborate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
quantitative	quantitative	JJ	B-NP	O	O
RT	RT	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
PCR	PCR	NN	I-NP	O	O
.	.	.	O	O	O

Western	Western	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
blot	blot	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
ALOX5	ALOX5	NN	B-NP	B-protein	O
was	be	VBD	B-VP	O	O
highly	highly	RB	I-VP	O	O
expressed	express	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
sensitive	sensitive	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
line	line	NN	I-NP	O	O
H929	H929	NN	I-NP	B-cell_line	O
and	and	CC	O	O	O
greatly	greatly	RB	B-VP	O	O
decreased	decrease	VBD	I-VP	O	O
upon	upon	IN	B-PP	O	O
DZNep	DZNep	NN	B-NP	O	S-drug_n
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Ectopic	Ectopic	JJ	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ALOX5	ALOX5	NN	B-NP	B-protein	O
reduced	reduce	VBD	B-VP	O	O
sensitivity	sensitivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
DZNep	DZNep	NN	B-NP	O	S-drug_n
in	in	IN	B-PP	O	O
H929	H929	NN	B-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
down	down	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ALOX5	ALOX5	NN	B-NP	B-protein	O
by	by	IN	B-PP	O	O
RNA	RNA	NN	B-NP	O	O
interference	interference	NN	I-NP	O	O
could	could	MD	B-VP	O	O
also	also	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
H929	H929	NN	B-NP	B-cell_line	O
.	.	.	O	O	O

Gene	Gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
on	on	IN	B-PP	O	O
MM	MM	NN	B-NP	O	O
patient	patient	NN	I-NP	O	O
dataset	dataset	NN	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
ALOX5	ALOX5	NN	B-NP	B-protein	O
expression	expression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
MM	MM	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	B-cell_type	O
plasma	plasma	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
Bcl	Bcl	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
2	2	CD	I-NP	I-protein	O
was	be	VBD	B-VP	O	O
overexpressed	overexpresse	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
DZNep	DZNep	NN	B-NP	B-cell_line	S-drug_n
insensitive	insensitive	JJ	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
,	,	,	O	O	O
and	and	CC	O	O	O
cotreatment	cotreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
DZNep	DZNep	NN	B-NP	O	S-drug_n-EF-1
and	and	CC	I-NP	O	O
ABT	ABT	NN	I-NP	B-protein	B-drug_n-EF-2
-	-	HYPH	O	I-protein	I-drug_n-EF-2
737	737	CD	B-NP	I-protein	E-drug_n-EF-2
,	,	,	O	O	O
a	a	DT	B-NP	O	O
Bcl	Bcl	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
family	family	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
synergistically	synergistically	RB	B-ADVP	O	O
inhibited	inhibit	VBD	B-VP	O	O
growth	growth	NN	B-NP	O	O
and	and	CC	O	O	O
induced	induce	VBD	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
DZNep	DZNep	NN	B-NP	B-cell_line	S-drug_n
insensitive	insensitive	JJ	I-NP	I-cell_line	O
MM	MM	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

Taken	Take	VBN	B-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
shows	show	VBZ	B-VP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DZNep	DZNep	NN	I-NP	O	S-drug_n
efficacy	efficacy	NN	I-NP	O	O
on	on	IN	B-PP	O	O
MM	MM	NN	B-NP	O	O
correlates	correlate	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-PP	O	O
down	down	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
regulate	regulate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
ALOX5	ALOX5	NN	I-NP	B-protein	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
DZNep	DZNep	NN	B-NP	O	S-drug_n
insensitivity	insensitivity	NN	I-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
overexpression	overexpression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Bcl	Bcl	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
2	2	CD	I-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ABT	ABT	NN	B-NP	O	B-drug_n-EF-1
-	-	HYPH	B-NP	O	I-drug_n-EF-1
737	737	CD	I-NP	O	E-drug_n-EF-1
and	and	CC	O	O	O
DZNep	DZNep	NN	B-NP	O	S-drug_n-EF-2
could	could	MD	B-VP	O	O
synergistically	synergistically	RB	I-VP	O	O
induced	induce	VBN	I-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
DZNep	DZNep	NN	B-NP	O	S-drug_n
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exploited	exploit	VBN	I-VP	O	O
therapeutically	therapeutically	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MM	MM	NN	B-NP	O	O
.	.	.	O	O	O

Implanon	Implanon	NN	B-NP	O	S-brand-EF-1
failure	failure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
HIV	HIV	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
on	on	IN	B-PP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	S-group-EF-2
therapy	therapy	NN	I-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
ectopic	ectopic	JJ	I-NP	O	O
pregnancies	pregnancy	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
introduction	introduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
1999	1999	CD	B-NP	O	O
,	,	,	O	O	O
Implanon	Implanon	NNP	B-NP	O	S-brand
remains	remain	VBZ	B-VP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
preferred	preferred	JJ	I-NP	O	O
contraceptive	contraceptive	JJ	I-NP	O	O
choices	choice	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
as	as	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
offers	offer	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
highly	highly	RB	I-NP	O	O
effective	effective	JJ	I-NP	O	O
means	mean	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
contraception	contraception	NN	I-NP	O	O
for	for	IN	B-PP	O	O
three	three	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
rely	rely	VB	I-VP	O	O
on	on	IN	B-PP	O	O
adherence	adherence	NN	B-NP	O	O
.	.	.	O	O	O

Like	Like	IN	B-PP	O	O
all	all	DT	B-NP	O	O
hormonal	hormonal	JJ	I-NP	O	B-group
contraceptives	contraceptive	NNS	I-NP	O	E-group
,	,	,	O	O	O
certain	certain	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	B-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	O	O
inducing	induce	VBG	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
interesting	interesting	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
HIV	HIV	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
on	on	IN	B-PP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	S-group-EF-1
therapy	therapy	NN	I-NP	O	O
having	have	VBG	B-VP	O	O
tubal	tubal	JJ	B-NP	O	O
pregnancies	pregnancy	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
two	two	CD	B-NP	O	O
separate	separate	JJ	I-NP	O	O
occasions	occasion	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Implanon	Implanon	NN	B-NP	O	S-brand-EF-2
in	in	IN	B-PP	O	O
place	place	NN	B-NP	O	O
.	.	.	O	O	O

Antidepressant	Antidepressant	JJ	B-NP	O	S-group
-	-	HYPH	I-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
interaction	interaction	NN	I-NP	O	O
and	and	CC	O	O	O
associated	associate	VBN	B-VP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
bleeding	bleed	VBG	I-NP	O	O
risk	risk	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Bleeding	Bleeding	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
worrisome	worrisome	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
factors	factor	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
might	might	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
bleeding	bleed	VBG	I-VP	O	O
risk	risk	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
interacting	interact	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
potentiate	potentiate	VBP	B-VP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
sought	seek	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	S-group
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
for	for	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
in	in	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

Medicaid	Medicaid	NNP	B-NP	O	O
claims	claim	VBZ	B-VP	O	O
data	datum	NNS	B-NP	O	O
(	(	(	O	O	O
1999	1999	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2005	2005	CD	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
perform	perform	VB	I-VP	O	O
an	an	DT	B-NP	O	O
observational	observational	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
nested	nest	VBN	B-VP	O	O
within	within	IN	B-PP	O	O
person	person	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
18	18	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
total	total	NN	B-NP	O	O
,	,	,	O	O	O
430,455	430,455	CD	B-NP	O	O
warfarin	warfarin	NN	I-NP	O	S-drug
users	user	NNS	I-NP	O	O
contributed	contribute	VBD	B-VP	O	O
407,370	407,370	CD	B-NP	O	O
person	person	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
use	use	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
for	for	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
bleeding	bleed	VBG	B-VP	O	O
among	among	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug
users	user	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
4.48	4.48	CD	B-NP	O	O
per	per	IN	B-PP	O	O
100	100	CD	B-NP	O	O
person	person	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
years	year	NNS	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
4.42	4.42	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4.55	4.55	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
cases	case	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
matched	match	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
50	50	CD	B-NP	O	O
controls	control	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
index	index	NN	B-NP	O	O
date	date	NN	I-NP	O	O
and	and	CC	I-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug-EF-1
users	user	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
odds	odd	NNS	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
upon	upon	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	O	O	O
1.73	1.73	CD	B-NP	O	O
[	[	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.25	1.25	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2.38	2.38	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	O	O	O
1.63	1.63	CD	B-NP	O	O
[	[	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.11	1.11	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2.38	2.38	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	O	O	O
1.64	1.64	CD	B-NP	O	O
[	[	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.27	1.27	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2.12	2.12	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug-EF-2
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	O	O	O
1.47	1.47	CD	B-NP	O	O
[	[	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.02	1.02	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2.11	2.11	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Also	Also	RB	B-NP	O	O
mirtazapine	mirtazapine	NN	I-NP	O	S-drug-EF-1
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
believed	believe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
interact	interact	VB	I-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GI	GI	NN	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	O	O	O
1.75	1.75	CD	B-NP	O	O
[	[	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.30	1.30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2.35	2.35	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Warfarin	Warfarin	NN	B-NP	O	S-drug-EF-1
users	user	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
initiated	initiate	VBD	B-VP	O	O
citalopram	citalopram	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
amitriptyline	amitriptyline	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
or	or	CC	O	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug-EF-2
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
for	for	IN	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
with	with	IN	B-PP	O	O
mirtazapine	mirtazapine	NN	B-NP	O	S-drug
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
all	all	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
precocene	precocene	NN	B-NP	O	B-drug_n
I	I	CD	I-NP	O	E-drug_n
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
slices	slice	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
comprehensive	comprehensive	JJ	I-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
approach	approach	NN	I-NP	O	O
to	to	TO	B-PP	O	O
assessing	assess	VBG	B-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
male	male	JJ	B-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
rat	rat	NN	I-NP	O	O
liver	liver	NN	I-NP	O	O
slices	slice	NNS	I-NP	O	O
incubated	incubate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
well	well	RB	I-NP	O	O
characterized	characterize	VBN	I-NP	O	O
hepatotoxicant	hepatotoxicant	NN	I-NP	O	O
,	,	,	O	O	O
precocene	precocene	NN	B-NP	O	B-drug_n
I	I	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
and	and	CC	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	I-protein	O
CYP	CYP	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
approach	approach	NN	I-NP	O	O
combines	combine	VBZ	B-VP	O	O
liquid	liquid	NN	B-NP	O	O
chromatography	chromatography	NN	I-NP	O	O
mass	mass	NN	I-NP	O	O
spectrometry	spectrometry	NN	I-NP	O	O
(	(	(	O	O	O
LC	LC	NN	B-NP	O	O
MS	MS	NN	I-NP	O	O
)	)	)	O	O	O
detection	detection	NN	B-NP	O	O
methods	method	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
endpoints	endpoint	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
enable	enable	VB	I-VP	O	O
identification	identification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
critical	critical	JJ	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
hepatotoxicity	hepatotoxicity	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incubations	incubation	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
specific	specific	JJ	I-NP	O	O
CYP	CYP	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
aminobenzotriazole	aminobenzotriazole	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
ABT	ABT	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
and	and	CC	O	O	O
isoform	isoform	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precocene	precocene	NN	B-NP	B-DNA	B-drug_n
I	I	CD	I-NP	I-DNA	E-drug_n
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
slices	slice	NNS	I-NP	O	O
shares	share	VBZ	B-VP	O	O
some	some	DT	B-NP	O	O
features	feature	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
profile	profile	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
also	also	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
that	that	DT	B-NP	O	O
epoxide	epoxide	NN	I-NP	B-protein	O
dihydrodiol	dihydrodiol	NN	I-NP	I-protein	O
hydrolysis	hydrolysis	NN	I-NP	I-protein	O
products	product	NNS	I-NP	I-protein	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
measurable	measurable	JJ	I-NP	O	O
extent	extent	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
examples	example	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
liver	liver	NN	I-NP	O	O
slice	slice	NN	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
identification	identification	NN	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
minor	minor	JJ	I-NP	O	O
glutathione	glutathione	NN	I-NP	O	O
adduct	adduct	NN	I-NP	O	O
and	and	CC	O	O	O
previously	previously	RB	B-NP	O	O
unreported	unreported	JJ	I-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
O	O	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
desmethyl	desmethyl	NN	I-NP	O	O
and	and	CC	O	O	O
glucuronidated	glucuronidate	VBN	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
precocene	precocene	NN	B-NP	O	B-drug_n
I	I	PRP	B-NP	O	E-drug_n
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Precocene	Precocene	NN	B-NP	O	B-drug_n
I	I	PRP	B-NP	O	E-drug_n
induced	induce	VBD	B-VP	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	O
necrosis	necrosis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
and	and	CC	O	O	O
time	time	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

ABT	ABT	NN	B-NP	O	S-drug_n-EF-1
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precocene	precocene	NN	B-NP	O	B-drug_n-EF-2
I	I	CD	I-NP	O	E-drug_n-EF-2
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
parent	parent	NN	B-NP	O	O
compound	compound	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
metabolite	metabolite	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
isoform	isoform	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
CYP	CYP	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
tested	test	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
precocene	precocene	NN	I-NP	O	B-drug_n
I	I	CD	I-NP	O	E-drug_n
metabolite	metabolite	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
,	,	,	O	O	O
only	only	RB	B-NP	O	O
tranylcypromine	tranylcypromine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
noticeably	noticeably	RB	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYPs	CYP	NNS	B-NP	B-protein	O
2A6	2A6	NN	I-NP	I-protein	O
,	,	,	O	O	O
2C9	2C9	NN	B-NP	B-protein	O
,	,	,	O	O	O
2Cl9	2Cl9	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
2E1	2E1	NN	B-NP	B-protein	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
order	order	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
inhibitor	inhibitor	NN	I-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
ABT	ABT	NN	B-NP	O	S-drug_n
>	>	SYM	B-NP	O	O
diethyldithiocarbamate	diethyldithiocarbamate	NN	I-NP	O	S-drug_n
~	~	SYM	I-NP	O	O
tranylcypromine	tranylcypromine	NN	I-NP	O	S-drug
>	>	SYM	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	O	S-drug
.	.	.	O	O	O

Furafylline	Furafylline	NN	B-NP	O	S-drug_n
and	and	CC	I-NP	O	O
sulfaphenazole	sulfaphenazole	NN	I-NP	O	S-drug_n
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
quinidine	quinidine	NN	B-NP	O	S-drug-EF-1
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
augment	augment	VB	I-VP	O	O
precocene	precocene	NN	B-NP	O	B-drug_n-EF-2
I	I	CD	I-NP	O	E-drug_n-EF-2
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
slices	slice	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
reproduce	reproduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
biotransformation	biotransformation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precocene	precocene	NN	B-NP	O	B-drug_n
I	I	CD	I-NP	O	E-drug_n
and	and	CC	O	O	O
therefore	therefore	RB	B-VP	O	O
may	may	MD	I-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
for	for	IN	B-PP	O	O
precocene	precocene	NN	B-NP	O	B-drug_n
I	I	CD	I-NP	O	E-drug_n
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
provide	provide	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
example	example	NN	I-NP	O	O
of	of	IN	B-PP	O	O
how	how	WRB	B-ADVP	O	O
small	small	JJ	B-NP	O	O
molecule	molecule	NN	I-NP	O	O
manipulation	manipulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B-protein	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
model	model	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
confirm	confirm	VB	I-VP	O	O
metabolism	metabolism	NN	B-NP	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
.	.	.	O	O	O

Glycosidic	Glycosidic	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
enhance	enhance	VBP	B-VP	O	O
retinal	retinal	JJ	B-NP	O	O
transduction	transduction	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
intravitreal	intravitreal	JJ	B-NP	O	O
delivery	delivery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AAV2	AAV2	NN	B-NP	B-protein	S-drug_n
.	.	.	O	O	O

To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
extracellular	extracellular	JJ	B-NP	B-protein	O
matrix	matrix	NN	I-NP	I-protein	O
degrading	degrade	VBG	B-VP	I-protein	O
enzymes	enzyme	NNS	B-NP	I-protein	O
improves	improve	VBZ	B-VP	O	O
retinal	retinal	JJ	B-NP	O	O
transduction	transduction	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
intravitreal	intravitreal	JJ	B-NP	O	O
delivery	delivery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adeno	adeno	AFX	B-NP	O	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
associated	associate	VBN	I-NP	O	I-drug_n
virus	virus	NN	I-NP	O	I-drug_n
-	-	HYPH	O	O	I-drug_n
2	2	CD	B-NP	O	E-drug_n
(	(	(	O	O	O
AAV2	AAV2	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
.	.	.	O	O	O

AAV2	AAV2	NN	B-NP	O	S-drug_n
containing	contain	VBG	B-VP	O	O
cDNA	cDNA	NN	B-NP	B-DNA	O
encoding	encoding	NN	I-NP	O	O
enhanced	enhance	VBD	B-VP	O	O
green	green	JJ	B-NP	B-protein	O
fluorescent	fluorescent	JJ	I-NP	I-protein	O
protein	protein	NN	I-NP	I-protein	O
(	(	(	O	O	O
GFP	GFP	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
chicken	chicken	NN	I-NP	B-DNA	O
-	-	HYPH	I-NP	I-DNA	O
actin	actin	NN	I-NP	I-DNA	O
promoter	promoter	NN	I-NP	I-DNA	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
delivered	deliver	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
intravitreal	intravitreal	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
to	to	TO	B-PP	O	O
adult	adult	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
enzymes	enzyme	NNS	B-NP	B-protein	O
including	include	VBG	B-PP	O	O
collagenase	collagenase	NN	B-NP	B-protein	S-drug_n
,	,	,	O	O	O
hyaluronan	hyaluronan	NN	B-NP	O	B-drug_n
lyase	lyase	NN	I-NP	O	E-drug_n
,	,	,	O	O	O
heparinase	heparinase	NN	B-NP	B-DNA	B-drug_n
III	III	CD	I-NP	I-DNA	E-drug_n
,	,	,	O	O	O
or	or	CC	O	O	O
chondroitin	chondroitin	NN	B-NP	O	B-drug_n
ABC	ABC	NN	I-NP	O	I-drug_n
lyase	lyase	NN	I-NP	O	E-drug_n
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
,	,	,	O	O	O
retinal	retinal	JJ	B-NP	O	O
flatmounts	flatmount	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
GFP	GFP	NN	B-NP	B-protein	O
expression	expression	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
confocal	confocal	JJ	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
.	.	.	O	O	O

Without	Without	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enzymes	enzyme	NNS	B-NP	B-protein	O
,	,	,	O	O	O
transduction	transduction	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
limited	limit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
occasional	occasional	JJ	B-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
retinal	retinal	JJ	I-NP	O	O
ganglion	ganglion	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
layer	layer	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparinase	heparinase	NN	B-NP	B-protein	B-drug_n
III	III	CD	I-NP	I-protein	E-drug_n
or	or	CC	O	O	O
chondroitin	chondroitin	NN	B-NP	O	B-drug_n
ABC	ABC	NN	I-NP	O	I-drug_n
lyase	lyase	NN	I-NP	O	E-drug_n
greatly	greatly	RB	B-VP	O	O
enhanced	enhance	VBD	I-VP	O	O
transduction	transduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
retinal	retinal	JJ	I-NP	O	O
ganglion	ganglion	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
layer	layer	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
depth	depth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
transduction	transduction	NN	B-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
outer	outer	JJ	I-NP	O	O
retina	retina	NN	I-NP	O	O
.	.	.	O	O	O

Hyaluronan	Hyaluronan	NN	B-NP	O	B-drug_n
lyase	lyase	NN	I-NP	O	E-drug_n
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
limited	limited	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	I-NP	O	O
collagenase	collagenase	NN	I-NP	B-protein	S-drug_n
was	be	VBD	B-VP	O	O
ineffective	ineffective	JJ	B-ADJP	O	O
.	.	.	O	O	O

Electroretinograms	Electroretinogram	NNS	B-NP	O	O
survived	survive	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparinase	heparinase	NN	B-NP	B-protein	B-drug_n
III	III	CD	I-NP	I-protein	E-drug_n
and	and	CC	O	O	O
chondroitin	chondroitin	NN	B-NP	O	B-drug_n
ABC	ABC	NN	I-NP	O	I-drug_n
lyase	lyase	NN	I-NP	O	E-drug_n
than	than	IN	B-SBAR	O	O
were	be	VBD	B-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
optimal	optimal	JJ	B-NP	O	O
retinal	retinal	JJ	I-NP	O	O
transduction	transduction	NN	I-NP	O	O
.	.	.	O	O	O

AAV2	AAV2	NN	B-NP	B-protein	S-drug_n-EF-1
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
retinal	retinal	JJ	I-NP	O	O
transduction	transduction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
improved	improve	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparinase	heparinase	NN	B-NP	B-DNA	B-drug_n-EF-2
III	III	CD	I-NP	I-DNA	E-drug_n-EF-2
or	or	CC	O	O	O
chondroitin	chondroitin	NN	B-NP	B-protein	B-drug_n-EF-2
ABC	ABC	NN	I-NP	I-protein	I-drug_n-EF-2
lyase	lyase	NN	I-NP	I-protein	E-drug_n-EF-2
.	.	.	O	O	O

Improved	Improve	VBN	B-NP	O	O
transduction	transduction	NN	I-NP	O	O
efficiency	efficiency	NN	I-NP	O	O
may	may	MD	B-VP	O	O
allow	allow	VB	I-VP	O	O
intravitreal	intravitreal	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
to	to	TO	B-VP	O	O
become	become	VB	I-VP	O	O
the	the	DT	B-NP	O	O
preferred	preferred	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
for	for	IN	B-PP	O	O
delivering	deliver	VBG	B-VP	O	O
gene	gene	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
to	to	TO	B-PP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
inner	inner	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
outer	outer	JJ	I-NP	O	O
retina	retina	NN	I-NP	O	O
.	.	.	O	O	O

Prevention	Prevention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
emergence	emergence	NN	B-NP	O	O
agitation	agitation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
children	child	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug
and	and	CC	O	O	O
propofol	propofol	NN	B-NP	O	S-drug
total	total	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Emergence	Emergence	NN	B-NP	O	O
agitation	agitation	NN	I-NP	O	O
(	(	(	O	O	O
EA	EA	NN	B-NP	O	O
)	)	)	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
distressing	distressing	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
reviewed	review	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
records	record	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
7	7	CD	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
oncology	oncology	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
propofol	propofol	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
(	(	(	O	O	O
TIVA	TIVA	NN	B-NP	O	O
)	)	)	O	O	O
repeatedly	repeatedly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
radiation	radiation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

EA	EA	NN	B-NP	O	O
signs	sign	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
7	7	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
propofol	propofol	NN	B-NP	O	S-drug
TIVA	TIVA	NN	I-NP	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
recur	recur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
123	123	CD	B-NP	O	O
subsequent	subsequent	JJ	I-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	O
sessions	session	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
propofol	propofol	NN	B-NP	O	S-drug
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
this	this	DT	B-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
ketamine	ketamine	NN	I-NP	O	S-drug-EF-1
added	add	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
propofol	propofol	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
prevention	prevention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
EA	EA	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EA	EA	NN	B-NP	B-protein	O
with	with	IN	B-PP	O	O
propofol	propofol	NN	B-NP	O	S-drug
TIVA	TIVA	NN	I-NP	O	O
.	.	.	O	O	O

Tamoxifen	Tamoxifen	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
CYP	CYP	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
:	:	:	O	O	O
caution	caution	NN	B-NP	O	O
.	.	.	O	O	O

Tamoxifen	Tamoxifen	NN	B-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
estrogen	estrogen	NN	I-NP	O	B-group
antagonist	antagonist	NN	I-NP	O	E-group
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
standard	standard	JJ	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
extensively	extensively	RB	I-VP	O	O
transformed	transform	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
enzyme	enzyme	NN	I-NP	I-protein	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
into	into	IN	B-PP	O	O
endoxifen	endoxifen	NN	B-NP	O	S-drug_n
by	by	IN	B-PP	O	O
isoenzyme	isoenzyme	NN	B-NP	B-protein	O
CYP	CYP	NN	I-NP	I-protein	O
2D6	2D6	NN	I-NP	I-protein	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
isoenzyme	isoenzyme	NN	B-NP	O	O
CYP	CYP	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
this	this	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Selective	Selective	JJ	B-NP	O	B-group
serotonin	serotonin	NN	I-NP	O	I-group
reuptake	reuptake	NN	I-NP	O	I-group
inhibitor	inhibitor	NN	I-NP	O	I-group
(	(	(	O	O	I-group
SSRI	SSRI	NN	B-NP	O	I-group
)	)	)	O	O	I-group
antidepressants	antidepressant	NNS	B-NP	O	E-group
inhibit	inhibit	VBP	B-VP	O	O
isoenzyme	isoenzyme	NN	B-NP	O	O
CYP	CYP	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
.	.	.	O	O	O

Paroxetine	Paroxetine	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	O	S-drug-ME-1
reduce	reduce	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endoxifen	endoxifen	NN	B-NP	O	S-drug_n-ME-2
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
epidemiological	epidemiological	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
about	about	IN	B-NP	O	O
3700	3700	CD	I-NP	O	O
women	woman	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
link	link	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SSRI	SSRI	NN	B-NP	O	B-group
antidepressants	antidepressant	NNS	I-NP	O	E-group
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
less	less	RBR	B-ADJP	O	O
convincing	convincing	JJ	I-ADJP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
CYP	CYP	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
they	they	PRP	B-NP	O	O
lacked	lack	VBD	B-VP	O	O
statistical	statistical	JJ	B-NP	O	O
power	power	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
better	good	JJR	B-ADJP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
prescribing	prescribe	VBG	I-VP	O	O
isoenzyme	isoenzyme	NN	B-NP	O	O
CYP	CYP	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
women	woman	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug-AD-1
for	for	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
SSRI	SSRI	NN	B-NP	O	B-group-AD-2
antidepressants	antidepressant	NNS	I-NP	O	E-group-AD-2
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
paroxetine	paroxetine	NN	B-NP	O	S-drug-AD-2
and	and	CC	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	O	S-drug-AD-2
.	.	.	O	O	O

Depression	Depression	NN	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
always	always	RB	I-VP	O	O
require	require	VB	I-VP	O	O
antidepressant	antidepressant	NN	B-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antidepressants	antidepressant	NNS	B-NP	O	S-group
have	have	VBP	B-VP	O	O
no	no	DT	B-NP	O	O
proven	proven	JJ	I-NP	O	O
preventive	preventive	JJ	I-NP	O	O
impact	impact	NN	I-NP	O	O
on	on	IN	B-PP	O	O
hot	hot	JJ	B-NP	O	O
flushes	flush	NNS	I-NP	O	O
linked	link	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
menopause	menopause	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	S-group-AD-1
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
advisable	advisable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
replace	replace	VB	I-VP	O	O
tamoxifen	tamoxifen	NN	B-NP	O	S-drug-AD-2
with	with	IN	B-PP	O	O
anastrozole	anastrozole	NN	B-NP	O	S-drug
.	.	.	O	O	O

Amphetamine	Amphetamine	NN	B-NP	O	S-drug
locomotor	locomotor	NN	I-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
and	and	CC	O	O	O
conditioned	condition	VBN	B-NP	O	O
place	place	NN	I-NP	O	O
preference	preference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adolescent	adolescent	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
neonatally	neonatally	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
quinpirole	quinpirole	NN	B-NP	O	S-drug_n
.	.	.	O	O	O

Neonatal	Neonatal	JJ	B-NP	O	O
quinpirole	quinpirole	NN	I-NP	O	S-drug_n
treatment	treatment	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	O	O
D2	D2	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
persists	persist	VBZ	B-VP	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
's	's	POS	B-NP	O	O
lifetime	lifetime	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
objective	objective	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
analyze	analyze	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
neonatal	neonatal	JJ	B-NP	O	O
quinpirole	quinpirole	NN	I-NP	O	S-drug_n
treatment	treatment	NN	I-NP	O	O
on	on	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
in	in	IN	B-PP	O	O
adolescent	adolescent	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
locomotor	locomotor	NN	B-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
and	and	CC	O	O	O
conditioned	condition	VBN	B-NP	O	O
place	place	NN	I-NP	O	O
preference	preference	NN	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
.	.	.	O	O	O

Sprague	Sprague	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
quinpirole	quinpirole	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
saline	saline	NN	B-NP	O	O
from	from	IN	B-PP	O	O
postnatal	postnatal	JJ	B-NP	B-protein	O
days	day	NNS	I-NP	I-protein	O
(	(	(	O	I-protein	O
P	P	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
1	1	CD	B-NP	I-protein	O
to	to	TO	B-PP	O	O
P11	P11	NN	B-NP	B-protein	O
and	and	CC	O	O	O
raised	raise	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
adolescence	adolescence	NN	B-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
locomotor	locomotor	NN	B-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
,	,	,	O	O	O
subjects	subject	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
saline	saline	NN	B-NP	O	O
every	every	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
from	from	IN	B-PP	O	O
P35	P35	NN	B-NP	B-protein	O
to	to	TO	B-PP	O	O
P47	P47	NN	B-NP	B-protein	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
placed	place	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
a	a	DT	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
arena	arena	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
neonatal	neonatal	JJ	B-NP	O	O
quinpirole	quinpirole	NN	I-NP	O	S-drug_n-EF-1
treatment	treatment	NN	I-NP	O	O
enhanced	enhance	VBD	B-VP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug-EF-2
locomotor	locomotor	NN	I-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
quinpirole	quinpirole	NN	B-NP	O	S-drug_n
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
controls	control	NNS	I-NP	O	O
sensitized	sensitize	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
.	.	.	O	O	O

Male	Male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
sensitization	sensitization	NN	B-NP	O	O
to	to	TO	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
muted	mute	VBN	I-VP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
neonatal	neonatal	JJ	B-NP	O	O
quinpirole	quinpirole	NN	I-NP	O	S-drug_n
.	.	.	O	O	O

For	For	IN	B-PP	O	O
conditioned	condition	VBN	B-NP	O	O
place	place	NN	I-NP	O	O
preference	preference	NN	I-NP	O	O
,	,	,	O	O	O
subjects	subject	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
conditioned	condition	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
P32	P32	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
39	39	CD	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
saline	saline	NN	B-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
preference	preference	NN	I-NP	O	O
test	test	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
P40	P40	NN	B-NP	B-protein	O
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
neonatal	neonatal	JJ	B-NP	O	O
quinpirole	quinpirole	NN	I-NP	O	S-drug_n
enhanced	enhance	VBD	B-VP	O	O
time	time	NN	B-NP	O	O
spent	spend	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	O	S-drug
-	-	HYPH	B-VP	O	O
paired	pair	VBN	B-NP	O	O
context	context	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
quinpirole	quinpirole	NN	B-NP	O	S-drug_n
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
controls	control	NNS	I-NP	O	O
conditioned	condition	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
only	only	RB	B-NP	O	O
female	female	JJ	I-NP	O	O
controls	control	NNS	I-NP	O	O
conditioned	condition	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
spent	spend	VBD	B-VP	O	O
more	more	JJR	B-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
paired	pair	VBN	I-NP	O	O
context	context	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
saline	saline	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
D	D	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	O	S-drug
,	,	,	O	O	O
but	but	CC	O	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
prevalent	prevalent	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
adolescent	adolescent	JJ	B-NP	O	O
female	female	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
CYP3A	CYP3A	NN	I-NP	B-protein	O
activity	activity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
renal	renal	JJ	B-NP	O	O
allograft	allograft	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
identified	identify	VBN	I-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
as	as	IN	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
inhibitors	inhibitor	NNS	I-NP	I-protein	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
allograft	allograft	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
and	and	CC	I-ADVP	O	O
orally	orally	RB	B-NP	O	O
administered	administer	VBN	I-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	B-DNA	O
probe	probe	NN	I-NP	I-DNA	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
generally	generally	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
differential	differential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pass	pass	NN	I-NP	O	O
CYP3A	CYP3A	NN	I-NP	O	O
activities	activity	NNS	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
apparent	apparent	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug-ME-1
clearance	clearance	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
269	269	CD	B-NP	O	O
73	73	CD	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
354	354	CD	B-NP	O	O
102	102	CD	I-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	O	O	O
min	min	NN	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.022	0.022	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
479	479	CD	B-NP	O	O
190	190	CD	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
688	688	CD	B-NP	O	O
265	265	CD	I-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	O	O	O
min	min	NN	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.013	0.013	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
lower	low	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug-ME-2
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
20	20	CD	B-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
matched	match	VBN	B-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
20	20	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
displayed	displayed	JJ	I-NP	O	O
midazolam	midazolam	NN	I-NP	O	S-drug
clearances	clearance	NNS	I-NP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
larger	large	JJR	I-NP	O	O
cohorts	cohort	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nonmatched	nonmatched	JJ	B-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
58	58	CD	B-NP	O	O
and	and	CC	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
80	80	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
calcineurin	calcineurin	NN	I-NP	B-protein	B-group
inhibitor	inhibitor	NN	I-NP	O	E-group
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
implies	imply	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pass	pass	NN	I-NP	O	O
CYP3A	CYP3A	NN	I-NP	O	O
activities	activity	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
receiving	receive	VBG	I-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	O	S-drug
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
generally	generally	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
,	,	,	O	O	O
cyclosporine	cyclosporine	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
stronger	strong	JJR	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
CYP3A	CYP3A	NN	B-NP	B-protein	O
inhibition	inhibition	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
observation	observation	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
important	important	JJ	B-NP	O	O
implications	implication	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
context	context	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
transplant	transplant	NN	B-NP	O	O
recipients	recipient	NNS	I-NP	O	O
.	.	.	O	O	O

Improved	Improve	VBN	B-NP	O	O
parathyroid	parathyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
control	control	NN	I-NP	O	O
by	by	IN	B-PP	O	O
cinacalcet	cinacalcet	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
darbepoetin	darbepoetin	NN	B-NP	O	S-drug
requirement	requirement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
end	end	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
stage	stage	NN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Uncontrolled	Uncontrolled	JJ	B-NP	O	O
hy	hy	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
per	per	NN	I-NP	O	O
-	-	HYPH	O	O	O
parathyroidism	parathyroidism	NN	B-NP	O	O
causes	cause	VBZ	B-VP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
erythropoietin	erythropoietin	NN	B-NP	B-protein	S-drug
(	(	(	O	O	O
EPO	EPO	NN	B-NP	B-protein	S-drug
)	)	)	O	O	O
resistance	resistance	NN	B-NP	O	O
.	.	.	O	O	O

Medical	Medical	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cinacalcet	cinacalcet	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
parathyroid	parathyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
(	(	(	O	O	O
PTH	PTH	NN	B-NP	O	O
)	)	)	O	O	O
levels	level	NNS	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
its	its	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
darbepoetin	darbepoetin	NN	B-NP	O	S-drug
dosing	dosing	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
AIMS	AIMS	NNS	I-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
conducted	conduct	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
cohort	cohort	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
stage	stage	NN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
(	(	(	O	O	O
ESRD	ESRD	NN	B-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
age	age	NN	B-NP	O	O
:	:	:	O	O	O
55	55	CD	B-NP	O	O
14	14	CD	I-NP	O	O
;	;	:	O	O	O
mean	mean	NN	B-NP	O	O
SD	SD	NNP	I-NP	O	O
;	;	:	O	O	O
21	21	CD	B-NP	O	O
:	:	:	O	O	O
male	male	JJ	B-ADJP	O	O
)	)	)	O	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
12	12	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cinacalcet	cinacalcet	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
14	14	CD	B-NP	O	O
peritoneal	peritoneal	JJ	I-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
,	,	,	O	O	O
18	18	CD	B-NP	O	O
conventional	conventional	JJ	I-NP	O	O
hemodialysis	hemodialysis	NN	I-NP	O	O
and	and	CC	O	O	O
8	8	CD	B-NP	O	O
nocturnal	nocturnal	JJ	I-NP	O	O
hemodialysis	hemodialysis	NN	I-NP	O	O
.	.	.	O	O	O

Standard	Standard	JJ	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
related	related	JJ	I-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
indices	index	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
medications	medication	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
objective	objective	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
ascertain	ascertain	VB	I-VP	O	O
the	the	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
darbepoetin	darbepoetin	NN	B-NP	O	S-drug
responsiveness	responsiveness	NN	I-NP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
12	12	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cinacalcet	cinacalcet	NN	B-NP	O	S-drug
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
secondary	secondary	JJ	I-NP	O	O
objective	objective	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
PTH	PTH	NN	B-NP	O	O
and	and	CC	I-NP	O	O
darbepoetin	darbepoetin	NN	I-NP	O	S-drug
requirement	requirement	NN	I-NP	O	O
.	.	.	O	O	O

Overall	Overall	RB	B-ADVP	O	O
,	,	,	O	O	O
PTH	PTH	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
197.5	197.5	CD	B-NP	O	O
(	(	(	O	O	O
151.8	151.8	CD	B-NP	O	O
;	;	:	O	O	O
249.2	249.2	CD	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
66.1	66.1	CD	B-NP	O	O
(	(	(	O	O	O
41.2	41.2	CD	B-NP	O	O
;	;	:	O	O	O
136.5	136.5	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
median	median	JJ	O	O	O
(	(	(	O	O	O
25th	25th	JJ	B-ADJP	O	O
;	;	:	O	O	O
75th	75th	JJ	B-NP	O	O
percentile	percentile	NN	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
pmol	pmol	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
;	;	:	O	O	O

p	p	NN	B-NP	O	O
&	&	CC	I-NP	O	O
lt	lt	NN	I-NP	O	O
;	;	:	O	O	O

0.001	0.001	CD	B-NP	O	O
.	.	.	O	O	O

Cinacalcet	Cinacalcet	NN	B-NP	O	S-drug
dose	dose	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
30.0	30.0	CD	B-NP	O	O
6	6	CD	I-NP	O	O
to	to	TO	B-PP	O	O
63	63	CD	B-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O

0.05	0.05	CD	B-NP	O	O
.	.	.	O	O	O

Hemoglobin	Hemoglobin	NN	B-NP	B-protein	O
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
(	(	(	O	O	O
116	116	CD	B-NP	O	O
13	13	CD	I-NP	O	O
to	to	TO	B-PP	O	O
116	116	CD	B-NP	O	O
13	13	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
darbepoetin	darbepoetin	NN	B-NP	O	S-drug
requirement	requirement	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
40	40	CD	B-NP	O	O
(	(	(	O	O	O
20	20	CD	B-NP	O	O
;	;	:	O	O	O
60	60	CD	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
24	24	CD	B-NP	O	O
(	(	(	O	O	O
19	19	CD	B-NP	O	O
;	;	:	O	O	O
59	59	CD	B-NP	O	O
)	)	)	O	O	O
g	g	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.02	0.02	CD	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
remainder	remainder	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
related	relate	VBN	B-NP	O	O
biochemistry	biochemistry	NN	I-NP	O	O
(	(	(	O	O	O
electrolytes	electrolyte	NNS	B-NP	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	O	O
,	,	,	O	O	O
phosphate	phosphate	NN	B-NP	O	O
,	,	,	O	O	O
iron	iron	NN	B-NP	O	O
status	status	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
vitamin	vitamin	NN	B-NP	O	O
D	D	NN	I-NP	O	O
use	use	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PTH	PTH	NN	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
82.5	82.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
40	40	CD	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
cohort	cohort	NN	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
responders	responder	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PTH	PTH	NN	B-NP	O	O
and	and	CC	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
darbepoetin	darbepoetin	NN	I-NP	O	S-drug
requirement	requirement	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
related	relate	VBN	I-VP	O	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
0.48	0.48	CD	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.004	0.004	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Reduction	Reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PTH	PTH	NN	B-NP	B-protein	O
by	by	IN	B-PP	O	O
cinacalcet	cinacalcet	NN	B-NP	O	S-drug-EF-1
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
darbepoetin	darbepoetin	NN	B-NP	O	S-drug-EF-2
requirement	requirement	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interface	interface	NN	I-NP	O	O
between	between	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
and	and	CC	I-NP	O	O
bone	bone	NN	I-NP	O	O
marrow	marrow	NN	I-NP	O	O
in	in	IN	B-PP	O	O
uremia	uremia	NN	B-NP	O	O
represents	represent	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
step	step	NN	I-NP	O	O
in	in	IN	B-PP	O	O
red	red	JJ	B-NP	B-cell_type	O
blood	blood	NN	I-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
production	production	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
merits	merit	VBZ	B-VP	O	O
further	further	JJ	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	B-group-EF-2
-	-	HYPH	I-NP	O	I-group-EF-2
cancer	cancer	NN	I-NP	O	I-group-EF-2
drugs	drug	NNS	I-NP	O	E-group-EF-2
is	be	VBZ	B-VP	O	O
antagonistic	antagonistic	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
other	other	JJ	B-NP	O	O
cancer	cancer	NN	I-NP	B-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Celecoxib	Celecoxib	NN	B-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclooxygenase	cyclooxygenase	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
being	be	VBG	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
enhancement	enhancement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigates	investigate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclooxygenase	cyclooxygenase	NN	B-NP	B-protein	B-group
-	-	HYPH	B-NP	O	I-group
2	2	CD	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
to	to	TO	B-VP	O	O
sensitize	sensitize	VB	I-VP	O	O
cells	cell	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
origins	origin	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
several	several	JJ	B-NP	O	O
chemotherapeutic	chemotherapeutic	JJ	I-NP	O	B-group
agents	agent	NNS	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
's	's	POS	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
and	and	CC	I-NP	O	O
sequence	sequence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
,	,	,	O	O	O
cell	cell	NN	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
,	,	,	O	O	O
apoptosis	apoptosis	NN	B-NP	O	O
and	and	CC	O	O	O
DNA	DNA	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
five	five	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
cancer	cancer	NN	I-NP	B-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
(	(	(	O	O	O
HeLa	HeLa	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
HCT116	HCT116	NN	B-NP	B-cell_line	O
,	,	,	O	O	O
HepG2	HepG2	NN	B-NP	B-protein	O
,	,	,	O	O	O
MCF7	MCF7	NN	B-NP	B-protein	O
and	and	CC	O	O	O
U251	U251	NN	B-NP	B-cell_line	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
5	5	CD	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
FU	FU	NN	I-NP	O	E-drug
,	,	,	O	O	O
cisplatin	cisplatin	NN	B-NP	O	S-drug
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
and	and	CC	O	O	O
etoposide	etoposide	NN	B-NP	O	S-drug
celecoxib	celecoxib	NN	I-NP	O	S-drug
following	follow	VBG	B-PP	O	O
different	different	JJ	B-NP	O	O
incubation	incubation	NN	I-NP	O	O
schedules	schedule	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
antagonism	antagonism	NN	B-NP	O	O
between	between	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
four	four	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
breast	breast	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
MCF7	MCF7	NN	I-NP	B-protein	O
following	follow	VBG	B-PP	O	O
all	all	DT	B-NP	O	O
incubation	incubation	NN	I-NP	O	O
schedules	schedule	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
between	between	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
cell	cell	NN	I-NP	B-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
two	two	CD	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HCT116	HCT116	NN	B-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

Celecoxib	Celecoxib	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
three	three	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
remaining	remain	VBG	I-NP	B-cell_line	O
four	four	CD	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
variable	variable	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Mechanistic	Mechanistic	JJ	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
exerts	exert	VBZ	B-VP	O	O
different	different	JJ	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
lines	line	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
abrogates	abrogate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
G2	G2	NN	I-NP	O	O
/	/	SYM	O	O	O
M	M	NN	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
enhancing	enhance	VBG	B-VP	O	O
pre	pre	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
mature	mature	JJ	I-NP	O	O
entry	entry	NN	I-NP	O	O
into	into	IN	B-PP	O	O
mitosis	mitosis	NN	B-NP	O	O
with	with	IN	B-PP	O	O
damaged	damage	VBN	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
thus	thus	RB	B-ADVP	O	O
increasing	increase	VBG	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
and	and	CC	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
synergism	synergism	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
enhances	enhance	VBZ	B-VP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
G2	G2	NN	I-NP	O	O
/	/	SYM	O	O	O
M	M	NN	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
allowing	allow	VBG	B-VP	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-VP	O	O
repair	repair	VB	I-VP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
damage	damage	NN	I-NP	O	O
before	before	IN	B-PP	O	O
entry	entry	NN	B-NP	O	O
into	into	IN	B-PP	O	O
mitosis	mitosis	NN	B-NP	O	O
and	and	CC	O	O	O
decreasing	decrease	VBG	B-VP	O	O
cell	cell	NN	B-NP	O	O
death	death	NN	I-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
antagonism	antagonism	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
combinations	combination	NNS	I-NP	O	O
,	,	,	O	O	O
celecoxib	celecoxib	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
abrogation	abrogation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
G2	G2	NN	B-NP	O	O
/	/	SYM	O	O	O
M	M	NN	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
but	but	CC	O	O	O
permanent	permanent	JJ	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
in	in	IN	B-PP	O	O
G1	G1	NN	B-NP	O	O
phase	phase	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
confirmed	confirm	VBN	B-VP	O	O
in	in	FW	B-PP	O	O
-	-	HYPH	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
,	,	,	O	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
suitable	suitable	JJ	I-NP	O	O
chemosensitizer	chemosensitizer	NN	I-NP	O	O
for	for	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
cancer	cancer	NN	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
cancers	cancer	NNS	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
combination	combination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
tailored	tailor	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
tumor	tumor	NN	I-NP	O	O
type	type	NN	I-NP	O	O
,	,	,	O	O	O
drug	drug	NN	B-NP	O	O
and	and	CC	O	O	O
administration	administration	NN	B-NP	O	O
schedule	schedule	NN	I-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Interaction	Interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
proton	proton	NN	I-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
]	]	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
proton	proton	NN	B-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
and	and	CC	I-NP	O	O
clopidogrel	clopidogrel	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
of	of	IN	B-PP	O	O
much	much	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
recent	recent	JJ	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

Contradictory	Contradictory	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
proton	proton	NN	B-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
on	on	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
reactivity	reactivity	NN	I-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
outcome	outcome	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
literature	literature	NN	B-NP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug-ME-1
and	and	CC	I-NP	O	O
clopidogrel	clopidogrel	NN	I-NP	O	S-drug-ME-2
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	O
's	's	POS	B-NP	O	O
active	active	JJ	I-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
by	by	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
sharply	sharply	RB	I-VP	O	O
increase	increase	VB	I-VP	O	O
platelet	platelet	NN	B-NP	O	O
reactivity	reactivity	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
by	by	IN	B-PP	O	O
omeprazole	omeprazole	NN	B-NP	O	S-drug
of	of	IN	B-PP	O	O
CYP2C19	CYP2C19	NN	B-NP	B-protein	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	B-protein	O
P450	P450	NN	I-NP	I-protein	O
(	(	(	O	I-protein	O
CYP	CYP	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
enzyme	enzyme	NN	B-NP	I-protein	O
.	.	.	O	O	O

Pantoprazole	Pantoprazole	NN	B-NP	O	S-drug-ME-1
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
much	much	RB	I-NP	O	O
weaker	weak	JJR	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug-ME-2
's	's	POS	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
reactivity	reactivity	NN	I-NP	O	O
during	during	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
proton	proton	NN	I-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
when	when	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
yet	yet	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
adequately	adequately	RB	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Regulatory	Regulatory	JJ	B-NP	O	O
agencies	agency	NNS	I-NP	O	O
state	state	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug-AD-1
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
CYP2C19	CYP2C19	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
omeprazole	omeprazole	NN	I-NP	O	S-drug-AD-2
and	and	CC	I-NP	O	O
esomeprazole	esomeprazole	NN	I-NP	O	S-drug-AD-2
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
date	date	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
conclusive	conclusive	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinically	clinically	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
proton	proton	NN	I-NP	O	B-group
pump	pump	NN	I-NP	O	I-group
inhibitors	inhibitor	NNS	I-NP	O	E-group
and	and	CC	O	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
minocycline	minocycline	NN	B-NP	O	S-drug
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fosfomycin	fosfomycin	NN	B-NP	O	S-drug
against	against	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
isolates	isolate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methicillin	methicillin	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
Staphylococcus	Staphylococcus	NNP	I-NP	O	O
aureus	aureus	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
minocycline	minocycline	NN	B-NP	O	S-drug
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fosfomycin	fosfomycin	NN	B-NP	O	S-drug
against	against	IN	B-PP	O	O
isolates	isolate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
methicillin	methicillin	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
Staphylococcus	Staphylococcus	NN	I-NP	O	O
aureus	aureus	NN	I-NP	O	O
(	(	(	O	O	O
MRSA	MRSA	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
87	87	CD	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
isolates	isolate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MRSA	MRSA	NN	B-NP	O	O
collected	collect	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
three	three	CD	B-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
hospitals	hospital	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
checkerboard	checkerboard	NN	I-NP	O	O
method	method	NN	I-NP	O	O
with	with	IN	B-PP	O	O
determination	determination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fractional	fractional	JJ	I-NP	O	O
IC	IC	NN	I-NP	O	O
index	index	NN	I-NP	O	O
(	(	(	O	O	O
FICI	FICI	NN	B-NP	B-protein	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
antibiotic	antibiotic	JJ	B-NP	O	S-group
combinations	combination	NNS	I-NP	O	O
act	act	VBP	B-VP	O	O
synergistically	synergistically	RB	B-ADVP	O	O
against	against	IN	B-PP	O	O
these	these	DT	B-NP	O	O
isolates	isolate	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
susceptibility	susceptibility	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
minocycline	minocycline	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
fosfomycin	fosfomycin	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
interpreted	interpret	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
following	following	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
:	:	:	O	O	O
76	76	CD	B-NP	O	O
isolates	isolate	NNS	I-NP	O	O
(	(	(	O	O	O
87.4	87.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
synergistic	synergistic	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
(	(	(	O	O	O
FICI	FICI	NN	B-NP	B-protein	O
0.5	0.5	CD	I-NP	I-protein	O
)	)	)	O	O	O
and	and	CC	O	O	O
11	11	CD	B-NP	O	O
isolates	isolate	NNS	I-NP	O	O
(	(	(	O	O	O
12.6	12.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
indifferent	indifferent	JJ	B-NP	O	O
interactions	interaction	NNS	I-NP	O	O
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
&	&	CC	I-NP	O	O
lt	lt	NN	I-NP	O	O
;	;	:	O	O	O
FICI	FICI	NNP	B-NP	O	O
&	&	CC	I-NP	O	O
lt	lt	NN	I-NP	O	O
;	;	:	O	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
antagonistic	antagonistic	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
(	(	(	O	O	O
FICI	FICI	NN	B-NP	B-protein	O
4	4	CD	I-NP	I-protein	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
minocycline	minocycline	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
fosfomycin	fosfomycin	NN	I-NP	O	S-drug-EF-2
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
synergistic	synergistic	JJ	B-ADJP	O	O
against	against	IN	B-PP	O	O
MRSA	MRSA	NN	B-NP	B-protein	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
alternative	alternative	NN	I-NP	O	O
for	for	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MRSA	MRSA	NN	B-NP	O	O
infections	infection	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levothyroxine	levothyroxine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
infant	infant	JJ	B-NP	O	O
colic	colic	JJ	I-NP	O	O
drops	drop	NNS	I-NP	O	O
.	.	.	O	O	O

Infacol	Infacol	NNP	B-NP	O	S-brand
(	(	(	O	O	O
Forest	Forest	NNP	B-NP	O	O
Laboratories	Laboratories	NNP	I-NP	O	O
UK	UK	NNP	I-NP	O	O
,	,	,	O	O	O
Kent	Kent	NNP	B-NP	O	O
,	,	,	O	O	O
UK	UK	NNP	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
widely	widely	RB	I-NP	O	O
available	available	JJ	B-ADJP	O	O
over	over	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
the	the	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
counter	counter	NN	I-NP	O	O
preparation	preparation	NN	I-NP	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
relieve	relieve	VB	I-VP	O	O
colic	colic	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
neonates	neonate	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
infants	infant	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
ingredient	ingredient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
simeticone	simeticone	NN	B-NP	O	S-drug
.	.	.	O	O	O

No	No	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
simeticone	simeticone	NN	B-NP	O	S-drug
are	be	VBP	B-VP	O	O
documented	document	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
summary	summary	NN	I-NP	O	O
of	of	IN	B-PP	O	O
product	product	NN	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
infant	infant	NN	I-NP	O	O
with	with	IN	B-PP	O	O
confirmed	confirm	VBN	B-NP	O	O
congenital	congenital	JJ	I-NP	O	O
hypothyroidism	hypothyroidism	NN	I-NP	O	O
on	on	IN	B-PP	O	O
levothyroxine	levothyroxine	NN	B-NP	O	S-drug-IN-1
who	who	WP	B-NP	O	O
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
simeticone	simeticone	NN	B-NP	O	S-drug-IN-2
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
levothyroxine	levothyroxine	NN	I-NP	O	S-drug
dosage	dosage	NN	I-NP	O	O
,	,	,	O	O	O
thyroid	thyroid	NN	B-NP	O	O
stimulating	stimulate	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
(	(	(	O	O	O
TSH	TSH	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
high	high	JJ	B-ADJP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
undertreatment	undertreatment	NN	B-NP	O	O
.	.	.	O	O	O

Questioning	Questioning	NNP	B-NP	O	O
revealed	reveal	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
child	child	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
Infacol	Infacol	NNP	B-NP	O	S-brand
drops	drop	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
feeds	feed	NNS	B-NP	O	O
while	while	IN	B-SBAR	O	O
on	on	IN	B-PP	O	O
levothyroxine	levothyroxine	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
colic	colic	JJ	I-NP	O	O
drops	drop	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
immediately	immediately	RB	I-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
and	and	CC	O	O	O
TSH	TSH	NN	B-NP	O	O
promptly	promptly	RB	B-VP	O	O
normalised	normalise	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
thyroxine	thyroxine	NN	B-NP	O	O
requirement	requirement	NN	I-NP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
age	age	NN	I-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thyroxine	thyroxine	NN	B-NP	O	S-drug
with	with	IN	B-PP	O	O
simeticone	simeticone	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
previously	previously	RB	B-ADVP	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
listed	list	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
British	British	NNP	I-NP	O	O
National	National	NNP	I-NP	O	O
Formulary	Formulary	NNP	I-NP	O	O
for	for	IN	B-PP	O	O
Children	Children	NNP	B-NP	O	O
.	.	.	O	O	O

Clinicians	Clinician	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
parents	parent	NNS	I-NP	O	O
need	need	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
unnecessary	unnecessary	JJ	B-NP	O	O
undertreatment	undertreatment	NN	I-NP	O	O
and	and	CC	O	O	O
prevent	prevent	VBP	B-VP	O	O
potential	potential	JJ	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
neurological	neurological	JJ	I-NP	O	O
sequelae	sequela	NNS	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
milligrams	milligram	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nonheme	nonheme	NN	B-NP	O	S-drug
or	or	CC	I-NP	O	O
heme	heme	NN	I-NP	O	B-drug
iron	iron	NN	I-NP	O	E-drug
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
800	800	CD	I-NP	O	O
milligrams	milligram	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
nonpregnant	nonpregnant	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug-ME-1
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
known	know	VBN	I-NP	O	O
component	component	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diet	diet	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
nonheme	nonheme	NN	B-NP	O	S-drug-ME-2
and	and	CC	O	O	O
heme	heme	NN	B-NP	O	B-drug-ME-2
iron	iron	NN	I-NP	O	E-drug-ME-2
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug-ME-1
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
iron	iron	NN	B-NP	O	S-drug-ME-2
absorption	absorption	NN	I-NP	O	O
mainly	mainly	RB	B-ADVP	O	O
comes	come	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
isolate	isolate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug
from	from	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
dietary	dietary	JJ	I-NP	O	O
components	component	NNS	I-NP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
meal	meal	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
objective	objective	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
establish	establish	VB	I-VP	O	O
potential	potential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug
on	on	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nonheme	nonheme	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
heme	heme	NN	I-NP	O	B-drug
iron	iron	NN	I-NP	O	E-drug
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
response	response	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
meal	meal	NN	I-NP	O	O
.	.	.	O	O	O

Fifty	Fifty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
four	four	CD	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
,	,	,	I-NP	O	O
nonpregnant	nonpregnant	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
selected	select	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
participate	participate	VB	I-VP	O	O
in	in	IN	B-PP	O	O
4	4	CD	B-NP	O	O
iron	iron	NN	I-NP	O	S-drug
absorption	absorption	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
iron	iron	NN	B-NP	O	O
radioactive	radioactive	JJ	I-NP	O	O
tracers	tracer	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
200	200	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1500	1500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
nonheme	nonheme	JJ	I-NP	O	B-drug
iron	iron	NN	I-NP	O	E-drug
(	(	(	O	O	O
as	as	IN	B-PP	O	O
ferrous	ferrous	JJ	B-NP	O	B-drug
sulfate	sulfate	NN	I-NP	O	E-drug
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug
doses	dose	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
200	200	CD	B-NP	O	O
and	and	CC	I-NP	O	O
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
heme	heme	NN	I-NP	O	B-drug
iron	iron	NN	I-NP	O	E-drug
[	[	(	O	O	O
as	as	IN	B-PP	O	O
concentrated	concentrate	VBN	B-NP	O	O
RBC	RBC	NN	I-NP	O	O
(	(	(	O	O	O
CRBC	CRBC	NN	B-NP	B-protein	O
)	)	)	O	O	O
]	]	)	O	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	B-drug
chloride	chloride	NN	I-NP	O	E-drug
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
minerals	mineral	NNS	I-NP	O	S-group
were	be	VBD	B-VP	O	O
ingested	ingest	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
empty	empty	JJ	I-NP	O	O
stomach	stomach	NN	I-NP	O	O
.	.	.	O	O	O

Calcium	Calcium	NN	B-NP	O	S-drug-ME-1
doses	dose	VBZ	B-VP	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
diminished	diminish	VBD	B-VP	O	O
nonheme	nonheme	JJ	B-NP	O	B-drug-ME-2
iron	iron	NN	I-NP	O	E-drug-ME-2
absorption	absorption	NN	I-NP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
49.6	49.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
calcium	calcium	NN	I-NP	O	S-drug-ME-1
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
diminished	diminish	VBD	B-VP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
heme	heme	NN	I-NP	O	B-drug-ME-2
iron	iron	NN	I-NP	O	E-drug-ME-2
by	by	IN	B-PP	O	O
37.7	37.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
isolated	isolate	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug-ME-1
(	(	(	O	O	O
as	as	IN	B-PP	O	O
chloride	chloride	NN	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
absorption	absorption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
iron	iron	NN	B-NP	O	O
provided	provide	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
nonheme	nonheme	NN	B-NP	O	S-drug-ME-2
(	(	(	O	O	O
as	as	IN	B-PP	O	O
sulfate	sulfate	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
heme	heme	NN	B-NP	B-protein	S-drug-ME-2
(	(	(	O	O	O
as	as	IN	B-PP	O	O
CRBC	CRBC	NN	B-NP	B-protein	O
)	)	)	O	O	O
iron	iron	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-SBAR	O	O
previously	previously	RB	B-ADVP	O	O
reported	report	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
meal	meal	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
starting	start	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
~	~	NN	B-NP	O	O
800	800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	O	S-drug
.	.	.	O	O	O

Synergistic	Synergistic	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug-IN-1
and	and	CC	I-NP	O	O
docetaxel	docetaxel	NN	I-NP	O	S-drug-IN-2
is	be	VBZ	B-VP	O	O
sequence	sequence	NN	B-NP	O	O
dependent	dependent	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
small	small	JJ	B-NP	O	O
lung	lung	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
with	with	IN	B-PP	O	O
EGFR	EGFR	NN	B-NP	B-protein	O
TKIs	TKI	NNS	I-NP	O	O
-	-	HYPH	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
mutation	mutation	NN	I-NP	O	O
.	.	.	O	O	O

Previous	Previous	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
tumor	tumor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
small	small	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
lung	lung	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
(	(	(	O	O	O
NSCLC	NSCLC	NN	B-NP	B-protein	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
aimed	aim	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug
and	and	CC	O	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
sequential	sequential	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
docetaxel	docetaxel	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
NSCLC	NSCLC	NN	B-NP	B-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
resistant	resistant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
EGFR	EGFR	NN	B-NP	B-protein	O
TKIs	TKI	NNS	I-NP	O	O
.	.	.	O	O	O

NSCLC	NSCLC	NN	B-NP	B-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
with	with	IN	B-PP	O	O
EGFR	EGFR	NN	B-NP	B-protein	O
T790M	T790M	NN	I-NP	O	O
mutation	mutation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
K	K	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
ras	ras	NN	I-NP	O	O
mutation	mutation	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
either	either	CC	O	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug
or	or	CC	O	O	O
docetaxel	docetaxel	NN	B-NP	O	S-drug
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
sequential	sequential	JJ	I-NP	O	O
administrations	administration	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
viability	viability	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
MTT	MTT	NN	B-NP	O	O
assay	assay	NN	I-NP	O	O
,	,	,	O	O	O
cell	cell	NN	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
flow	flow	NN	B-NP	O	O
cytometry	cytometry	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
signaling	signaling	NN	B-NP	O	O
pathway	pathway	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
immunoblotting	immunoblotting	NN	B-NP	O	O
.	.	.	O	O	O

Sunitinib	Sunitinib	NN	B-NP	O	S-drug
exhibited	exhibit	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
growth	growth	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
NSCLC	NSCLC	NN	B-NP	B-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
and	and	CC	O	O	O
arrested	arrest	VBN	B-NP	O	O
cell	cell	NN	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
at	at	IN	B-PP	O	O
G1	G1	NN	B-NP	O	O
phase	phase	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
docetaxel	docetaxel	NN	B-NP	O	S-drug
arrested	arrest	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
S	S	NN	B-NP	O	O
phase	phase	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
single	single	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
concurrent	concurrent	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
docetaxel	docetaxel	NN	I-NP	O	S-drug-EF-2
has	have	VBZ	B-VP	O	O
some	some	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
proliferative	proliferative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
sequential	sequential	JJ	I-NP	O	O
administrations	administration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
remarkably	remarkably	RB	B-ADVP	O	O
enhanced	enhance	VBD	B-VP	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	O	O	O
tumor	tumor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
cells	cell	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
docetaxel	docetaxel	NN	B-NP	O	S-drug-EF-1
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug-EF-2
,	,	,	O	O	O
synergism	synergism	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
synergism	synergism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
signaling	signaling	NN	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
initially	initially	RB	I-VP	O	O
activated	activate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
docetaxel	docetaxel	NN	B-NP	O	S-drug-EF-1
exposure	exposure	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
efficiently	efficiently	RB	I-VP	O	O
suppressed	suppress	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subsequent	subsequent	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
reverse	reverse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
sequential	sequential	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
antagonism	antagonism	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
differential	differential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
arrest	arrest	NN	I-NP	O	O
.	.	.	O	O	O

Sunitinib	Sunitinib	NN	B-NP	O	S-drug
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
exhibits	exhibit	VBZ	B-VP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
proliferative	proliferative	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
NSCLC	NSCLC	NN	B-NP	B-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
with	with	IN	B-PP	O	O
EGFR	EGFR	NN	B-NP	B-protein	O
T790M	T790M	NN	I-NP	O	O
and	and	CC	I-NP	O	O
K	K	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
ras	ras	NN	I-NP	O	O
mutations	mutation	NNS	I-NP	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
sequential	sequential	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
docetaxel	docetaxel	NN	B-NP	O	S-drug-EF-1
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug-EF-2
is	be	VBZ	B-VP	O	O
superior	superior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
sunitinib	sunitinib	NN	B-NP	O	S-drug
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
docetaxel	docetaxel	NN	B-NP	O	S-drug
and	and	CC	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Distinct	Distinct	JJ	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	B-protein	S-drug
and	and	CC	I-NP	O	O
methylglyoxal	methylglyoxal	NN	I-NP	O	S-drug_n
against	against	IN	B-PP	O	O
Pseudomonas	Pseudomonas	NNP	B-NP	O	O
aeruginosa	aeruginosa	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dicarbonyl	dicarbonyl	NN	I-NP	O	O
compound	compound	NN	I-NP	O	O
methylglyoxal	methylglyoxal	NN	I-NP	O	S-drug_n
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
natural	natural	JJ	I-NP	O	O
constituent	constituent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Manuka	Manuka	NNP	B-NP	O	O
honey	honey	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
Manuka	Manuka	NNP	B-NP	O	O
flowers	flower	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
New	New	NNP	B-NP	O	O
Zealand	Zealand	NNP	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
possess	possess	VB	I-VP	O	O
both	both	CC	O	O	O
anticancer	anticancer	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
antibacterial	antibacterial	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
observations	observation	NNS	I-NP	O	O
prompted	prompt	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methylglyoxal	methylglyoxal	NN	B-NP	O	S-drug_n
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
against	against	IN	B-PP	O	O
multidrug	multidrug	JJ	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
Pseudomonas	Pseudomonas	NN	I-NP	O	O
aeruginosa	aeruginosa	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
test	test	NN	I-NP	O	O
P	P	NN	I-NP	O	O
.	.	.	O	O	O

aeruginosa	aeruginosa	NN	B-NP	O	O
strains	strain	NNS	I-NP	O	O
isolated	isolate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
hospitals	hospital	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
resistances	resistance	NNS	I-NP	O	O
against	against	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	S-group
,	,	,	O	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
applied	apply	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P	P	NN	B-NP	O	O
.	.	.	O	O	O

aeruginosa	aeruginosa	NN	B-NP	O	O
infections	infection	NNS	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
strains	strain	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
resistant	resistant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
many	many	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
only	only	RB	B-NP	O	O
piperacillin	piperacillin	NN	I-NP	B-protein	S-drug
,	,	,	I-NP	O	O
carbenicillin	carbenicillin	NN	I-NP	B-protein	S-drug
,	,	,	I-NP	O	O
amikacin	amikacin	NN	I-NP	O	S-drug
and	and	CC	I-NP	O	O
ciprofloxacin	ciprofloxacin	NN	I-NP	O	S-drug
showed	show	VBD	B-VP	O	O
resistances	resistance	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
comparatively	comparatively	RB	B-NP	O	O
lower	low	JJR	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
experimentations	experimentation	NNS	I-NP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
methylglyoxal	methylglyoxal	NN	B-NP	O	S-drug_n
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
antimicrobic	antimicrobic	JJ	B-ADJP	O	O
against	against	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
strains	strain	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
comparable	comparable	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Distinct	Distinct	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
synergism	synergism	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
methylglyoxal	methylglyoxal	NN	B-NP	O	S-drug_n-EF-1
and	and	CC	I-NP	O	O
piperacillin	piperacillin	NN	I-NP	B-protein	S-drug-EF-2
by	by	IN	B-PP	O	O
disc	disc	NN	B-NP	O	O
diffusion	diffusion	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
individual	individual	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
fractional	fractional	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
index	index	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
evaluated	evaluate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
checkerboard	checkerboard	NN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
0.5	0.5	CD	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
confirmed	confirm	VBD	B-VP	O	O
synergism	synergism	NN	B-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pair	pair	NN	I-NP	O	O
.	.	.	O	O	O

Synergism	Synergism	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
noted	note	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
methylglyoxal	methylglyoxal	NN	B-NP	O	S-drug_n-EF-1
was	be	VBD	B-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
carbenicillin	carbenicillin	NN	B-NP	B-protein	S-drug-EF-2
and	and	CC	I-NP	O	O
amikacin	amikacin	NN	I-NP	O	S-drug-EF-2
.	.	.	O	O	O

Protective	Protective	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetyl	acetyl	NN	B-NP	O	B-drug
-	-	HYPH	I-NP	O	I-drug
l	l	NN	I-NP	O	I-drug
-	-	HYPH	I-NP	O	I-drug
carnitine	carnitine	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
alpha	alpha	NN	I-NP	O	B-drug_n
lipoic	lipoic	JJ	I-NP	O	I-drug_n
acid	acid	NN	I-NP	O	E-drug_n
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diepoxybutane	diepoxybutane	NN	B-NP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
lymphocytes	lymphocyte	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
biotransformation	biotransformation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
may	may	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
1,2	1,2	CD	B-NP	O	O
:	:	:	O	O	O
3,4	3,4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
diepoxybutane	diepoxybutane	NN	I-NP	O	O
(	(	(	O	O	O
DEB	DEB	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
lymphocytes	lymphocyte	NNS	I-NP	I-cell_type	O
of	of	IN	B-PP	O	O
Fanconi	Fanconi	NNP	B-NP	O	O
Anemia	Anemia	NNP	I-NP	O	O
(	(	(	O	O	O
FA	FA	NN	B-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
identification	identification	NN	I-NP	O	O
of	of	IN	B-PP	O	O
putative	putative	JJ	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bioactivation	bioactivation	NN	B-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
determination	determination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidant	oxidant	JJ	B-NP	O	O
defenses	defense	NNS	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
DEB	DEB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
,	,	,	O	O	O
can	can	MD	B-VP	O	O
help	help	VB	I-VP	O	O
to	to	TO	I-VP	O	O
understand	understand	VB	I-VP	O	O
what	what	WP	B-NP	O	O
is	be	VBZ	B-VP	O	O
failing	fail	VBG	I-VP	O	O
in	in	IN	B-PP	O	O
FA	FA	NN	B-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
work	work	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
contribution	contribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
DEB	DEB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
acute	acute	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
lymphocyte	lymphocyte	NN	I-NP	O	O
suspensions	suspension	NNS	I-NP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
epoxide	epoxide	NN	B-NP	B-protein	O
hydrolases	hydrolas	NNS	I-NP	I-protein	O
,	,	,	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
protective	protective	JJ	B-NP	B-protein	O
enzymes	enzyme	NNS	I-NP	I-protein	O
as	as	IN	B-PP	O	O
glutathione	glutathione	NN	B-NP	B-protein	O
S	S	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	I-protein	O
transferase	transferase	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
catalase	catalase	NN	I-NP	B-protein	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
depletion	depletion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glutathione	glutathione	NN	B-NP	O	O
(	(	(	O	O	O
GSH	GSH	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
;	;	:	O	O	O

and	and	CC	O	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
putative	putative	JJ	B-NP	O	O
protective	protective	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
antioxidants	antioxidant	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
protective	protective	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
reports	report	VBZ	B-VP	O	O
two	two	CD	B-NP	O	O
novel	novel	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
:	:	:	O	O	O
(	(	(	B-LST	O	O
i	i	LS	I-LST	O	O
)	)	)	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
clearly	clearly	RB	I-VP	O	O
evidenced	evidence	VBN	I-VP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
freshly	freshly	RB	B-NP	B-cell_type	O
isolated	isolate	VBN	I-NP	I-cell_type	O
human	human	JJ	I-NP	I-cell_type	O
lymphocytes	lymphocyte	NNS	I-NP	I-cell_type	O
to	to	TO	B-PP	O	O
DEB	DEB	NN	B-NP	B-protein	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
GSH	GSH	NN	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ATP	ATP	NN	B-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
death	death	NN	I-NP	O	O
;	;	:	O	O	O

(	(	(	B-LST	O	O
ii	ii	LS	I-LST	O	O
)	)	)	O	O	O
acetyl	acetyl	NN	B-NP	O	B-drug-EF-1
-	-	HYPH	B-NP	O	I-drug-EF-1
l	l	NN	I-NP	O	I-drug-EF-1
-	-	HYPH	B-NP	O	I-drug-EF-1
carnitine	carnitine	NN	I-NP	O	E-drug-EF-1
elicits	elicit	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
DEB	DEB	NN	B-NP	B-protein	O
induced	induce	VBD	B-VP	O	O
toxicity	toxicity	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	O	B-drug-EF-2
-	-	HYPH	B-NP	O	I-drug-EF-2
lipoic	lipoic	JJ	I-NP	O	I-drug-EF-2
acid	acid	NN	I-NP	O	E-drug-EF-2
.	.	.	O	O	O

Collectively	Collectively	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
contribute	contribute	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DEB	DEB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
induce	induce	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	O
and	and	CC	O	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
very	very	RB	B-ADJP	O	O
useful	useful	JJ	I-ADJP	O	O
when	when	WRB	B-ADVP	O	O
applied	apply	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
lymphocytes	lymphocyte	NNS	B-NP	B-cell_type	O
from	from	IN	B-PP	O	O
FA	FA	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
find	find	VB	I-VP	O	O
out	out	RP	B-PRT	O	O
a	a	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
against	against	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
DEB	DEB	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
chromosome	chromosome	NN	I-NP	O	O
instability	instability	NN	I-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Influence	Influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hemantane	hemantane	NN	B-NP	O	S-drug_n
and	and	CC	I-NP	O	O
doxycycline	doxycycline	NN	I-NP	O	S-drug
on	on	IN	B-PP	O	O
MPTP	MPTP	NN	B-NP	B-protein	O
-	-	HYPH	O	O	O
evoked	evoke	VBN	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
violations	violation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
C57BL	C57BL	NN	B-NP	B-protein	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
]	]	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	B-group
-	-	HYPH	I-NP	O	I-group
parkinsonian	parkinsonian	JJ	I-NP	O	I-group
drug	drug	NN	I-NP	O	E-group
hemantane	hemantane	NN	I-NP	O	S-drug_n
[	[	(	O	O	O
(	(	(	O	O	B-drug_n
2	2	CD	B-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
adamantyl	adamantyl	NN	I-NP	O	I-drug_n
)	)	)	O	O	I-drug_n
hexamethylenimine	hexamethylenimine	NN	B-NP	O	E-drug_n
]	]	)	O	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
p.	p.	NN	B-NP	O	O
o	o	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
antibiotic	antibiotic	JJ	B-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
doxycycline	doxycycline	NN	I-NP	O	S-drug
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
p.	p.	NN	B-NP	O	O
o	o	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
neurotoxin	neurotoxin	NN	B-NP	B-protein	O
1	1	CD	I-NP	I-protein	B-drug_n
-	-	HYPH	I-NP	O	I-drug_n
methyl	methyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
4	4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
phenyl	phenyl	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
1,2,3,4	1,2,3,4	CD	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
tetrahydropyridine	tetrahydropyridine	NN	I-NP	O	E-drug_n
(	(	(	O	O	O
MPTP	MPTP	NN	B-NP	O	S-drug_n
)	)	)	O	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
x	x	SYM	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.	i.	JJ	B-NP	O	O
p	p	NN	I-NP	O	O
.	.	.	O	O	O
)	)	)	O	O	O

were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
elevated	elevate	VBN	B-VP	O	O
plus	plus	CC	O	O	O
maze	maze	VB	B-VP	O	O
test	test	NN	B-NP	O	O
on	on	IN	B-PP	O	O
C57BL	C57BL	NN	B-NP	B-protein	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
second	second	JJ	B-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
,	,	,	O	O	O
MPTP	MPTP	NN	B-NP	B-protein	S-drug_n
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
locomot	locomot	NN	I-NP	O	O
or	or	CC	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
to	to	TO	B-PP	O	O
saline	saline	NN	B-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hemantane	hemantane	NN	B-NP	O	S-drug_n-EF-1
or	or	CC	I-NP	O	O
doxycycline	doxycycline	NN	I-NP	O	S-drug-EF-2
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
influence	influence	VB	I-VP	O	O
locomotion	locomotion	NN	B-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
their	their	PRP$	B-NP	O	O
combination	combination	NN	I-NP	O	O
normalized	normalize	VBD	B-VP	O	O
motor	motor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
confirm	confirm	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
processes	process	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
parkinsonism	parkinsonism	NN	B-NP	O	O
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
expediency	expediency	NN	B-NP	O	O
of	of	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
pharmacotherapy	pharmacotherapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurodegenerative	neurodegenerative	JJ	B-NP	O	O
diseases	disease	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p27	p27	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
Kip1	Kip1	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
in	in	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug-EF-1
-	-	HYPH	B-NP	O	O
enhanced	enhance	VBN	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	O	S-drug-EF-2
cytotoxicity	cytotoxicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
ovarian	ovarian	JJ	I-NP	I-cell_type	O
cancer	cancer	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Less	Less	RBR	B-NP	O	O
than	than	IN	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	O	O
cancers	cancer	NNS	I-NP	O	O
respond	respond	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
.	.	.	O	O	O

Effective	Effective	JJ	B-NP	O	O
strategies	strategy	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
sensitivity	sensitivity	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
library	library	NN	I-NP	O	O
of	of	IN	B-PP	O	O
silencing	silencing	JJ	B-NP	B-RNA	O
RNAs	RNA	NNS	I-NP	I-RNA	O
(	(	(	O	O	O
siRNAs	siRNA	NNS	B-NP	B-RNA	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
kinases	kinase	NNS	B-NP	B-protein	O
that	that	WDT	B-NP	O	O
regulate	regulate	VBP	B-VP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
sensitivity	sensitivity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_line	O
ovarian	ovarian	JJ	I-NP	I-cell_line	O
cancer	cancer	NN	I-NP	I-cell_line	O
SKOv3	SKOv3	NN	I-NP	I-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Src	Src	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
Abl	Abl	NN	I-NP	B-protein	O
kinases	kinase	NNS	I-NP	I-protein	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
sensitivity	sensitivity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	B-cell_type	O
cancer	cancer	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
and	and	CC	O	O	O
HEY	HEY	NN	B-NP	O	O
xenografts	xenograft	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
roles	role	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
p27	p27	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
Kip1	Kip1	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
,	,	,	O	O	O
Bcl	Bcl	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
2	2	CD	B-NP	I-protein	O
,	,	,	O	O	O
and	and	CC	O	O	O
Cdk1	Cdk1	NN	B-NP	B-protein	O
in	in	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	O	S-drug
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
terminal	terminal	JJ	I-NP	B-protein	O
deoxynucleotidyl	deoxynucleotidyl	NN	I-NP	I-protein	O
transferase	transferase	NN	I-NP	I-protein	O
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
dUTP	dUTP	NN	I-NP	O	O
nick	nick	NN	I-NP	O	O
-	-	HYPH	O	O	O
end	end	NN	B-NP	O	O
labeling	labeling	NN	I-NP	O	O
(	(	(	O	O	O
TUNEL	TUNEL	NN	B-NP	O	O
)	)	)	O	O	O
assay	assay	NN	B-NP	O	O
,	,	,	O	O	O
siRNA	siRNA	NN	B-NP	O	O
knockdown	knockdown	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
,	,	,	O	O	O
transfection	transfection	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Bcl	Bcl	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
2	2	CD	I-NP	I-protein	O
and	and	CC	O	O	O
Cdk1	Cdk1	NN	B-NP	B-DNA	O
expression	expression	NN	I-NP	I-DNA	O
vectors	vector	NNS	I-NP	I-DNA	O
,	,	,	O	O	O
and	and	CC	O	O	O
flow	flow	NN	B-NP	O	O
cytometry	cytometry	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
statistical	statistical	JJ	I-NP	O	O
tests	test	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
sided	sided	JJ	I-NP	O	O
.	.	.	O	O	O

Src	Src	NN	B-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
Abl	Abl	NN	I-NP	B-protein	O
kinases	kinase	NNS	I-NP	I-protein	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
modulators	modulator	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
sensitivity	sensitivity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
SKOv3	SKOv3	NN	B-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
siRNA	siRNA	NN	I-NP	O	O
knockdown	knockdown	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Src	Src	NN	B-NP	B-protein	O
,	,	,	O	O	O
Fyn	Fyn	NN	B-NP	B-protein	O
,	,	,	O	O	O
or	or	CC	O	O	O
Abl1	Abl1	NN	B-NP	B-protein	O
enhanced	enhance	VBD	B-VP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
growth	growth	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	B-cell_type	O
cancer	cancer	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
siRNA	siRNA	NN	I-NP	O	O
.	.	.	O	O	O

HEY	HEY	NN	B-NP	B-cell_line	O
cells	cell	NNS	I-NP	I-cell_line	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	O	S-drug-EF-2
formed	form	VBD	B-VP	O	O
fewer	few	JJR	B-NP	O	O
colonies	colony	NNS	I-NP	O	O
than	than	IN	B-SBAR	O	O
did	do	VBD	O	O	O
cells	cell	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
HEY	HEY	NN	B-NP	O	O
xenograft	xenograft	NN	I-NP	O	O
-	-	HYPH	O	O	O
bearing	bear	VBG	B-VP	O	O
mice	mouse	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug-EF-1
plus	plus	CC	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	O	S-drug-EF-2
inhibited	inhibit	VBD	B-VP	O	O
tumor	tumor	NN	B-NP	O	O
growth	growth	NN	I-NP	O	O
more	more	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
agent	agent	NN	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
(	(	(	O	O	O
average	average	JJ	B-NP	O	O
tumor	tumor	NN	I-NP	O	O
volume	volume	NN	I-NP	O	O
per	per	IN	B-PP	O	O
mouse	mouse	NN	B-NP	O	O
,	,	,	O	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
+	+	SYM	B-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	O	S-drug
vs	vs	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug
:	:	:	O	O	O
0.28	0.28	CD	B-NP	O	O
vs.	vs.	IN	B-PP	O	O
0.81	0.81	CD	B-NP	O	O
cm3	cm3	NN	I-NP	O	O
,	,	,	O	O	O
difference	difference	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.53	0.53	CD	B-NP	O	O
cm3	cm3	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
]	]	)	O	O	O
=	=	SYM	B-VP	O	O
0.44	0.44	CD	B-NP	O	O
to	to	TO	B-PP	O	O
0.62	0.62	CD	B-NP	O	O
cm3	cm3	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.014	.014	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O

dasatinib	dasatinib	NN	B-NP	O	S-drug
+	+	SYM	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	O	S-drug
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

dasatinib	dasatinib	NN	B-NP	O	S-drug
:	:	:	O	O	O
0.28	0.28	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

0.55	0.55	CD	B-NP	O	O
cm3	cm3	NN	I-NP	O	O
,	,	,	O	O	O
difference	difference	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.27	0.27	CD	B-NP	O	O
cm3	cm3	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
0.21	0.21	CD	B-NP	O	O
to	to	TO	B-PP	O	O
0.33	0.33	CD	B-NP	O	O
cm3	cm3	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.035	.035	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Combined	Combine	VBN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
induced	induce	VBD	B-VP	O	O
more	more	JJR	B-NP	O	O
TUNEL	TUNEL	NN	I-NP	B-protein	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	B-cell_type	O
apoptotic	apoptotic	JJ	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
than	than	IN	B-SBAR	O	O
did	do	VBD	O	O	O
either	either	CC	O	O	O
agent	agent	NN	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
siRNA	siRNA	NN	I-NP	O	O
knockdown	knockdown	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p27	p27	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
Kip1	Kip1	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
decreased	decrease	VBD	B-VP	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	O	S-drug
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
siRNA	siRNA	NN	I-NP	O	O
(	(	(	O	O	O
sub	sub	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
G1	G1	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
,	,	,	O	O	O
control	control	NN	B-NP	O	O
siRNA	siRNA	NN	I-NP	O	O
vs.	vs.	CC	O	O	O
p27	p27	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
Kip1	Kip1	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
siRNA	siRNA	NN	B-NP	O	O
:	:	:	O	O	O
42.5	42.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs.	vs.	IN	B-PP	O	O
20.1	20.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
difference	difference	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
22.4	22.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
20.1	20.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
24.7	24.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.017	.017	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
forced	force	VBN	B-NP	O	O
expression	expression	NN	I-NP	O	O
and	and	CC	O	O	O
siRNA	siRNA	NN	B-NP	O	O
knockdown	knockdown	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bcl	Bcl	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
2	2	CD	I-NP	I-protein	O
and	and	CC	O	O	O
Cdk1	Cdk1	NN	B-NP	B-protein	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug-EF-1
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p27	p27	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
Kip1	Kip1	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
enhanced	enhance	VBD	B-VP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug-EF-2
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
negatively	negatively	RB	B-VP	O	O
regulating	regulate	VBG	I-VP	O	O
Bcl	Bcl	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
2	2	CD	B-NP	I-protein	O
and	and	CC	O	O	O
Cdk1	Cdk1	NN	B-NP	B-protein	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Src	Src	NN	B-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
and	and	CC	I-NP	O	O
Abl	Abl	NN	I-NP	O	O
kinases	kinase	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
siRNAs	siRNA	NNS	B-NP	O	O
or	or	CC	O	O	O
dasatinib	dasatinib	NN	B-NP	O	S-drug-EF-1
enhances	enhance	VBZ	B-VP	O	O
paclitaxel	paclitaxel	NN	B-NP	O	S-drug-EF-2
sensitivity	sensitivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	B-cell_type	O
cancer	cancer	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
through	through	IN	B-PP	O	O
p27	p27	NN	B-NP	B-protein	O
(	(	(	O	I-protein	O
Kip1	Kip1	NN	B-NP	I-protein	O
)	)	)	O	I-protein	O
-	-	HYPH	B-NP	O	O
mediated	mediated	JJ	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bcl	Bcl	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
2	2	CD	I-NP	I-protein	O
and	and	CC	O	O	O
Cdk1	Cdk1	NN	B-NP	B-protein	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

Phase	Phase	NN	B-NP	O	O
I	I	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lenalidomide	lenalidomide	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
CCI	CCI	NN	I-NP	B-protein	B-drug
-	-	HYPH	O	O	I-drug
779	779	CD	B-NP	O	E-drug
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
relapsed	relapse	VBN	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
myeloma	myeloma	NN	I-NP	O	O
:	:	:	O	O	O
evidence	evidence	NN	B-NP	O	O
for	for	IN	B-PP	O	O
lenalidomide	lenalidomide	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
CCI	CCI	NN	I-NP	B-protein	B-drug
-	-	HYPH	I-NP	O	I-drug
779	779	CD	I-NP	O	E-drug
interaction	interaction	NN	I-NP	O	O
via	via	IN	B-PP	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B-protein	O
.	.	.	O	O	O

Multiple	Multiple	JJ	B-NP	O	O
myeloma	myeloma	NN	I-NP	O	O
(	(	(	O	O	O
MM	MM	NN	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
incurable	incurable	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
cell	cell	NN	I-NP	O	O
neoplasm	neoplasm	NN	I-NP	O	O
for	for	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
most	most	JJS	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
involve	involve	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	O	S-drug
.	.	.	O	O	O

The	The	DT	B-NP	O	O
preclinical	preclinical	JJ	I-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lenalidomide	lenalidomide	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mTOR	mTOR	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
CCI	CCI	NN	I-NP	O	B-drug-EF-2
-	-	HYPH	O	O	I-drug-EF-2
779	779	CD	B-NP	O	E-drug-EF-2
has	have	VBZ	B-VP	O	O
displayed	display	VBN	I-VP	O	O
synergy	synergy	NN	B-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
represents	represent	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
combination	combination	NN	I-NP	O	O
in	in	IN	B-PP	O	O
MM	MM	NN	B-NP	O	O
.	.	.	O	O	O

Enhancement	Enhancement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
humoral	humoral	JJ	B-NP	O	O
immune	immune	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
inactivated	inactivate	VBN	B-NP	O	O
Newcastle	Newcastle	NNP	I-NP	O	O
disease	disease	NN	I-NP	O	O
and	and	CC	O	O	O
avian	avian	JJ	B-NP	O	B-group
influenza	influenza	NN	I-NP	O	I-group
vaccines	vaccine	NNS	I-NP	O	E-group
by	by	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ginseng	ginseng	NN	B-NP	O	B-drug_n
stem	stem	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
and	and	CC	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
leaf	leaf	NN	I-NP	B-protein	I-drug_n
saponins	saponin	NNS	I-NP	I-protein	E-drug_n
in	in	IN	B-PP	O	O
chickens	chicken	NNS	B-NP	O	O
.	.	.	O	O	O

Newcastle	Newcastle	NN	B-NP	O	O
disease	disease	NN	I-NP	O	O
(	(	(	O	O	O
ND	ND	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
avian	avian	JJ	B-NP	O	O
influenza	influenza	NN	I-NP	O	O
(	(	(	O	O	O
AI	AI	NN	B-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
common	common	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
poultry	poultry	NN	I-NP	O	O
industry	industry	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
objective	objective	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ginseng	ginseng	NN	B-NP	O	B-drug_n
stem	stem	NN	I-NP	O	I-drug_n
-	-	HYPH	B-NP	O	I-drug_n
and	and	CC	I-NP	O	I-drug_n
-	-	HYPH	I-NP	O	I-drug_n
leaf	leaf	NN	I-NP	O	I-drug_n
saponins	saponin	NNS	I-NP	O	E-drug_n
(	(	(	O	O	O
GSLS	GSLS	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
humoral	humoral	JJ	I-NP	O	O
immune	immune	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chickens	chicken	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
inactivated	inactivate	VBN	B-NP	O	B-drug
ND	ND	NN	I-NP	O	E-drug
and	and	CC	I-NP	O	O
AI	AI	NN	I-NP	O	O
vaccines	vaccine	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
experiment	experiment	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GSLS	GSLS	NN	B-NP	B-protein	S-drug_n
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BW	BW	NN	B-NP	B-protein	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
d	d	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
immune	immune	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
chickens	chicken	NNS	B-NP	O	O
intramuscularly	intramuscularly	RB	B-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
inactivated	inactivate	VBN	B-NP	O	B-drug
ND	ND	NN	I-NP	O	I-drug
vaccine	vaccine	NN	I-NP	O	E-drug
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
GSLS	GSLS	NN	B-NP	B-protein	S-drug_n
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
antibody	antibody	NN	I-NP	O	O
level	level	NN	I-NP	O	O
against	against	IN	B-PP	O	O
ND	ND	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chickens	chicken	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
experiment	experiment	NN	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GSLS	GSLS	NN	B-NP	B-protein	S-drug_n-EF-1
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
chickens	chicken	NNS	B-NP	O	O
inoculated	inoculate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
inactivated	inactivate	VBN	B-NP	O	B-drug-EF-2
AI	AI	NN	I-NP	O	I-drug-EF-2
vaccines	vaccine	NNS	I-NP	O	E-drug-EF-2
,	,	,	O	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
enhanced	enhance	VBN	I-NP	O	O
serum	serum	NN	I-NP	O	O
antibody	antibody	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
AI	AI	NN	B-NP	O	O
vaccination	vaccination	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Considering	Consider	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GSLS	GSLS	NN	B-NP	B-protein	S-drug_n
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
,	,	,	O	O	O
GSLS	GSLS	NN	B-NP	B-protein	S-drug_n
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
promising	promising	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
adjuvant	adjuvant	NN	I-NP	O	O
to	to	TO	B-VP	O	O
improve	improve	VB	I-VP	O	O
immunization	immunization	NN	B-NP	O	O
in	in	IN	B-PP	O	O
poultry	poultry	NN	B-NP	O	O
.	.	.	O	O	O

Interaction	Interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dacarbazine	dacarbazine	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
imexon	imexon	NN	I-NP	O	S-drug_n
,	,	,	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
A375	A375	NN	I-NP	I-cell_type	O
melanoma	melanoma	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
interaction	interaction	NN	B-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alkyating	alkyate	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
dacarbazine	dacarbazine	NN	I-NP	O	S-drug
(	(	(	O	O	O
DTIC	DTIC	NN	B-NP	O	S-drug
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pro	pro	AFX	I-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
oxidant	oxidant	NN	I-NP	O	O
,	,	,	O	O	O
imexon	imexon	NN	B-NP	O	S-drug
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	B-cell_line	O
A375	A375	NN	I-NP	I-cell_line	O
melanoma	melanoma	NN	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
line	line	NN	I-NP	I-cell_line	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DTIC	DTIC	NN	B-NP	O	S-drug
and	and	CC	I-NP	O	O
imexon	imexon	NN	I-NP	O	S-drug
,	,	,	O	O	O
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
growth	growth	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
(	(	(	O	O	O
MTT	MTT	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
radiolabeled	radiolabele	VBN	B-NP	O	O
drug	drug	NN	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
,	,	,	O	O	O
cellular	cellular	JJ	B-NP	O	O
thiol	thiol	NN	I-NP	O	O
content	content	NN	I-NP	O	O
(	(	(	O	O	O
HPLC	HPLC	NN	B-NP	B-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
DNA	DNA	NN	B-NP	O	O
strand	strand	NN	I-NP	O	O
breaks	break	NNS	I-NP	O	O
(	(	(	O	O	O
Comet	Comet	NN	B-NP	O	O
assay	assay	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Pharmacokinetic	Pharmacokinetic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
antitumor	antitumor	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Growth	Growth	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
was	be	VBD	B-VP	O	O
additive	additive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
or	or	CC	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DNA	DNA	NN	B-NP	O	O
strand	strand	NN	I-NP	O	O
breaks	break	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
>	>	JJR	I-NP	O	O
75	75	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cellular	cellular	JJ	B-NP	O	O
glutathione	glutathione	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cysteine	cysteine	NN	I-NP	O	O
with	with	IN	B-PP	O	O
imexon	imexon	NN	B-NP	O	S-drug
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
DTIC	DTIC	NN	B-NP	O	S-drug
.	.	.	O	O	O

Co	Co	AFX	B-NP	B-DNA	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
caused	cause	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
human	human	JJ	B-NP	O	O
A375	A375	NN	I-NP	O	O
melanoma	melanoma	NN	I-NP	O	O
tumors	tumor	NNS	I-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

Imexon	Imexon	NN	B-NP	O	S-drug-EF-1
and	and	CC	I-NP	O	O
dacarbazine	dacarbazine	NN	I-NP	O	S-drug-EF-2
show	show	VBP	B-VP	O	O
additive	additive	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
but	but	CC	I-ADVP	O	O
not	not	RB	I-ADVP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	B-cell_type	O
A375	A375	NN	I-NP	I-cell_type	O
melanoma	melanoma	NN	I-NP	I-cell_type	O
cells	cell	NNS	I-NP	I-cell_type	O
.	.	.	O	O	O

Lapatinib	Lapatinib	NN	B-NP	B-protein	S-drug-EF-1
enhances	enhance	VBZ	B-VP	O	O
herceptin	herceptin	NN	B-NP	B-protein	S-brand-EF-2
-	-	HYPH	O	I-protein	O
mediated	mediate	VBN	B-NP	I-protein	O
antibody	antibody	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
cellular	cellular	JJ	I-NP	O	O
cytotoxicity	cytotoxicity	NN	I-NP	O	O
by	by	IN	B-PP	O	O
up	up	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cell	cell	NN	B-NP	B-protein	O
surface	surface	NN	I-NP	I-protein	O
HER2	HER2	NN	I-NP	I-protein	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
previously	previously	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug-EF-1
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Herceptin	Herceptin	NN	B-NP	B-protein	S-brand-EF-2
improved	improve	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
progression	progression	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug
alone	alone	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Herceptin	Herceptin	NN	B-NP	B-protein	S-brand
-	-	HYPH	O	O	O
refractory	refractory	JJ	B-NP	O	O
HER2	HER2	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
metastatic	metastatic	JJ	I-NP	O	O
breast	breast	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
purported	purport	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
antiproliferative	antiproliferative	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
relating	relate	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
synergism	synergism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
how	how	WRB	B-ADVP	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug
interacts	interact	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
Herceptin	Herceptin	NN	B-NP	B-protein	S-brand
in	in	IN	B-PP	O	O
HER2	HER2	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
breast	breast	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
particular	particular	JJ	I-NP	O	O
focus	focus	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Herceptin	Herceptin	NN	B-NP	B-protein	S-brand
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
antibody	antibody	NN	I-NP	B-protein	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
cellular	cellular	JJ	I-NP	O	O
cytotoxicity	cytotoxicity	NN	I-NP	O	O
(	(	(	O	O	O
ADCC	ADCC	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
assay	assay	NN	I-NP	O	O
,	,	,	O	O	O
lapatinib	lapatinib	NN	B-NP	O	S-drug-EF-1
induced	induce	VBD	B-VP	O	O
HER2	HER2	NN	B-NP	B-protein	O
expression	expression	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
surface	surface	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HER2	HER2	NN	B-NP	B-cell_line	O
-	-	HYPH	B-NP	I-cell_line	O
positive	positive	JJ	I-NP	I-cell_line	O
breast	breast	NN	I-NP	I-cell_line	O
cancer	cancer	NN	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Herceptin	Herceptin	NN	B-NP	B-protein	S-brand-EF-2
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
ADCC	ADCC	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
Herceptin	Herceptin	NN	I-NP	O	S-brand-EF-1
treatment	treatment	NN	I-NP	O	O
following	follow	VBG	B-NP	O	O
lapatinib	lapatinib	NN	I-NP	O	S-drug-EF-2
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
shrinkage	shrinkage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
metastatic	metastatic	JJ	I-NP	O	O
tumors	tumor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HER2	HER2	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
breast	breast	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
.	.	.	O	O	O

Lapatinib	Lapatinib	NN	B-NP	O	S-drug
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
to	to	TO	B-VP	O	O
convert	convert	VB	I-VP	O	O
Herceptin	Herceptin	NN	B-NP	B-protein	S-brand
-	-	HYPH	O	O	O
refractory	refractory	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Herceptin	Herceptin	NN	B-NP	B-protein	S-brand
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
tumors	tumor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HER2	HER2	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
breast	breast	NN	I-NP	O	O
cancer	cancer	NN	I-NP	O	O
by	by	IN	B-PP	O	O
up	up	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
surface	surface	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HER2	HER2	NN	B-NP	B-protein	O
.	.	.	O	O	O

Antitumor	Antitumor	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CRM197	CRM197	NN	B-NP	B-protein	S-drug_n
,	,	,	O	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
EGF	EGF	NN	B-NP	I-protein	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
T	T	NN	B-NP	B-cell_type	O
-	-	HYPH	I-NP	I-cell_type	O
cell	cell	NN	I-NP	I-cell_type	O
acute	acute	JJ	I-NP	O	O
lymphoblastic	lymphoblastic	JJ	I-NP	O	O
leukemia	leukemia	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
for	for	IN	B-PP	O	O
T	T	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
cell	cell	NN	I-NP	O	O
acute	acute	JJ	I-NP	O	O
lymphoblastic	lymphoblastic	JJ	I-NP	O	O
leukemia	leukemia	NN	I-NP	O	O
(	(	(	O	O	O
T	T	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ALL	ALL	NN	I-NP	O	O
)	)	)	O	O	O
remains	remain	VBZ	B-VP	O	O
poor	poor	JJ	B-ADJP	O	O
;	;	:	O	O	O

thus	thus	RB	B-ADVP	O	O
,	,	,	O	O	O
novel	novel	NN	B-NP	O	O
,	,	,	O	O	O
targeted	target	VBN	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
urgently	urgently	RB	I-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Recently	Recently	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
heparin	heparin	NN	B-NP	B-protein	O
-	-	HYPH	O	I-protein	O
binding	bind	VBG	B-VP	I-protein	O
epidermal	epidermal	JJ	B-NP	I-protein	O
growth	growth	NN	I-NP	I-protein	O
factor	factor	NN	I-NP	I-protein	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
growth	growth	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
(	(	(	O	O	O
HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
EGF	EGF	NN	I-NP	I-protein	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
member	member	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
EGF	EGF	NN	I-NP	B-protein	O
family	family	NN	I-NP	I-protein	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
promising	promising	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
EGF	EGF	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
for	for	IN	B-PP	O	O
T	T	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
ALL	ALL	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
further	further	RB	I-VP	O	O
elucidate	elucidate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antitumor	antitumor	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
EGF	EGF	NN	I-NP	I-protein	O
,	,	,	O	O	O
cross	cross	AFX	O	O	B-drug_n
-	-	HYPH	O	O	I-drug_n
reacting	react	VBG	B-VP	O	I-drug_n
material	material	NN	B-NP	O	I-drug_n
197	197	CD	I-NP	O	E-drug_n
(	(	(	O	O	O
CRM197	CRM197	NN	B-NP	B-protein	S-drug_n
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
elucidated	elucidate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
EGF	EGF	NN	I-NP	I-protein	O
in	in	IN	B-PP	O	O
T	T	NN	B-NP	B-cell_line	O
-	-	HYPH	I-NP	I-cell_line	O
ALL	ALL	NN	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
,	,	,	O	O	O
and	and	CC	O	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CRM197	CRM197	NN	B-NP	B-protein	S-drug_n
on	on	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cells	cell	NNS	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
anticancer	anticancer	JJ	B-NP	O	B-group
agent	agent	NN	I-NP	O	E-group
.	.	.	O	O	O

The	The	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EGFR	EGFR	NN	B-NP	B-protein	O
and	and	CC	I-NP	O	O
EGFR	EGFR	NN	I-NP	B-protein	O
ligands	ligand	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
flow	flow	NN	B-NP	O	O
cytometry	cytometry	NN	I-NP	O	O
,	,	,	O	O	O
RT	RT	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
PCR	PCR	NN	I-NP	O	O
and	and	CC	O	O	O
real	real	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
time	time	NN	I-NP	O	O
quantitative	quantitative	JJ	I-NP	O	O
PCR	PCR	NN	I-NP	O	O
.	.	.	O	O	O

Induction	Induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
TUNEL	TUNEL	NN	B-NP	O	O
assay	assay	NN	I-NP	O	O
.	.	.	O	O	O

HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	I-NP	O	O
EGF	EGF	NN	I-NP	B-protein	O
was	be	VBD	B-VP	O	O
strongly	strongly	RB	I-VP	O	O
expressed	express	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
T	T	NN	B-NP	B-cell_line	O
-	-	HYPH	I-NP	I-cell_line	O
ALL	ALL	NN	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
lines	line	NNS	I-NP	I-cell_line	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	O	O
EGF	EGF	NN	I-NP	B-protein	O
and	and	CC	I-NP	O	O
EGFR	EGFR	NN	I-NP	B-protein	O
was	be	VBD	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	O	S-drug
.	.	.	O	O	O

CRM197	CRM197	NN	B-NP	B-protein	S-drug_n
induced	induce	VBD	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
furthermore	furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CRM197	CRM197	NN	B-NP	B-protein	S-drug_n-EF-1
plus	plus	CC	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	O	S-drug-EF-2
enhanced	enhance	VBD	B-VP	O	O
cytotoxicity	cytotoxicity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
T	T	NN	I-NP	B-cell_line	O
-	-	HYPH	I-NP	I-cell_line	O
ALL	ALL	NN	I-NP	I-cell_line	O
cell	cell	NN	I-NP	I-cell_line	O
line	line	NN	I-NP	I-cell_line	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
HB	HB	NN	B-NP	B-protein	O
-	-	HYPH	B-NP	I-protein	O
EGF	EGF	NN	I-NP	I-protein	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
promising	promising	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
for	for	IN	B-PP	O	O
T	T	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
ALL	ALL	NN	I-NP	O	O
.	.	.	O	O	O

Ephedrine	Ephedrine	NN	B-NP	O	S-drug-EF-1
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug-EF-2
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Dexmedetomidine	Dexmedetomidine	NN	B-NP	O	S-drug
,	,	,	O	O	O
a	a	DT	B-NP	O	O
highly	highly	RB	I-NP	O	O
selective	selective	JJ	I-NP	O	O
alpha	alpha	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
recently	recently	RB	I-VP	O	O
introduced	introduce	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
for	for	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
sedative	sedative	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
psychostimulant	psychostimulant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
ephedrine	ephedrine	NN	I-NP	O	S-drug
has	have	VBZ	B-VP	O	O
any	any	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
antinociception	antinociception	NN	I-NP	O	O
and	and	CC	I-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
both	both	DT	B-NP	O	O
sexes	sex	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
swiss	swiss	JJ	B-NP	O	O
albino	albino	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
;	;	:	O	O	O

antinociception	antinociception	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
hot	hot	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
plate	plate	NN	I-NP	O	O
test	test	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
,	,	,	O	O	O
exploratory	exploratory	JJ	B-NP	O	O
activities	activity	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
holed	hole	VBN	B-NP	O	O
open	open	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
;	;	:	O	O	O

saline	saline	NN	B-NP	O	O
+	+	SYM	I-NP	O	O
saline	saline	NN	I-NP	O	O
,	,	,	O	O	O
ephedrine	ephedrine	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	I-NP	O	O
+	+	JJ	I-NP	O	O
saline	saline	NN	I-NP	O	O
,	,	,	O	O	O
saline	saline	NN	B-NP	O	O
+	+	SYM	O	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug
(	(	(	O	O	O
15	15	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ephedrine	ephedrine	NN	B-NP	O	S-drug
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
+	+	SYM	B-NP	O	O
dexmedetomidine	dexmedetomidine	NN	I-NP	O	S-drug
(	(	(	O	O	O
15	15	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
,	,	,	O	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
hot	hot	JJ	B-NP	O	O
plate	plate	NN	I-NP	O	O
or	or	CC	O	O	O
holed	hole	VBD	B-VP	O	O
open	open	JJ	B-NP	O	O
field	field	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hot	hot	JJ	I-NP	O	O
plate	plate	NN	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
,	,	,	O	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
dexmedetomidine	dexmedetomidine	NN	I-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
ephedrine	ephedrine	NN	I-NP	O	S-drug-EF-2
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
enhanced	enhance	VBN	B-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
also	also	RB	B-ADVP	O	O
prolonged	prolong	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antinociception	antinociception	NN	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug
.	.	.	O	O	O

At	At	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
locomotor	locomotor	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug-EF-1
was	be	VBD	B-VP	O	O
counteracted	counteract	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ephedrine	ephedrine	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
concluded	conclude	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug-EF-1
with	with	IN	B-PP	O	O
ephedrine	ephedrine	NN	B-NP	O	S-drug-EF-2
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
beneficial	beneficial	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pain	pain	NN	B-NP	O	O
without	without	IN	B-PP	O	O
causing	cause	VBG	B-VP	O	O
sedation	sedation	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
limits	limit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	O	S-drug
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
analgesic	analgesic	NN	I-NP	O	S-group
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

[	[	(	O	O	O
Efficacy	Efficacy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fixed	fix	VBN	B-NP	O	O
combination	combination	NN	I-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
valsartan	valsartan	NN	I-NP	O	S-drug
in	in	IN	B-PP	O	O
hospitalized	hospitalize	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
]	]	)	O	O	O

Efficacy	Efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fixed	fix	VBN	B-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
valsartan	valsartan	NN	I-NP	O	S-drug
combination	combination	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
86	86	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
hospitalized	hospitalize	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
departments	department	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
internal	internal	JJ	I-NP	O	O
medicine	medicine	NN	I-NP	O	O
or	or	CC	I-NP	O	O
cardiology	cardiology	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
indications	indication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
either	either	CC	B-PP	O	O
to	to	TO	I-PP	O	O
fixed	fix	VBN	B-NP	O	O
combination	combination	NN	I-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug
/	/	SYM	O	O	O
valsartan	valsartan	NN	B-NP	O	S-drug
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
43	43	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
to	to	TO	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
which	which	WDT	B-NP	O	O
corresponded	correspond	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
formulary	formulary	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
43	43	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Correction	Correction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	S-group
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
treating	treat	VBG	B-VP	O	O
physician	physician	NN	B-NP	O	O
at	at	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
rounds	round	NNS	I-NP	O	O
.	.	.	O	O	O

Self	Self	NN	B-NP	O	O
-	-	HYPH	O	O	O
control	control	NN	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
BP	BP	NN	B-NP	B-protein	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
UA767PC	UA767PC	NN	B-NP	O	O
apparatus	apparatus	NN	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
BP	BP	NN	B-NP	B-protein	O
self	self	AFX	O	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
measurements	measurement	NNS	I-NP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
detect	detect	VB	I-VP	O	O
concealed	concealed	JJ	B-NP	O	O
inefficacy	inefficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
.	.	.	O	O	O

Rate	Rate	NN	B-NP	O	O
of	of	IN	B-PP	O	O
achievement	achievement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
target	target	NN	B-NP	O	O
BP	BP	NN	I-NP	O	O
with	with	IN	B-PP	O	O
fixed	fix	VBN	B-NP	O	O
combination	combination	NN	I-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug
/	/	SYM	B-NP	O	O
valsartan	valsartan	NN	I-NP	O	S-drug
(	(	(	O	O	O
93	93	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
on	on	IN	B-PP	O	O
traditional	traditional	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

But	But	CC	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fixed	fix	VBN	B-NP	O	O
combination	combination	NN	I-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug-EF-1
/	/	SYM	B-NP	O	O
valsartan	valsartan	NN	I-NP	O	S-drug-EF-2
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
traditional	traditional	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	O	O	O
self	self	PRP	B-NP	O	O
measured	measure	VBN	B-VP	O	O
BP	BP	NN	B-NP	O	O
,	,	,	O	O	O
quicker	quicker	NN	B-NP	O	O
achievement	achievement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
target	target	NN	B-NP	O	O
BP	BP	NN	I-NP	O	O
(	(	(	O	O	O
5.8	5.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.3	2.3	CD	B-NP	O	O
and	and	CC	I-NP	O	O
9.2	9.2	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
1.8	1.8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
lesser	less	JJR	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
(	(	(	O	O	O
2.5	2.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.6	0.6	CD	B-NP	O	O
and	and	CC	I-NP	O	O
3.0	3.0	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
0.9	0.9	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
lower	low	JJR	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concealed	concealed	JJ	B-NP	O	O
inefficacy	inefficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
and	and	CC	I-NP	O	O
31	31	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Conclusions	Conclusion	NNS	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
appropriateness	appropriateness	NN	B-NP	O	O
of	of	IN	B-PP	O	O
inhospital	inhospital	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fixed	fix	VBN	B-NP	O	O
amlodipine	amlodipine	NN	I-NP	O	S-drug-EF-1
/	/	SYM	B-NP	O	O
valsartan	valsartan	NN	I-NP	O	S-drug-EF-2
combination	combination	NN	I-NP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
approach	approach	NN	I-NP	O	O
allowing	allow	VBG	B-VP	O	O
to	to	TO	I-VP	O	O
achieve	achieve	VB	I-VP	O	O
target	target	NN	B-NP	O	O
BP	BP	NN	I-NP	O	O
in	in	IN	B-PP	O	O
shorter	short	JJR	B-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fewer	few	JJR	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	B-group
drugs	drug	NNS	I-NP	O	E-group
,	,	,	O	O	O
and	and	CC	O	O	O
diminishing	diminish	VBG	B-VP	O	O
concealed	concealed	JJ	B-NP	O	O
inefficacy	inefficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Ticagrelor	Ticagrelor	NN	B-NP	O	S-drug
(	(	(	O	O	O
Brilinta	Brilinta	NN	B-NP	O	S-brand
)	)	)	O	O	O
-	-	SYM	O	O	O
-	-	HYPH	O	O	O
better	good	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug
(	(	(	O	O	O
Plavix	Plavix	NN	B-NP	O	S-brand
)	)	)	O	O	O

The	The	DT	B-NP	O	O
FDA	FDA	NNP	I-NP	O	O
has	have	VBZ	B-VP	O	O
approved	approve	VBN	I-VP	O	O
ticagrelor	ticagrelor	NN	B-NP	O	S-drug-EF-1
(	(	(	O	O	O
Brilinta	Brilinta	NNP	B-NP	O	S-brand-EF-1
-	-	HYPH	O	O	O
AstraZeneca	AstraZeneca	NNP	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
antiplatelet	antiplatelet	JJ	I-NP	O	B-group
drug	drug	NN	I-NP	O	E-group
,	,	,	O	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aspirin	aspirin	NN	I-NP	O	S-brand-EF-2
to	to	TO	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombotic	thrombotic	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
(	(	(	O	O	O
ACS	ACS	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
will	will	MD	B-VP	O	O
compete	compete	VB	I-VP	O	O
with	with	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	O	S-drug
(	(	(	O	O	O
Plavix	Plavix	NN	B-NP	O	S-brand
)	)	)	O	O	O
and	and	CC	O	O	O
prasugrel	prasugrel	NN	B-NP	O	S-drug
(	(	(	O	O	O
Effient	Effient	NN	B-NP	O	S-brand
)	)	)	O	O	O
for	for	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Clopidogrel	Clopidogrel	NN	B-NP	O	S-drug
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
become	become	VB	I-VP	O	O
available	available	JJ	B-ADJP	O	O
generically	generically	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
US	US	NNP	I-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
next	next	JJ	I-NP	O	O
few	few	JJ	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

Influence	Influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
piperine	piperine	NN	B-NP	O	S-drug_n
on	on	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
induced	induce	VBD	B-VP	O	O
antinociception	antinociception	NN	B-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
.	.	.	O	O	O

Piperine	Piperine	NN	B-NP	O	S-drug_n
(	(	(	O	O	O
CAS	CAS	NN	B-NP	B-DNA	O
94	94	CD	I-NP	I-DNA	O
-	-	HYPH	B-NP	O	O
62	62	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
alkaloid	alkaloid	NN	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
Piper	Piper	NNP	B-NP	O	O
nigrum	nigrum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
P	P	NN	I-NP	O	O
.	.	.	O	O	O

longum	longum	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B-protein	O
isozymes	isozyme	NNS	I-NP	I-protein	O
)	)	)	O	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
biotransformation	biotransformation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
piperine	piperine	NN	B-NP	O	S-drug_n
improves	improve	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
bioavailability	bioavailability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
piperine	piperine	NN	I-NP	O	S-drug_n-EF-1
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-2
evaluated	evaluate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
both	both	CC	O	O	O
acetic	acetic	JJ	B-NP	O	B-drug
acid	acid	NN	I-NP	O	E-drug
writhing	writhing	NN	I-NP	O	O
and	and	CC	O	O	O
formalin	formalin	NN	B-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
.	.	.	O	O	O

Ibuprofen	Ibuprofen	NN	B-NP	O	S-drug-ME-1
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
piperine	piperine	NN	B-NP	O	S-drug_n-ME-2
.	.	.	O	O	O

The	The	DT	B-NP	O	O
synergistic	synergistic	JJ	I-NP	O	O
antinociception	antinociception	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-ME-1
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
piperine	piperine	NN	B-NP	O	S-drug_n-ME-2
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug
.	.	.	O	O	O

From	From	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
it	it	PRP	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
piperine	piperine	NN	B-NP	O	S-drug_n-EF-1
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bioenhancer	bioenhancer	NN	I-NP	O	O
along	along	IN	B-PP	O	O
with	with	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	O	S-drug-EF-2
.	.	.	O	O	O

